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ABSTRACT
Mitochondria are essential organelles that play crucial roles in many aspects of cellular
homeostasis. More importantly, the mitochondria are home to the majority of the metabolic
pathways within the cell and are responsible for producing most of the cell’s useable energy in
the form of adenine triphosphate (ATP) through oxidative phosphorylation (OXPHOS). In
mammals, the majority of OXPHOS complex subunits are encoded by nuclear deoxyribonucleic
acid (DNA); however, 13 core subunits essential for the function of OXPHOS complexes I, III,
IV, and V are encoded in the mitochondrial (mt) DNA (mtDNA) and are synthesized within the
mitochondria by its own transcription and translation machinery. Changes in the expression and
post-translational modifications (PTMs) of OXPHOS subunits and mitochondrial proteins can be
detrimental to mitochondrial energy production. In fact, alterations in mitochondrial functions
impact cellular energy metabolism as well as influence whole-body metabolism and have been
identified as underlying causes for several diseases including neurological disorders, insulin
resistance, type 2 diabetes (T2D), and numerous cancer types. This has led to an extensive search
for a better understanding of key players involved in mitochondrial function in disease states, in
addition to new preventative and therapeutic strategies that are aimed at exploiting key
components of mitochondrial biogenesis and energy metabolism. Our laboratory has shown that
differences in mitochondrial biogenesis can be caused by changes in the sequence and/or PTMs
of mitochondrial proteins, resulting in altered mitochondrial function and energy metabolism. In
the present studies, we investigated changes in mitochondrial energy metabolism in two major
metabolic diseases, T2D and liver cancer, and evaluated potential targets and therapies. We first
investigated mitochondrial biogenesis and energy metabolism in T2D by studying the differences
in the expression and activity of OXPHOS complexes in the liver and kidney of the polygenic
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T2D model, TALLYHO/Jng (TH), and normal, C57BL/6J (B6), mice. A significant decrease
was observed in the expression of both nuclear- and mitochondrial-encoded subunits of
complexes I and IV, respectively, in TH mice compared to B6, which coincided with significant
reductions in their enzymatic activities. Furthermore, we identified sequence variants in several
mitochondrial proteins including OXPHOS complex subunits, a mitochondrial transfer
ribonucleic acid (tRNA) synthetase, and mitochondrial ribosomal proteins (MRPs). The
sequence variants identified in mitochondrial proteins might contribute to impaired
mitochondrial biogenesis and energy metabolism by diminishing OXPHOS expression and
activity in TH mice. In addition to T2D, we investigated liver cancer and demonstrated impaired
mitochondrial OXPHOS complex expression and activity in cancerous liver biopsies compared
to non-cancerous biopsies. The expression of the Src family kinases (SFKs), c-Src and Fyn, were
increased in liver cancer cell lines and tissues. In fact, aberrant expression of c-Src kinase was
observed in metastatic liver cancer tissues and the hepatic cell line Hep3B, which was correlated
to a significant reduction in OXPHOS complex expression and activity. Additionally, increased
c-Src expression was associated with decreased OXPHOS expression and activity in mouse
embryonic fibroblast (MEF) cell lines, demonstrating the role of c-Src on mitochondrial
OXPHOS in both health and disease. An inhibition of c-Src with the SFK inhibitor, PP2, and cSrc-specific small interfering ribonucleic acid (siRNA) alleviated the negative impact of c-Src on
OXPHOS expression and improved mitochondrial energy metabolism while significantly
impairing cell proliferation in normal and cancerous cells. In contrast, increased expression of
Fyn kinase was associated with an elevated OXPHOS subunit expression in the liver cancer cell
line, HepG2. Continuous OXPHOS activity can lead to high production of reactive oxygen
species (ROS), which can cause mitochondrial damage; therefore, we explored the effects of Fyn

xv

kinase, along with the effects of its inhibition on OXPHOS expression and cell proliferation, by
treating cells with the SFK inhibitor SU6656 and natural antioxidants kaempferol and
resveratrol. An increase in Fyn expression was associated with high OXPHOS expression, which
was reduced in the presence of SU6656 and kaempferol. Furthermore, the treatment of the
HepG2 cell line with SU6656, kaempferol, and resveratrol significantly inhibited cell
proliferation. These treatments reduced OXPHOS activity and slowed cell growth by impairing
cell proliferation in HepG2 cells, possibly by inhibiting Fyn activity. Evidence provided in these
studies indicate that increased expression of c-Src and Fyn are found in liver cancer and more
importantly regulate mitochondrial energy metabolism by altering the expression of OXPHOS
complexes, which can contribute to the development of cancer and other metabolic diseases. Our
data suggests that the suppression of SFKs can reduce cell proliferation and improve
mitochondrial function and energy metabolism and should be further evaluated as targets for the
treatment of liver cancer. Together, our studies demonstrated that changes in the expression of
OXPHOS complexes due to sequence variants or PTMs, can significantly impair mitochondrial
energy metabolism and may be underlying factors in both T2D and liver cancer. The
identification of factors contributing to mitochondrial dysfunction will allow us to improve
disease prognosis and treatments in various disease states.
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CHAPTER 1
THE MITOCHONDRIA
1.1. The Mitochondria and its Genome
Mitochondria are one of the most complex, multifunctional organelles in the cell. The
mitochondrion was derived from the engulfment of an alpha-proteobacterium by a precursor of
the modern eukaryotic cell roughly two billion years ago (Gray, Burger, & Lang, 1999; Lane &
Martin, 2010; D. Yang, Oyaizu, Oyaizu, Olsen, & Woese, 1985). The mitochondria are shaped
by two membranes: 1) the outer membrane (OM) which is a smooth and continuous membrane
that outlines the oblong shape of the organelle and forms an envelope to act as a barrier to restrict
the passage of small molecules into the mitochondria and 2) the inner membrane (IM) which is
highly invaginated (cristae) to increase its surface area to surround the inter soluble portion of
the mitochondria, the mitochondrial matrix (MM), and is also the site of oxidative
phosphorylation (OXPHOS) which is responsible for cellular respiration. The portion between
the OM and the IM is the intermembrane space (IMS).
Over time, the mitochondria have been transformed to contribute to a variety of functions
within the eukaryotic cell and play important roles in cell proliferation, senescence, apoptosis,
immune response, detoxifying oxygen, ketone body production, heme biosynthesis, reactive
oxygen species (ROS) production, and calcium and iron homeostasis (Ames, Atamna, & Killilea,
2005; Duchen, 2004; Osellame, Blacker, & Duchen, 2012). Although these pathways are vital to
cellular function, perhaps the most significant function of the mitochondria is that they are the
metabolic control center of the cell and contain the majority of metabolic pathways within the
mitochondrial matrix, such as the citric acid cycle (CAC) or tricarboxylic acid cycle (TCA), fatty
acid oxidation, and the urea cycle, all of which contribute to OXPHOS and energy production in
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the cell. The primary role of the mitochondria is to convert the metabolites derived from the
catabolism of proteins, carbohydrates, and fats to carbon dioxide (CO2) and water (H2O), using
OXPHOS to drive adenosine triphosphate (ATP) synthesis.
During mitochondrial evolution, most genetic information was transferred to the nucleus,
leaving the mitochondria with its own genome containing relatively few genes. In mammals, the
mitochondrial (mt) deoxyribonucleic acid (DNA) (mtDNA) contains less than 1% of the total
cellular DNA and has multiple copies inside the matrix of a single mitochondrion. The
mitochondrial genome is a double-stranded (heavy- (H-) and light- (L-) strands), circular
molecule that is roughly 16,569 base pairs in length and contains 37 genes (Anderson et al.,
1981; Bibb, Van Etten, Wright, Walberg, & Clayton, 1981; Gray, 2012; Taanman, 1999). The
structure of the mtDNA, as well as the gene organization, is highly conserved among mammals
and is compact with nearly a complete absence of non-coding regions (Taanman, 1999;
Wolstenholme, 1992). The mitochondrial genome encodes two ribosomal ribonucleic acids
(RNA) (rRNAs), 22 transfer RNAs (tRNAs), and 11 messenger RNAs (mRNAs), two of which
are bi-cistronic (Fig. 1). Additionally, the mtDNA also encodes the displacement loop (D-loop)
which is a triple-stranded structure that encompasses key promoters for transcription, contains
the leading strand origin of replication, and is the major control site for mtDNA expression
(Kasamatsu & Vinograd, 1974; Taanman, 1999; Walberg & Clayton, 1981).
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Figure 1. The organization of the human mitochondrial genome. The genome
encodes 2 rRNA, 22 tRNA, and 13 mRNAs.
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The mitochondrial genome encodes 22 tRNAs that are responsible for the synthesis of
mitochondrial-encoded proteins. The mitochondrial tRNAs have a basic cloverleaf structure of
canonical tRNAs but also have several distinguishing features that make them shorter and lack a
number of conserved tertiary interactions (Helm et al., 2000; Wakita et al., 1994; Yokogawa et
al., 1991). The compliment of mitochondrial tRNAs is sufficient to decode the simplified
mitochondrial genetic code, which is distinct from the universal code, since each tRNA codes for
one amino acid, except for leucine (Leu) and serine (Ser) which have two (Barrell, Bankier, &
Drouin, 1979). In addition to its own tRNAs, the mitochondrial genome encodes two rRNAs, the
12S (small) and 16S (large), which are roughly only 25-30% of the total RNA (Christian &
Spremulli, 2012; E. C. Koc & Koc, 2012; Pietromonaco, Denslow, & O'Brien, 1991).
The most important genes encoded in the mitochondrial genome are the 13 mRNAs
which are essential proteins that compose the enzymatic cores of OXPHOS complexes I, III, IV,
and V. Complex I (nicotinamide adenine dinucleotide plus hydrogen (NADH) dehydrogenase) is
composed of seven mitochondrial-encoded proteins, NADH dehydrogenase (ND) 1, ND2, ND3,
ND4, ND4L, ND5, and ND6; complex III (cytochrome (cyt) c reductase) contains one
mitochondrial-encoded protein, cyt b; complex IV (cytochrome c oxidase (CO)) has three
mitochondrial-encoded proteins, COI, COII, and COIII; and complex V (ATP synthase) contains
two mitochondrial-encoded proteins, ATP6 and ATP8 (listed in Table 1). These 13 proteins are
encoded by nine monocistronic and two dicistronic mRNAs which contain overlapping reading
frames (Anderson et al., 1981; Anderson et al., 1982). For example, the first 46 nucleotides from
the ATP6 gene are the last nucleotides of the ATP8 gene, while the last nucleotides on the ATP6
gene are the first nucleotides of the COIII gene. These overlapping regions allow the mtDNA to
remain densely packed.
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Mitochondrial Complex

Mitochondrial Complex Number

Gene Name
ND1
ND2
ND3

NADH dehydrogenase

I

ND4
ND4L
ND5
ND6

Cytochrome c reductase

III

Cyt b
COI

Cytochrome c oxidase

IV

COII
COIII
ATP6

ATP synthase

V

Table 1. Mitochondrial-encoded OXPHOS subunits.
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ATP8

Interestingly, the mitochondrial mRNAs are different than nuclear mRNAs because they
lack a 5’ untranslated region (5’-UTR) and have zero to eight nucleotides right before the start
codon. Additionally, the start codons are located near the 5’-end of each mRNA and can be
either AUG (adenine, uracil, guanine) or AUA (adenine, uracil, adenine) both of which encode
methionine (Met), instead of the strict AUG in the nucleus and are used to start the transcription
process of the mtDNA (Montoya, Ojala, & Attardi, 1981). Mitochondrial DNA replication,
transcription, and translation are performed by their own machinery; however, besides the 37
genes (22 tRNAs, 2 rRNAs, and 13 mRNAs) encoded in the mtDNA, the remainder of the
~2,000 mitochondrial proteins are encoded in the nuclear DNA, synthesized on cytosolic
ribosomes, and transported into the mitochondria.
1.2. Transcription and Translation in Mammalian Mitochondria
All mitochondrial functions are directly or indirectly linked to OXPHOS; therefore,
mitochondrial gene expression is required for maintaining cellular homeostasis. The
mitochondria utilize their own machinery to synthesize mitochondrial-encoded proteins, which is
unique to mitochondria due to the two origins of the transcription and translation components.
Most mitochondrial protein factors are encoded in the nuclear genome and all mitochondrial
RNAs are encoded in the mitochondrial genome (D'Souza & Minczuk, 2018). Mitochondrial
transcription begins in the major non-coding region of the genome at the L-strand (LSP) and Hstrand (HSP) promoters (D'Souza & Minczuk, 2018; Shokolenko & Alexeyev, 2017). The LSP
controls the transcription of eight tRNAs and the mitochondrial ND6 gene, and the HSP, which
is broken into 2 promoter systems HSP1 and HSP2, control the transcription of different
mitochondrial genes. HSP1 produces transcripts for tRNAPhe, tRNAVal, and 2 ribosomal RNAs,
and HSP2 spans the mitochondrial genome (Chang & Clayton, 1984; Montoya, Christianson,
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Levens, Rabinowitz, & Attardi, 1982). Transcription factor A mitochondrial (TFAM) initiates
transcription by binding to high-affinity sites upstream of the HSP1 and LSP promoters and
induces a sharp bend in mtDNA, which may be important for the positioning of the remainder of
the mitochondrial transcription machinery (Fisher, Lisowsky, Parisi, & Clayton, 1992; Ngo,
Lovely, Phillips, & Chan, 2014). The complex formed between TFAM and mtDNA recruits the
DNA-dependent RNA polymerase (POLRMT) and mitochondrial transcription factor B2
(TFB2M), which facilitate promoter recruitment of substrate to the POLRMT catalytic site
(Morozov et al., 2014; Sologub, Litonin, Anikin, Mustaev, & Temiakov, 2009). TFB2M initiates
the elongation step once it dissociates from POLRMT, recruiting the mitochondrial
transcriptional elongation factor (TEFM) to the elongation complex (Minczuk et al., 2011;
Sologub et al., 2009). TEFM further promotes POLRMT activity and stimulates the formation of
longer transcripts (Posse, Shahzad, Falkenberg, Hallberg, & Gustafsson, 2015). Once the length
of the polycistronic transcript has been processed, transcription termination is initiated and
carried out by mitochondrial termination factor 1 (MTERF1) (M. Martin, Cho, Cesare, Griffith,
& Attardi, 2005; Yakubovskaya, Mejia, Byrnes, Hambardjieva, & Garcia-Diaz, 2010).
Mitochondrial transcription results in primary transcripts that need to be processed. The mRNAs
undergo maturation and stabilization by cleavage and polyadenylation, and the tRNAs
synthesized also undergo processing such as the addition of CCA tails and chemical nucleotide
modifications (D'Souza & Minczuk, 2018; Shokolenko & Alexeyev, 2017). Additionally, tRNAs
are aminoacylated and charged with a cognate amino acid, which is performed by mitochondrial
aminoacyl tRNA synthetases (ARS2s), such as aspartyl-tRNA synthetase 2 (DARS2) (Chihara,
Luginbuhl, & Luo, 2007). After processing of the mitochondrial mRNAs and tRNAs, they are
assembled into the mitochondria ribosome for translation.
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The mammalian mitochondria contain their own ribosomes that sediment as 55S particles
and are made of 28S (small) and 39S (large) subunits (Christian & Spremulli, 2012; O'Brien,
1971). The mitochondrial ribosomes are associated with the inner membrane to allow the
mitochondrial-encoded OXPHOS complex subunits to be synthesized near their sites of insertion
(Vogel, Bornhovd, Neupert, & Reichert, 2006). Interestingly, mitochondrial ribosomes are more
closely related to bacterial ribosomes than the eukaryotic counterparts, but mainly differ in
composition and proteins. Mitochondrial ribosomes are slightly larger and more porous due to
the higher protein to RNA ratio (69% to 31%) which is opposite of the bacterial ribosome
composition (33% to 67%) (M. R. Sharma et al., 2003). The mitochondrial ribosomal large
subunit (LSU) and small subunit (SSU) are composed of mitochondrial ribosomal proteins
(MRPs), most of which have homologous ribosomal proteins in bacteria. The mitochondrial
large subunit is involved in catalyzing the peptidyl-transferase reaction (Kaushal et al., 2014; E.
H. Koc, ME; Spremulli, LL, 2010) and is comprised of 48 MRPs, 15 of which are mitochondrial
specific, and the mitochondrial-encoded 16S rRNA (E. C. Koc, Burkhart, Blackburn, Moyer, et
al., 2001; O'Brien et al., 2000; Suzuki et al., 2001b). The small subunit (SSU) provides the
platform for the binding and decoding of the mitochondrial mRNAs (Kaushal et al., 2014; E. H.
Koc, ME; Spremulli, LL, 2010) and is composed of 29 MRPs, 8 mitochondrial specific, and the
mitochondrial-encoded 12S rRNA (E. C. Koc, Burkhart, Blackburn, Koc, et al., 2001; O'Brien et
al., 2000; Suzuki et al., 2001a). Recently, all of the MRPs have been identified using mass
spectrometry-based proteomic approaches (E. C. Koc, Burkhart, Blackburn, Koc, et al., 2001; E.
C. Koc, Burkhart, Blackburn, Moyer, et al., 2001; Suzuki et al., 2001a, 2001b), but their
functions are not yet fully understood. In addition to their involvement in mitochondrial
translation, some MRPs have extra ribosomal functions and are involved in other cellular
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regulatory processes. In fact, the mitochondrial ribosomal protein of the small subunit (MRPS)
29 (MRPS29) and 30 (MRPS30) are also involved in programmed cell death or apoptosis
(Cavdar Koc, Burkhart, Blackburn, Moseley, & Spremulli, 2001; Cavdar Koc, Ranasinghe, et al.,
2001; E. C. Koc, Burkhart, Blackburn, Koc, et al., 2001).
Although some of the details of the mitochondrial translation system remain to be
discovered, the mammalian mitochondrial protein biosynthesis takes place in four phases, each
of which require a set of auxiliary factors: 1) initiation, 2) elongation, 3) termination, and 4)
recycling. Briefly, the initiation phase results in a completed 55S initiation complex with the help
of mitochondrial initiation factors 2 and 3 (mtIF2 and mtIF3) (Christian & Spremulli, 2012; E. C.
Koc & Spremulli, 2002; Schwartzbach, Farwell, Liao, & Spremulli, 1996; M. R. Sharma et al.,
2003; Spurio et al., 2000). The 55S initiation complex moves into the elongation phase of protein
synthesis, which is responsible for peptide elongation on the ribosome and involves key
mitochondrial proteins such as the mitochondrial elongation factor Tu (mtEF-Tu), elongation
factor G1 (mtEF-G1), and elongation factor Ts (mtEF-Ts) (Cai, Bullard, Thompson, &
Spremulli, 2000a, 2000b; Christian & Spremulli, 2012; Schwartzbach et al., 1996; Schwartzbach
& Spremulli, 1989, 1991). The elongation process adds one amino acid on at a time, until the
stop codon appears in the A-site of the ribosome and is recognized by the mitochondrial
translation release factor 1a (mtRF1a) which is released from the ribosome, along with the
completed peptide. The ribosome complex is then dissociated and translation factors are recycled
with the help of the mitochondrial ribosome recycling factors 1 and 2 (mtRRF1 and mtRRF2), so
another round of protein synthesis can begin (Christian & Spremulli, 2012; ChrzanowskaLightowlers, Pajak, & Lightowlers, 2011; Y. Zhang & Spremulli, 1998).
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Mitochondrial translation takes place at the IM due to the location of the mitochondrial
ribosomes. This also allows the 13 synthesized mitochondrial-encoded OXPHOS subunits to be
inserted directly into their respective complexes, which is a co-translational process (Ott &
Herrmann, 2010). The synthesis of the mitochondrial-encoded proteins by their own machinery
is essential for OXPHOS function (Fig. 2). The OXPHOS complexes are contributions from both
the nuclear and mitochondrial DNA, two physically and functionally separate genomes.
Disruption of the synthesis of mitochondrial proteins on either genome could be detrimental to
OXPHOS and mitochondrial energy metabolism. Therefore, the coordinated expression and
regulation of both nuclear- and mitochondrial-encoded subunits is essential for the assembly and
function of OXPHOS complexes to prevent impaired energy production and mitochondrial
dysfunction, which can cause several disease states to emerge.
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Figure 2. Overview of mitochondrial transcription and translation. Mammalian
mitochondria contain a ~16.5 kilobase circular genome (mtDNA) that encodes two
rRNAs, 22 tRNAs, and 13 mRNAs. The mtDNA is transcribed by its own transcription
and translation machinery, which is responsible for the synthesis of the 13 mitochondrialencoded subunits of complexes I (purple), III (blue), IV (green), and V (ATP synthase)
(pink). The mtDNA is transcribed by its transcription machinery (TFAM, POLRMT,
TEFM TFB2M, MTERF1, and ARS2s). The mammalian mitochondrial 55S ribosome
(28S and 39S subunits) and rRNAs, along with other translation factors, such as
mitochondrial initiation factors (mtIF2 and mtIF3), mitochondrial elongation factors
(mtEF-Tu, mtEF-Ts, and mtEF-G1), and mitochondrial ribosomal release and recycling
factors (mtRF1a, mtRRF1, and mtRRF2), are responsible for the synthesis of the 13
mitochondrial encoded subunits of complexes I (ND1, ND2, ND3, ND4, ND4L, ND5, and
ND6), III (cyt b), IV (COI, COII, and COIII), and V (ATP6 and ATP8). The bovine 55S
mammalian ribosome (PDB # 3J9M) was modeled and shown in light purple with
mitochondrial rRNAs highlighted in green. Bovine mtEF-Tu (PDB #1XB2) and
Escherichia coli aminoacyl tRNACys (PDB # IB23) were modeled to show the interaction
of tRNA with mtEF-Tu and are presented in violet and blue, respectively. Figure adapted
from (C. A. Hunter et al., 2019).
11

1.3. The Role of Mitochondria in Metabolic Disorders
The mitochondria host many pathways that are necessary for ATP production.
Mitochondrial dysfunction, caused by pathogenic alterations and changes in the expression of
mitochondrial proteins resulting in diminished ATP and increased ROS production, is an
underlying factor in the development and progression of many metabolic diseases, including
cancer, cardiovascular disease, obesity, and type 2 diabetes (T2D) (Dalle-Donne, Rossi,
Colombo, Giustarini, & Milzani, 2006; Dhalla, Temsah, & Netticadan, 2000; Garcia-Escudero,
Martin-Maestro, Perry, & Avila, 2013; Hassanein & Frederick, 2004; Kelley, He, Menshikova,
& Ritov, 2002; J. A. Kim, Wei, & Sowers, 2008; E. C. Koc et al., 2015; Sayre, Smith, & Perry,
2001; Wallace, 1999). Mitochondrial dysfunction has been associated with characteristics
ranging from poor mitochondrial quality to reduced mitochondrial number and size to the
inability to properly undergo cellular respiration by OXPHOS and build new mitochondria,
mitochondrial biogenesis, in numerous disease states. Therefore, a better understanding of the
cause of mitochondrial dysfunction and the effects on cellular signaling in diseases is essential to
determine if the functional impairments are remedial and to discover a potential for novel
treatments to target these deficiencies.
Mitochondrial OXPHOS plays a central role in cellular metabolism and impaired
OXPHOS function can be the cause of disease pathogenesis. While OXPHOS disorders can be
caused by mutations in the nuclear or mitochondrial genomes, there remains a lack of
understanding in the pathogenic mechanisms that result in clinical symptoms observed in many
patients. Mutations in the mitochondrial OXPHOS genes encoded within the mitochondrial and
nuclear genomes, along with reduced expression and/or changes in PTMs result in lower
OXPHOS expression, activity, and reduced ATP generation in metabolic disorders (Chandra &
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Singh, 2011; Minocherhomji, Tollefsbol, & Singh, 2012). Additionally, OXPHOS inhibition can
result in the toxic accumulation of ROS, which can damage nucleic acids, lipids, and
mitochondrial and cellular proteins, including the iron-sulfur centers of OXPHOS complexes I,
II, and III, resulting in diminished mitochondrial energy production and impaired mitochondrial
function (Wallace, 1999, 2005). Due to the complexity of the mitochondria in numerous critical
cellular functions which rely on OXPHOS activity, identifying key factors involved in the
deregulation of OXPHOS in metabolic diseases such as T2D and cancer is crucial.
1.3.1. Mitochondrial Function, OXPHOS, and Insulin Signaling
Mitochondria play critical roles in numerous cellular processes, especially energy
production by OXPHOS since almost all cellular processes require ATP. Therefore, both
physiological alterations in energy demand and fuel supply influence mitochondrial biogenesis,
dynamics, and mitophagy (Liesa & Shirihai, 2013; Ruegsegger, Creo, Cortes, Dasari, & Nair,
2018). Since mitochondrial OXPHOS is a major function of the mitochondria and plays a pivotal
role in normal cellular processes, its deregulation can be detrimental to cellular metabolism and
has been suggested as a global pathogenic mechanism in the development of many diseases,
especially insulin resistance and T2D (Smeitink, Zeviani, Turnbull, & Jacobs, 2006).
The prevalence of obesity and T2D is increasing rapidly and has recently grown to epic
proportions worldwide due to an increase in sedentary lifestyles and increased consumption of
calorie dense food. Although there are many factors that contribute to the development of
obesity, insulin resistance, and T2D, mitochondrial dysfunction has been implicated in the
development and progression of these disease states (Chow, From, & Seaquist, 2010; Kelley et
al., 2002; J. A. Kim et al., 2008; Petersen et al., 2003; Rector et al., 2010).
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Insulin resistance is a major characteristic in the pathogenesis of T2D and is the primary
factor leading to insufficient pancreatic β-cell function. Insulin is the predominant hormone
involved in fuel metabolism and is secreted in the pancreatic β-cell (Ashcroft & Rorsman, 2012;
Muoio & Newgard, 2008) which is largely controlled by mitochondrial OXPHOS activity. Under
normal conditions, glucose and other cellular fuels are oxidized to produce reducing equivalents
that are fed into mitochondrial OXPHOS complexes and used to produce ATP. The increase in
ATP closes the ATP-sensitive potassium (K+) channel, depolarizes the plasma membrane of the
β-cell, opens the voltage-gated calcium (Ca2+) channels, and triggers the release of the cellular
granule containing insulin (Fex et al., 2018; Henquin, 2000). This KATP-dependent pathway is
dependent on mitochondrial OXPHOS activity, thereby demonstrating the essential role of the
mitochondria in the control of insulin release in the pancreatic β-cell. Decreased insulin release
has been associated with diminished mitochondrial function and reduced OXPHOS activity (J.
A. Kim et al., 2008). This results in the inability of tissues to respond to physiological levels of
insulin, which leads to insulin resistance and the development of T2D.
Interestingly, insulin secretion is controlled by mitochondrial function and OXPHOS
activity; however, insulin is also one of the hormones that regulates mitochondrial functions and
has been identified as a critical regulator of mitochondrial biogenesis in numerous tissue types
(Ruegsegger et al., 2018). The presence of insulin stimulates the activities of the glucose
transporter 4 (GLUT4) and fatty acid transport protein (FATP), enhancing the uptake of these
substrates by the cell, which are then oxidized and fed into the mitochondrial OXPHOS for ATP
production (Y. Zhang & Ye, 2012). Insulin has also been shown to promote mitochondrial
oxidative energy metabolism and ATP synthesis by inducing pyruvate dehydrogenase (PDH)
activity through dephosphorylation to enhance glucose utilization (Y. Zhang & Ye, 2012).
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Insulin promotes mitochondrial function by increasing substrate availability for oxidation as well
as controlling mitochondrial biogenesis and metabolism (Y. Zhang & Ye, 2012). Briefly, in the
insulin signaling pathway, insulin binds to the insulin receptor and induces receptor
autophosphorylation, causing a downstream signaling cascade that leads to the recruitment and
phosphorylation of insulin receptor substrates 1 and 2 (IRS1 and IRS2) and activation of the
AKT pathway (De Meyts, 2000; Ruegsegger et al., 2018). The insulin/IRS/AKT pathway plays
an important regulatory role in mitochondrial function and oxidative metabolism. This pathway
increases the expression of nuclear- and mitochondrial-encoded genes by inhibiting Forkhead
box O1 (FOXO1) and activating the mammalian target of rapamycin (mTOR). The inhibition of
FOXO1 influences the activity and expression of the peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC-1α) which is an inducible transcriptional coactivator that has
been shown to interact with nuclear respiratory factors-1and 2 (NRF-1 and NRF-2) and stimulate
the transcription of nuclear-encoded mitochondrial genes (Cheng et al., 2009; Heilbronn, Gan,
Turner, Campbell, & Chisholm, 2007; McCarty, 2005; Mootha et al., 2003). PGC-1α also
enhances mitochondrial gene transcription through transcription factor A, mitochondrial
(TFAM). The activation of mTOR causes the downstream activation of other targets responsible
for the increased synthesis of nuclear-encoded mitochondrial proteins involved in the TCA cycle,
β-oxidation, and OXPHOS (Cunningham et al., 2007; Ruegsegger et al., 2018; Schieke et al.,
2006). Collectively, these findings demonstrate insulin signaling is critical in the mitochondrial
metabolic activity of the cell and is clearly involved in the synthesis and expression of OXPHOS
complexes. Therefore, identifying key players in mitochondrial dysfunction in insulin resistance
is essential to determine if mitochondrial dysfunction is a cause or consequence of insulin
resistance and the pathogenesis of T2D.
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1.3.1.1. Mitochondrial Dysfunction in Obesity and Type 2 Diabetes
Defects in OXPHOS and energy production is one of the central factors contributing to
T2D and insulin resistance. In fact, reduced gene and protein expression has been observed and
reported in multiple subunits of each of the five OXPHOS complexes, leading to significant
decreases in ATP synthesis in both animal models and human subjects with obesity, T2D, and
insulin resistance (Haythorne et al., 2019; Heilbronn et al., 2007; Heinonen et al., 2015; Hou et
al., 2017; Patti et al., 2003; Rong et al., 2007; Segerstolpe et al., 2016; Skov et al., 2007). Several
studies also demonstrated reduced enzymatic activity along with decreased expression of
OXPHOS complexes in obesity and/or T2D (Kelley et al., 2002; Ruegsegger et al., 2018;
Simoneau, Veerkamp, Turcotte, & Kelley, 1999). Additionally, studies have also shown that the
activity of mitochondrial enzymes that control OXPHOS activities, such as PDH, are also
inhibited in diabetic and insulin resistant conditions in various tissues in animals and human
subjects (Alves et al., 2011; Mondon, Jones, Azhar, Hollenbeck, & Reaven, 1992; Y. Zhang &
Ye, 2012). These studies show significant impairment in ATP generation and fatty acid synthesis
in most tissues, further demonstrating mitochondrial dysfunction by reduced energy metabolism.
In an effort to uncover the role of mitochondrial dysfunction by OXPHOS in T2D and insulin
resistance, many studies have investigated numerous mitochondrial proteins involved in
mitochondrial biogenesis and energy metabolism.
Mitochondrial function is largely controlled by mitochondrial biogenesis and is
determined by the size, number, and quality of the mitochondria (Fex et al., 2018). Interestingly,
in the subcutaneous adipose tissue (SAT) and skeletal muscle of obese and T2D subjects,
reduced mitochondrial number, size, mass, and activity was observed (Heinonen et al., 2015;
Kelley et al., 2002). Abnormal cristae structure within the mitochondria in obese subjects has
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also been reported (Bach et al., 2003; Joseph, Joanisse, Baillot, & Hood, 2012; Kelley et al.,
2002), suggesting defects in the inner mitochondrial membrane, which could also alter
mitochondrial function and OXPHOS activity.
Mitochondria are dynamic and undergo network remodeling by continuous fusion and
fission to adapt to changes in cellular energy demands. Under normal conditions, mitochondrial
fusion results in the formation of a mitochondrial network that allows the redistribution of
proteins and mtDNA between multiple mitochondria to prevent the accumulation of mutated or
damaged mtDNA in a cell (Bo, Zhang, & Ji, 2010; Joseph et al., 2012; Otera & Mihara, 2011).
The inhibition of mitochondrial fusion is commonly associated with increased ROS generation
and can impair the insulin signaling pathways, leading to insulin resistance and T2D (Joseph et
al., 2012). In fact, decreased expression and loss of function of mitofusin 2 (Mfn2) and optic
atrophy 1 (OPA1) was observed and reported in T2D and insulin resistant subject and was shown
to alter the mitochondrial morphology and impair mitochondrial metabolism and oxygen
consumption in skeletal muscle and a variety of other tissues and cell types (Bach et al., 2005;
Bach et al., 2003; H. Chen, Chomyn, & Chan, 2005; Kelley et al., 2002; Pich et al., 2005).
Collectively, these studies were shown to decrease mitochondrial energy metabolism, further
demonstrating mitochondrial dysfunction in T2D, insulin resistance and obesity.
Decreases in the amount of mtDNA and mitochondrial content have been reported in
obese twins, as well as obese and insulin resistant adults and offspring of parents with T2D
(Heinonen et al., 2015; Mootha et al., 2003; Patti et al., 2003; Petersen, Dufour, Befroy, Garcia,
& Shulman, 2004; Sreekumar, Halvatsiotis, Schimke, & Nair, 2002). These findings implicate
changes in mitochondrial biogenesis as a contributing factor to the development of insulin
resistance, obesity, and T2D. Additionally, changes in mitochondrial gene expression and protein
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synthesis have also been observed and contribute to alterations in mitochondrial biogenesis.
Mitochondrial biogenesis relies on the coordinated regulation of both nuclear and mitochondrial
protein expression for energy metabolism via OXPHOS. Interestingly, one of the most common
pathogenic variants linked to T2D was found in the mitochondrial genome. The variant at
position 3243 in the mtDNA substitutes adenine (A) with guanine (G) (A3243G) in the gene that
encodes the mitochondrial tRNA which recognizes Leu, tRNA(Leu) (Kami et al., 2012; Maassen
et al., 2004; Scaglia & Northrop, 2006). This mutation decreased mitochondrial protein synthesis
and caused a defect in the expression and function of OXPHOS complexes, diminished ATP
production, and impaired the insulin secretion response (Maassen et al., 2004).
In mammals, mitochondrial biogenesis is regulated by PGC-1α (Heilbronn et al., 2007;
McCarty, 2005; Mootha et al., 2003). A coordinated reduction in the mitochondrial transcriptionrelated factors PGC-1α and PGC1-beta (PGC-1β), and their responsive gene NRF-1 was found in
obesity and T2D subjects and obese subjects with a family history of diabetes (Heinonen et al.,
2015; Mootha et al., 2003; Patti et al., 2003). Additionally, changes in the expression of
mitochondrial translation factors has also been observed in subjects with obesity and T2D and
shown to alter energy metabolism by changes in OXPHOS. In fact, haploinsufficiency and/or the
heterogenous expression of pentatricopeptide repeat domain 1 (PTCD1) resulted in decreased
protein synthesis and impaired RNA processing, which was shown to cause adult onset obesity
(Perks et al., 2017).
Additionally, the altered expression and/or sequence variants of numerous mitochondrial
ribosomal proteins also contributes to reduced mitochondrial energy metabolism via impaired
mitochondrial protein synthesis and T2D (Bains et al., 2004; Heinonen et al., 2015; Rong et al.,
2007). One of the essential translation factors, mtEF-Tu, was identified as the most connected
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mitochondrial protein to the insulin signaling cascade and is strongly associated with human
obesity and T2D (Mercader et al., 2012). In obese Zucker rats, exercise was suggested to
increase mitochondrial metabolism and improve impaired mitochondrial function. Exercise
resulted in higher mRNA expression of mitochondrial transcription factor A (TFAM), mtIF2,
and Tu translation elongation factor, mitochondrial (TUFM), while the protein expression of
mtEF-Tu was only increased in lean Zucker rats (Greene et al., 2014). The lack of increase in
mtEF-Tu expression in obese rats further implies that decreased regulation of mitochondrial
translation elongation is a possible candidate in impaired mitochondrial biogenesis in obesity and
T2D, demonstrating the role of mitochondrial translation in disease development.
Although many studies highlight the role of mitochondrial dysfunction in the
development and progression of obesity, insulin resistance, and T2D, there is still a major gap in
the molecular pathogenesis. Therefore, further studies should be performed to identify impaired
mitochondrial proteins involved in the pathogenesis of the diseases.
1.3.2. Mitochondrial Dysfunction in Cancer
In addition to T2D and other metabolic diseases, mitochondrial dysfunction has also been
established as an underlying player in various cancer types. One of the hallmarks of cancer is the
metabolic reprogramming of cancer cells which not only alters energy metabolism but also
supports the bioenergetic demand of the cell, synthesis of macromolecules, and cellular survival
(Hanahan & Weinberg, 2011; Pavlova & Thompson, 2016; Vyas, Zaganjor, & Haigis, 2016).
Since mitochondria are the major metabolic hubs of the cells, they are responsible for cellular
reprogramming through multiple mechanisms. Interestingly, mitochondrial energy production as
well as mitochondrial mass, dynamics, redox homeostasis, cell death regulation, and metabolic
signaling influence the initiation, growth, survival, and metastasis of cancer cells (Vyas et al.,
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2016). Therefore, their flexibility allows for cell growth and survival in adverse environmental
conditions and contributes to tumorigenesis (Vyas et al., 2016).
Mitochondrial OXPHOS is required for specific phases of tumor progression causing
mitochondria to be essential for cancer cells (Iommarini, Ghelli, Gasparre, & Porcelli, 2017;
Wallace, 2012). However, mitochondrial dysfunction has been established as an underlying
factor for tumorigenesis and has been observed in aggressive tumors (Gogvadze, Zhivotovsky, &
Orrenius, 2010; Seyfried, 2015; Simonnet et al., 2002). In fact, in 1927 Otto Warburg observed
that cancer cells rely more on glycolysis than OXPHOS for ATP production even in the presence
of oxygen, known as the Warburg effect or aerobic glycolysis (Warburg, 1956a, 1956b;
Warburg, Wind, & Negelein, 1927). Although the Warburg effect is a prominent feature of many
cancer cells, this discovery suggested that mitochondrial defects might be central to cancer cell
biology. Mitochondrial dysfunction of cancer cells is a result of impaired respiration and energy
production caused at the genetic level by sequence variants in the nuclear- and mitochondrialencoded proteins, or at the protein level, by PTMs of mitochondrial proteins.
1.3.2.1. Mutations in Mitochondrial Genes in Cancer
For the past several decades, sequence variants in mitochondrial genes have been
associated with an increased risk of cancer; however, it wasn’t until recently that mutations in the
mtDNA were also reported and linked to the development and progression of cancer (Horton et
al., 1996; van Gisbergen et al., 2015). Recent studies have demonstrated the importance of
mtDNA in cancer cells by replacing the cancer cell mtDNA with normal and pathogenic
mtDNA, resulting in changes in the phenotypes (Ishikawa et al., 2008; Petros et al., 2005;
Shidara et al., 2005). Due to the proximity of the mtDNA to damaging ROS, which is produced
as a byproduct of OXPHOS, mtDNA is more susceptible to mutations. In fact, over 190 tumor-
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specific mtDNA variants have been reported in various cancer types (Brandon, Baldi, &
Wallace, 2006). Many mtDNA variants found in cancer cells inhibit OXPHOS, increase ROS
production, and promote tumor cell proliferation leading to invasion and metastasis (pathogenic
or deleterious mutations). Other variants facilitate in the adaptation of tumor cells to the
environmental conditions and bioenergetic demands of the cell, such as increased tolerance for
high ROS toxicity and exposure to pro-apoptotic conditions, without altering OXPHOS (adaptive
or beneficial mutations) (Ashton, McKenna, Kunz-Schughart, & Higgins, 2018; Brandon et al.,
2006; Wallace, 2012). Therefore, the identification of variants in mtDNA and their effects on
mitochondrial function, OXPHOS, and energy production is essential to determine the relevance
of pathogenic mutations in cancer development.
The mitochondria contain their own transcription and translation machinery, most of
which is encoded in the nuclear genome. Interestingly, sequence variants have been found in
some of the mitochondrial proteins involved in transcription and translation of the mtDNA and
result in changes in the expression of OXPHOS complexes. For example, heterozygous variants
in TFAM were associated with mtDNA depletion, increased mtDNA damage and oxidative
stress, loss of certain OXPHOS complexes, and significant mitochondrial dysfunction in
colorectal cancer (J. Guo et al., 2011; Han et al., 2011; Larsson et al., 1998; Woo et al., 2012).
Additionally, decreases in the expression of MRPs, including mitochondrial ribosomal protein of
the large subunit 11 (MRPL11), were identified by our laboratory and shown to impair OXPHOS
expression and activity in head and neck cancer (E. C. Koc et al., 2015). Sequence variants were
also found in the mitochondrial-encoded tRNAs encoding for tyrosine (Tyr), tryptophan (Trp),
and leucine (Leu) and shown to impair mitochondrial protein synthesis and reduce the expression
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of OXPHOS complexes in liver tumors and breast cancer (Bianchi, Bianchi, & Bailliet, 1995;
Taira, Yoshida, Kobayashi, Yaginuma, & Koike, 1983).
Additionally, variants in the mtDNA encoding for OXPHOS subunits have been reported
in various cancer types. Sequence variants in the coding region of the mtDNA have been found
in colon cancer, endometrial cancer, and cervical cancer (Chinnery, Samuels, Elson, & Turnbull,
2002; Copeland, Wachsman, Johnson, & Penta, 2002; V. W. Liu et al., 2003; Zhai, Chang,
Zhang, Liu, & Wu, 2011). Outside of the control region variants, variants have been reported in
the ND1, ND3, ND4, ND5, and ND6 genes of OXPHOS complex I, which were associated with
structural alterations, decreased complex I activity, and truncated mRNA in renal
adenocarcinoma, osteosarcomas, and invasive breast cancer (Canter, Kallianpur, Parl, &
Millikan, 2005; Horton et al., 1996; Iommarini et al., 2014). Some of these variants were
correlated with decreased OXPHOS activity and expression, increased ROS generation,
increased resistance to apoptosis, and promotion of tumor growth (Cruz-Bermudez et al., 2015;
Ishikawa et al., 2008; L. K. Sharma et al., 2011; van Gisbergen et al., 2015). Sequence variants
were also found in the mitochondrial-encoded COI gene of complex IV in prostate cancer and
epithelial ovarian cancer (Pereira, Soares, Maximo, & Samuels, 2012; Petros et al., 2005).
Interestingly, variants within the mtDNA have been shown to influence cancer progression and
metastasis, and the aggressiveness of cancer is often correlated with the decreased OXPHOS
activity (Dasgupta et al., 2012; Ishikawa et al., 2008; Larman et al., 2012; V. W. Liu et al., 2001;
Petros et al., 2005; Polyak et al., 1998; Simonnet et al., 2002).
During the genetic mapping of oncogenes, sequence variants in the nuclear-encoded
mitochondrial proteins were identified in some cancers. Variants were found in enzymes
involved in metabolic pathways that converge onto OXPHOS, such as fumarate hydratase (FH)
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and isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in numerous cancer types (Frezza et al.,
2011; Lehtonen et al., 2004; Paschka et al., 2010; Picaud et al., 2011; Yan et al., 2009).
Mutations were also found in the nuclear-encoded OXPHOS subunits of complexes I and II and
shown to impair mitochondrial function. Decreases in the expression of NADH:ubiquinone
oxidoreductase core subunit V1 (NDUFV1), NADH:ubiquinone oxidoreductase subunit A13
(NDUFA13), and NADH:ubiquinone oxidoreductase core subunit S3 (NDUFS3) of complex I
were associated with increased metastatic behavior and mesenchymal properties (Gaude &
Frezza, 2014; Kulawiec et al., 2008; Pereira et al., 2012; Taylor et al., 2010), demonstrating the
correlation between epithelial to mesenchymal transition (EMT) induction and OXPHOS
impairment. Additionally, variants were found in three of the subunits of succinate
dehydrogenase (SDH) (complex II), SDH subunit B (SDHB), SDH subunit C (SDHC), and SDH
subunit D (SDHD), in multiple cancer types (Ishii et al., 2005; Janeway et al., 2011; H. J. Kim &
Winge, 2013; Ricketts et al., 2008).
Along with mutations in both nuclear- and mitochondrial-encoded proteins, changes in
the mitochondrial number and amount of mtDNA were also shown to contribute to the decreased
expression of OXPHOS complexes in many cancers including breast cancer, lung cancer, human
hepatocellular carcinoma, non-small cell lung cancer, and gastric cancer (Ashton et al., 2018;
Pedersen, 1978; van Gisbergen et al., 2015; Vyas et al., 2016). Surprisingly, OXPHOS was
upregulated in some cancers such as leukemias, lymphomas, melanomas, ovarian cancer, and
head and neck cancers, due to increased mitochondrial number and mtDNA amount which were
stimulated to compensate for metabolic defects caused by sequence variants and increased
oxidative stress (Ashton et al., 2018; van Gisbergen et al., 2015; Yu, 2011). The mitochondrial
diversity between different cancers and within the same cancer type explains why mitochondrial
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proteins are defined as both tumor suppressors and promotors, stimulate and inhibit
mitochondrial biogenesis, and/or increase and decrease OXPHOS and energy production. These
variations signify that mitochondrial biology and tumorigenic signaling intersects at multiple
levels; therefore, it is essential to identify oncogenic variants or other regulatory mechanisms of
mitochondrial proteins to better understand mitochondrial energy metabolism in cancer.
1.3.2.2. Post-Translational Modifications in Cancer
Post-translational modifications (PTMs) are one of the critical cellular regulatory
mechanisms that affects numerous biological functions and have been associated with the
pathogenesis of many diseases, especially cancer (B.S. Sharma et al., 2019; V. Singh et al., 2017;
Stram & Payne, 2016). PTMs such as acetylation, phosphorylation, methylation, and
ubiquitination have emerged as dynamic regulators of target proteins that play key roles in
cellular processes including signal transduction, cell growth and division, and protein synthesis
(Hofer & Wenz, 2014; Paik, Paik, & Kim, 2007; Park, Jo, Kim, Kim, & Ahn, 2015).
Phosphorylation is the most widespread class of PTMs and one of the most common signaling
mechanisms used in signal transduction (Manning, Whyte, Martinez, Hunter, & Sudarsanam,
2002). Due to its role in the regulation of cellular processes such as cell growth, signaling, and
apoptosis in the healthy condition, deregulation of the signaling cascade and alterations in other
phosphorylated pathways result in various cancer types (Hofer & Wenz, 2014; Marmiroli,
Fabbro, Miyata, Pierobon, & Ruzzene, 2015; V. Singh et al., 2017). In cancer, overactive protein
kinases are often due to an overexpression of activated kinases and/or mutations in the kinase
genes that hold the kinases in an activated conformation (Marmiroli et al., 2015), resulting in
stimulated signal transduction and increased cancer cell growth or metastasis.
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Although serine (Ser) and threonine (Thr) phosphorylation have been well studied and
identified as the most prevalent forms of phosphorylation, tyrosine (Tyr) phosphorylation has
recently emerged as a major cellular regulatory mechanism (Z.Chen et al., 2016; Du, Zhang,
Hassan, Biswas, &Balaji, 2010; Hofer & Wenz, 2014; Roskoski, 2005; B.S. Sharma et al., 2019).
Alterations in the pathways caused by deregulated kinases result in several cancer types. In fact,
the greatest number of oncoproteins are encompassed within the Tyr kinase family including
members of the receptor and non-receptor tyrosine kinases (V. Singh et al., 2017; Takeuchi &
Ito, 2011). Tyrosine kinases play critical roles in the modulation of growth factor signaling
(Arora & Scholar, 2005); therefore, activated forms of these kinases cause tumorigenesis by
increasing cell proliferation and growth, inhibiting apoptosis, and inducing metastasis. One of
the major groups of tyrosine kinases commonly deregulated in cancer is the Src family kinases
(SFKs). The Src family non-receptor protein tyrosine kinases play vital roles in the signal
transduction pathways and are capable of inducing malignant transformations in epithelial and
non-epithelial cancer types such as colorectal, breast cancer, liver cancer, melanomas, head and
neck cancer, lung cancer, brain cancer, pancreatic cancer, and blood cancers (Sen & Johnson,
2011; Summy & Gallick, 2003; Yeatman, 2004; J. Zhao et al., 2013; R. Zhao et al., 2015). SFKs
play prominent roles in tumor invasion and progression, metastasis, angiogenesis, epithelial-tomesenchymal transition, resistance to apoptosis, and cell proliferation and migration (Sen &
Johnson, 2011; Summy & Gallick, 2003). The contribution of SFKs to tumor development and
progression remain to be completely defined, although are further discussed in this dissertation.
Interestingly, along with cell signaling pathways, SFKs have been shown to regulate
numerous mitochondrial pathways, especially those involved in energy metabolism (HebertChatelain, 2013; Hebert-Chatelain et al., 2012; Miyazaki, Neff, Tanaka, Horne, & Baron, 2003;
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Salvi, Brunati, & Toninello, 2005). In fact, only five SFKs have been located within the
mitochondria (Miyazaki et al., 2003; Salvi et al., 2002; Salvi et al., 2005; Vahedi, S., Chueh,
Chandran, & Yu, 2015). Two of these mitochondrial SFKs, c-Src and Fyn, are ubiquitously
expressed in all cell types and have been shown to regulate mitochondrial functions (HebertChatelain, 2013; Hebert-Chatelain et al., 2012; E. C. Koc, Miller-Lee, & Koc, 2016; Thomas,
Soriano, & Imamoto, 1995); yet their roles in the regulation of mitochondrial energy metabolism
and OXPHOS in cancer are largely unknown. Since mitochondrial dysfunction is one of the
hallmarks of cancer and SFKs have been shown to contribute to cancer development by the
induction of the Warburg effect, a better understanding of the role of SFKs in the regulation of
mitochondrial energy metabolism in cancer is essential. The effect of SFKs, c-Src and Fyn, on
mitochondrial energy metabolism in health and disease, along with potential treatment options to
inhibit SFKs and improve mitochondrial function and slow liver cancer progression, are explored
in this dissertation.
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CHAPTER 2
THE REGULATION OF MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION
AND ENERGY METABOLISM BY SRC FAMILY KINASES

2.1. Mitochondrial Regulation by Tyrosine Phosphorylation
Mitochondria are the major metabolic hubs of the cell and are crucial for energy
generation and dysfunction of any of these pathways can lead to oxidative stress, energy
deprivation, and the development of various pathologies. Therefore, due to their essential role in
the cell, mitochondrial functions need to be tightly regulated, making many of the auxiliary
factors involved in these processes targets for regulatory interventions. In the last several
decades, post-translational modifications have emerged as powerful regulators of mitochondrial
processes (Hofer & Wenz, 2014; E. C. Koc & Koc, 2012). Although acetylation has been
frequently studied and shown to play a critical role in the regulation of mitochondrial energy
metabolism in mammals (Guan & Xiong, 2011; E. C. Koc & Koc, 2012; Lu, Scott, Webster, &
Sack, 2009; Sack, 2011), phosphorylation was identified as one of the primary ways to regulate
mitochondrial processes to rapidly adjust protein activity without permanently altering its
structure (Hebert-Chatelain, 2013).
Recently, Tyr phosphorylation has emerged as a major regulator of cellular pathways and
has become more crucial as a regulator of mitochondrial proteins (Hebert-Chatelain, 2013; Salvi
et al., 2005). In fact, of the 90 Tyr kinases identified in the human genome by Manning et al., 25
were located within the mitochondria (Manning et al., 2002; Pagliarini & Dixon, 2006;
Roskoski, 2004). Of these 25 mitochondrial Tyr kinases, several belong to one of the major
family of non-receptor Tyr kinases, Src family kinases (SFKs) (Manning et al., 2002; Salvi et al.,
2002). To date, several SFK members have been shown to phosphorylate mitochondrial proteins
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and regulate mitochondrial function and bioenergetics within the cells (Hebert-Chatelain et al.,
2012; E. C. Koc et al., 2016; Miyazaki et al., 2003; Salvi et al., 2002; Salvi, Morrice, Brunati, &
Toninello, 2007; Vahedi, Chueh, Chandran, & Yu, 2015), establishing their regulatory role on
mitochondrial energy metabolism.
2.2. Src Family Kinases
c-Src is a non-receptor SFK that has been under investigation for several decades and has
been shown to play key roles in a number of different cellular pathways, including cell growth
and division, cell motility, differentiation, morphology, and survival (G. S. Martin, 2001;
Roskoski, 2004, 2005). In 1911, Peyton Rous studied the Rous Sarcoma virus (RSV) and
identified a transforming viral protein responsible for the development of chicken tumors, v-Src,
along with its cellular homologue, c-Src, which were both established as activated tyrosine
kinases (Brown & Cooper, 1996; Collett & Erikson, 1978; Czernilofsky et al., 1980; Levinson,
Oppermann, Levintow, Varmus, & Bishop, 1978; Rous, 1911; Stehelin, Varmus, Bishop, &
Vogt, 1976). In fact, due to these findings, c-Src became the first molecularly defined and
characterized proto-oncogene. c-Src was encoded in a physiological gene in normal cells which
resulted in an investigation of its function and a search for other related proteins. This led to the
discovery of 11 proteins that had similar amino acid sequence homology, structural features, and
functions to c-Src which formed what is now known as the SFKs: Fyn, Yes, Yrk, Blk, Fgr, Hck,
Lck, Lyn, Frk, Srm, and Brk (Brown & Cooper, 1996; Manning et al., 2002; Thomas & Brugge,
1997).
The SFKs can be divided into 3 groups of enzymes based on their sequence homology:
group I includes c-Src, Yes, Fyn, and Fgr, group II is made of Blk, Lyn, Lck, and Blk, and the
distantly related group III consists of Frk, Srm, and Brk. These kinases have been found in
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multiple different cell types with a restricted pattern of expression; however, three of the kinases,
c-Src, Yes, and Fyn, are expressed in all cell types (Brown & Cooper, 1996; Thomas & Brugge,
1997). SFKs regulate many cellular pathways and couple with distinct cellular targets to activate
downstream signaling to promote cell survival (Thomas & Brugge, 1997). SFKs are controlled
and activated by a diverse class of cellular receptor tyrosine kinases (RTKs), including G-protein
coupled receptors, integrin receptors, steroid hormone receptors, epidermal growth factor
receptor (EGFR), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF),
and cytokine receptors (Fleming et al., 1997; W. Mao et al., 1997; Munshi, Groopman, Gill, &
Ganju, 2000; Thomas & Brugge, 1997). Additionally, the activation of c-Src and SFKs can lead
to the upregulation of secretory factors involved in metastasis, migration, proliferation, adhesion,
and invasion. SFKs are key downstream transducers that initiate cell signaling to promote
survival by stimulating cellular growth and proliferation and maintaining cellular functions.
More importantly, five of the SFK members are translocated into the mitochondria and regulate
cellular energy metabolism, as shown in Fig. 3.
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Figure 3. Src signaling pathways. Src interacts with multiple receptor tyrosine kinases
(RTKs) including insulin-like growth factor-1 receptor (IGF-1R), human epidermal
growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), plateletderived growth factor receptor (PDGFR), and c-Met (Met), and activated their
downstream signaling to promote cell survival. Additionally, Src is also activated by
these RTKs as well as integrins and the erythropoietin receptor (E-cadherin), and other
downstream signaling events such as the loss of phosphatase and tensin homolog
(PTEN). The activation of Src leads to other cellular signaling events including the
activation of Akt for cell growth and proliferation, the activation of signal transducer and
activator of transcription 3 (STAT3), and upregulation of secretary factors that are
involved in metastasis, migration, proliferation, adhesion and invasion. Matrix
metalloproteinases (MMPs) promote the breakdown of the extracellular matrix for the
invasion of the surrounding tissue, while the production of interleukin-8 (IL-8) and
vascular endothelial growth factor (VEGF), signaling molecules that promote tumor
angiogenesis, are increased by c-Src activation. Five of the Src family kinase members
(Fgr, c-Src, Fyn, Lyn, and Lck) are translocated into the mitochondria where they
modulate cellular energy metabolism by the phosphorylation of key enzymes involved in
metabolic pathways, including oxidative phosphorylation (OXPHOS). Figure partially
adapted from (Roskoski, 2015; Yeatman, 2004; S. Zhang & Yu, 2012).
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2.3. Organization of SFKs
The human c-Src gene encodes a protein that is 536 amino acids long, roughly 52-62
kilodaltons (kDa), while the chicken c-Src gene encodes a protein that has 533 residues and
exhibits 99.6% sequence identity to the human c-Src gene with the largest variation near the Nterminus (Roskoski, 2015). Interestingly, c-Src, Yes, and Fyn have a high sequence homology of
roughly 77-84% identity in their conserved regions (E. C. Koc et al., 2016) with an even higher
percentage of sequence identity in their kinase domains, described below. Their high sequence
homology causes them to have overlapping functions that make them redundant and able to
compensate for the loss of each other to maintain cellular functions (Thomas et al., 1995).
Although many studies have been performed with the human c-Src kinase, the numbering system
from the chicken c-Src kinase is historically used in most of the literature and will be used in the
remainder of this dissertation, unless otherwise stated.
2.3.1. SFK Domain Organization
The SFKs display similar kinase structure and domain organization with over 70%
sequence identity between SFK members (Brown & Cooper, 1996). Each kinase is composed of
six distinct regions, from the N- to C- terminus: 1) the N-terminal 14-carbon myristoyl group
attached to the Src homology (SH) 4 domain, 2) the unique region, 3) the SH3 domain, 4) the
SH2 domain, 5) the protein kinase domain (SH1) which is attached to the SH2 domain by a
linker region, and 6) the C-terminal regulatory tail (Boggon & Eck, 2004; Brown & Cooper,
1996), as shown in Fig 4A.
The SH4 domain contains a short N-terminal membrane anchor that encompasses a seven
N-terminal amino acid residue chain and a myristoylation site (or palmitylation in some SFKs)
(Resh, 1993; Thomas & Brugge, 1997), which is required for the attachment of the SFKs to
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cellular membranes and kinase activity (Brown & Cooper, 1996; Kaplan, Mardon, Bishop, &
Varmus, 1988; Roskoski, 2015; Schultz, Henderson, Oroszlan, Garber, & Hanafusa, 1985;
Thomas & Brugge, 1997). Following the SH4 domain is the unique domain which is composed
of 50 to 70 poorly conserved amino acids and is distinct for each family member. It has been
proposed that this unique region is important for the interactions of certain family members with
specific receptors or proteins.
The next three domains, the SH3, SH2, and the protein kinase domain (SH1), are
important for the modular structure of the Src family kinases. The SH3 and SH2 domains are
protein-binding domains that are found in lipid kinases, protein and lipid phosphatases, adaptor
molecules, transcription factors, cytoskeletal proteins, and other proteins, and aid in the binding
of SFKs with their adaptor proteins (B. J. Mayer & Baltimore, 1993; Roskoski, 2004; Thomas &
Brugge, 1997). The SH3 domain binds to proteins containing proline rich motifs (PXXP
consensus), which is important for inter- and intramolecular interactions that recruit substrates,
regulate the catalytic activity, and localize Src kinases (Cohen, Ren, & Baltimore, 1995; Rickles
et al., 1995; Thomas & Brugge, 1997), while the SH2 domain binds to phosphotyrosine sites of
other proteins, preparing the SFKs for activity. Fyn, c-Src, Lck, and Fgr, have preferences to
interact with other proteins that contain the phosphotyrosine motif (pYEEI) compared to other
sequences (B. A. Liu, Engelmann, & Nash, 2012; Superti-Furga, 1995).
The SH1 or kinase domain is made of two lobes that form the catalytic cleft. This domain
provides the enzymatic activity for the SFKs (Brown & Cooper, 1996; Roskoski, 2004; SupertiFurga, 1995) and contains one of the most important Tyr phosphorylation sites, Tyr416, while
the second, Tyr527, resides in the short C-terminal tail that follows the kinase domain. The two
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regulating Tyr residues, Tyr416 and Tyr527, are highly conserved among all SFKs, especially
between c-Src, Yes, and Fyn (Fig. 4B).
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Figure 4. Src family kinase domain structure. A) Six domains compose the structure
of the kinases and are lined from the N-terminal to the C-terminal: the Src homology 4
(SH4) domain (yellow), the unique region (orange), the SH3 domain (green), the SH2
domain (purple), the SH1 or kinase domain (blue) which contains the conserved tyrosine
residue (Tyr416) involved in the activation and autophosphorylation of SFKs, and the Cterminal regulatory tail which encompasses a second conserved tyrosine residue (Tyr527)
that is responsible for keeping the SKFs in the inactive state. B) The conservation
between YES, SRC, and FYN at the activating loop and the C-terminal regulatory tail.
The activating and inhibiting tyrosine residues, Tyr416 and Tyr527, respectively, are
shown in red.
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2.3.2. Activation and Inactivation of SFKs
The activity of SFKs is mainly regulated by the phosphorylation and dephosphorylation
of the two major Tyr residues, Tyr416 and Tyr527. Similar to many Tyr kinases, SFKs are kept
in the inactive state 90-95% of the time (Roskoski, 2015; Salvi et al., 2005; Zheng, Resnick, &
Shalloway, 2000). Under basal conditions, Tyr527 is phosphorylated (pTyr527), binds to the
SH2 domain by intramolecular interactions, and forms a salt bridge. This stabilizes the enzyme
in a dormant or “closed” conformation and inhibits the ability for external ligands to interact
with the SH3 or SH2 domains (Brown & Cooper, 1996; Roskoski, 2004; Thomas & Brugge,
1997). In the closed conformation, Tyr416 is sequestered so it is inaccessible to other kinases
and unable to be phosphorylated, preventing kinase activation (Fig 5A). Both Csk (C-terminal
Src kinase) or Chk kinases are responsible for the phosphorylation of Tyr527 and inactivation of
SFKs (Okada, 2012; Okada & Nakagawa, 1989; Zrihan-Licht et al., 1997).
The activation of SKFs occurs in two steps. In the first step, protein tyrosine
phosphatases, such as the protein tyrosine phosphatase alpha (PTPα), phosphoenolpyruvate
phosphatase (PEP), and Src homology 2 domain-containing protein tyrosine phosphatase 1 and 2
(SHP-1 and SHP-2), displace pTyr527 from the SH2 domain pocket and mediate the
dephosphorylation of Tyr527 (Zheng et al., 2000; Zheng, Wang, & Pallen, 1992). During the
second step, the enzymatic catalytic cleft opens and exposes Tyr416 to autophosphorylation
(Brown & Cooper, 1996; Huse & Kuriyan, 2002; Xu, Doshi, Lei, Eck, & Harrison, 1999).
Tyr416 phosphorylation stabilizes the enzyme in the active conformation and allows for
continued phosphorylation and activation of SFKs by other Tyr kinases (Fig 5B).
SFKs are also redox-sensitive and can be activated by ROS, including hydrogen peroxide
(H2O2) and peroxynitrite (Akhand et al., 1999). In fact, ROS activation of SFKs leads to a third,
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highly active conformation (Giannoni, Buricchi, Raugei, Ramponi, & Chiarugi, 2005; Giannoni,
Taddei, & Chiarugi, 2010; Krasnowska et al., 2008). SFKs contain two conserved, redoxregulated cysteine (Cys) residues at 245 and 487 (Cys245 and Cys487) which are located in the
SH2 and kinase domains, respectively (Giannoni & Chiarugi, 2014; Giannoni et al., 2010). When
the SFK is activated by ROS, these two Cys residues become oxidized, resulting in the formation
of an intramolecular disulfide bond between the SH2 and kinase domain, to protect the
dephosphorylation of Tyr416 and keep the kinase in a highly active conformation (Fig 5C). The
constitutively active kinases can cause significant defects in downstream signaling and can result
in cytoskeletal rearrangement and cell spreading, leading to physiological disturbances and the
development of various diseases, such as cancer (Giannoni et al., 2005).
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Figure 5. Activation of Src family kinases. A) Resting cells exposed to normal
environmental conditions exhibit an inactive (closed) conformation, characterized by
intramolecular interactions between the SH2 domain and the phosphorylated Tyr527 and
associations between the SH3 and linker domain, sequestering Tyr416 in its
dephosphorylated state. B) Once Src is activated in the early stage of cell adhesion or by
growth factor stimulations, phosphorylated Tyr527 (pTyr527) is dissociated from the
SH2 domain and dephosphorylated by several protein tyrosine phosphatases. The
catalytic cleft opens and Tyr416 is autophosphorylated by another Src kinase molecule,
stabilizing the enzyme in its active conformation and allowing for continued
phosphorylation and activation. C) During high ROS generation, Src is oxidized in one or
both of the redox-regulated cysteine residues, Cys245 and Cys487, located in the SH2
domain and kinase domain, respectively, resulting in the formation of an intramolecular
disulfide bond (S-S) between the SH2 and kinase domain, keeping the Src kinase in a
highly active conformation. Activating Tyr residue (green); inactivated Tyr residue (red)
(see text for details). Figure partially adapted from (Giannoni & Chiarugi, 2014).
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2.4. Src Family Kinases and the Mitochondria
2.4.1. Src Kinases are Translocated into the Mitochondria
Recently, five of the SFK members, c-Src, Fyn, Lyn, Fgr, and Lck, along with their
regulator kinase Csk, have been found in the intermembrane space and inner membrane of the
mitochondria in rat brain tissues and cell lines (Miyazaki et al., 2003; Salvi et al., 2002; Salvi et
al., 2005; Vahedi et al., 2015). Additionally, they are activated via phosphorylation by a variety
of mitochondrial signals, such as redox state, ATP level, hypoxia, and calcium concentration
(Hebert-Chatelain, 2013; Hofer & Wenz, 2014; Sato et al., 2005), demonstrating their
significance in the regulation of mitochondrial functions. Although some studies suggested that
these SFKs permanently reside in the mitochondria (Salvi et al., 2005), other studies
demonstrated continuous import and export of SFKs into and out of the mitochondria (Boerner,
Demory, Silva, & Parsons, 2004; Demory et al., 2009).
Since SFKs lack a mitochondrial localization sequence, they rely on interactions with
adaptor proteins to be translocated into the mitochondria. The C-terminal proline-rich motif in
the SH3 domain of SFKs was established as a key player in directing the SFKs to their final
destination, which is carried out by the presence of a localization signal on the SFK interacting
partners. Several proteins including the protein kinase A (PKA) anchoring protein 121/84
(AKAP121/84) and the protein tyrosine phosphatase D1 (PTPD1) (Cardone et al., 2004; Livigni
et al., 2006), the human T-cell leukemia virus type 1 accessory protein p13 (Tibaldi et al., 2011),
and the downstream of Tyr kinase docking protein 4 (Dok-4) (Itoh et al., 2005), are involved in
the translocation of Src kinases into the mitochondria, further highlighting the importance of
these SFKs within the mitochondria.
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2.4.2. Mitochondrial Energy Metabolism is Regulated by SFKs
SFK phosphorylation impacts the function of many mitochondrial proteins, including
those involved in metabolic pathways that feed into and regulate mitochondrial OXPHOS and
energy metabolism (Fig. 6). In fact, several enzymes involved in carbohydrate metabolism,
pyruvate decarboxylation, and the TCA cycle, have been identified as SFK targets.
Mitochondrial translation components, responsible for the synthesis of the 13 core OXPHOS
proteins, as well as the subunits of OXPHOS complexes I-V were also identified as targets for
SFK phosphorylation, summarized in Table 2.
Src family kinases are implicated in the regulation of carbohydrate metabolism
(glycolysis) through the phosphorylation of key enzymes such as glycerol-3-phosphate
dehydrogenase, which links carbohydrate and lipid metabolism, and hexokinases 1 and 2 (HK1
and HK2), which catalyzes the phosphorylation of glucose to glucose-6-phosphate
(Lewandrowski et al., 2008). Although the physiological role of the phosphorylation of glycerol3-phosphate dehydrogenase is unknown, the phosphorylation of HK1 and HK2 by c-Src kinase
was shown to decrease their activities and significantly impair mitochondrial OXPHOS (J.
Zhang et al., 2017). c-Src has also been shown to regulate pyruvate decarboxylation by
phosphorylating PDH and inhibiting its activity (Y. Jin et al., 2016; Lewandrowski et al., 2008;
J. Zhang et al., 2017). Furthermore, the first two steps of the TCA cycle were found to be
phosphorylated by Src kinases. Citrate synthase (CS) and aconitase are phosphorylated by SFKs
(Lewandrowski et al., 2008; Salvi et al., 2007); however, the physiological relevance of these
modifications and their effects on energy metabolism is not currently known. Interestingly,
aconitase is also implicated in the stabilization of mtDNA and iron metabolism; therefore, the
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phosphorylation of aconitase by Fgr at Tyr71, Tyr544, and Tyr665 (Salvi et al., 2007), could
have multiple effects on metabolism, yet these effects remain to be elucidated.
Mitochondrial translation components and, therefore, the expression of OXPHOS
complexes, are also regulated by SFKs. Recently, our group has demonstrated the association of
Fyn kinase with mitochondrial translation machinery, MRPs, and showed an induction of
mitochondrial protein synthesis and OXPHOS expression in liver cancer cell lines (E. C. Koc et
al., 2016). On the contrary, Lck kinase was also reported to interact with mitochondrial
translation machinery by competitively binding to CR6-interacting factor (CRIF1), a
mitochondrial ribosomal protein (E. C. Koc et al., 2013), and inhibiting OXPHOS expression
and activity (Vahedi et al., 2015). Since mitochondrial translation is responsible for the synthesis
of the 13 essential OXPHOS subunits, SFK phosphorylation plays a clear role in regulating
energy metabolism.
In fact, SFKs have also modulated the activity of OXPHOS complexes by directly
phosphorylating their subunits (described in Table 2). Interestingly, the first identified
mitochondrial protein phosphorylated by c-Src kinase was COII, a mitochondrial-encoded
subunit of OXPHOS complex IV (Miyazaki et al., 2003). This phosphorylation event was the
first to demonstrate the regulation of OXPHOS activity by Src-dependent phosphorylation of
OXPHOS complexes. Since then, SFKs have been shown to phosphorylate several subunits from
OXPHOS complexes I-V (Augereau et al., 2005; Hebert-Chatelain et al., 2012; Lewandrowski et
al., 2008; Ogura, Yamaki, Homma, & Homma, 2012; Salvi et al., 2007), summarized in Fig. 6.
The 39 kDa and 75 kDa subunits, NADH dehydrogenase [ubiquinone] flavoprotein 2
(NDUFV2), and NADH:ubiquinone oxidoreductase subunit B10 (NDUFB10) of complex I were
identified as SFK targets (Augereau et al., 2005; Hebert-Chatelain et al., 2012; Ogura et al.,
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2012). Although the physiological relevance of the phosphorylation of the 39 kDa and 75 kDa
subunits remains to be identified, the phosphorylation of the core subunit, NDUFV2, and
NDUFB10 by c-Src is required for the NADH activity and, therefore, increases complex I
activity resulting in stimulated OXPHOS function. Additionally, succinate dehydrogenase
subunit A (SDHA) of complex II, subunits I and II of complex III, and subunits α, β, γ, and ε of
complex V were also phosphorylated by SFKs, with the phosphorylation of complex III and V
leading to a decrease in their complex activities (Augereau et al., 2005; Hebert Chatelain, Dupuy,
Letellier, & Dachary-Prigent, 2011; Lewandrowski et al., 2008).
The phosphorylation of COII by c-Src induced the enzymatic activity of complex IV in
osteoclasts (Miyazaki et al., 2003; Miyazaki, Tanaka, Sanjay, & Baron, 2006). However, when
COII was phosphorylated in combination with the epidermal growth factor receptor (EGFR), the
activity of OXPHOS complex IV was significantly reduced (Boerner et al., 2004; Demory et al.,
2009) implying further studies should be performed to identify the effects of c-Src on COII in
health and disease. In addition to regulating OXPHOS complexes, SFKs also regulate energy
metabolism by targeting the ATP/ADP antiporters, adenine nucleotide translocase 1 and 2
(ANT1 and ANT2), which are involved in transporting ADP to the ATPase (complex V) and
providing ATP to the cell by exporting it from the mitochondria (Lewandrowski et al., 2008),
although the effect of SFK phosphorylation on ANT1 and ANT2 are not yet known. Together,
these studies clearly demonstrate the regulation of mitochondrial energy metabolism through the
phosphorylation of mitochondrial proteins by SFKs in health and disease.
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Figure 6. OXPHOS complex subunits phosphorylated by Src family kinases.
Subunits of oxidative phosphorylation complexes are phosphorylated by Src family
tyrosine kinases to alter ATP production. The yellow stars represent phosphorylation sites
of SFKs that have not been identified, and the green stars represent Tyr phosphorylation
sites of c-Src kinase.
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In addition to energy metabolism, apoptosis is also established as a major factor in
mitochondrial function. Interestingly, SFKs also regulate different mitochondrial-dependent
apoptotic pathways. Lck is involved in the activity of the apoptotic signal transduction pathways
after irradiation and ceramide exposure (Belka et al., 1999; Hur, Yun, & Won, 2004; Manna &
Aggarwal, 2000), and has, therefore, been identified as a positive regulator of apoptosis (Samraj,
Stroh, Fischer, & Schulze-Osthoff, 2006). Lyn was suggested to contribute to apoptosis after
exposure to radiation and the deprivation of growth factors (Qin, Minami, Kurosaki, &
Yamamura, 1997; Uckun et al., 1996), implicating its role in pro-apoptotic events; however, Lyn
was also suggested to preserve mitochondrial integrity and protect against apoptosis during liver
regeneration (Ferri et al., 2005; F. Y. Lee et al., 1999). Other SFKs, such as c-Src, also possess
anti-apoptotic properties (Lluis, Buricchi, Chiarugi, Morales, & Fernandez-Checa, 2007).
Therefore, a better understanding of how these SFKs regulate mitochondrial functions including
OXPHOS and apoptosis is essential for disease prevention.
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Pathway

Target

Residue

Kinase

Alteration

References

Glycerol-3-phosphate
dehydrogenase

Unidentified

Src kinases

Unknown

(Lewandrowski, Sickmann et al. 2008)

Hexokinases 1 and 2

Tyr732 and Tyr686

c-Src kinase

Decreases activity of HK1
and HK2

(Lewandrowski, Sickmann et al. 2008, Zhang,
Wang et al. 2017)

Pyruvate dehydrogenase

Tyr289

c-Src kinase

Decreases activity of PDH

(Jin, Cai et al. 2016)

Aconitase Hydratase

Tyr71, Tyr544, Tyr665

Fgr kinase

Unknown

(Salvi, Morrice et al. 2007)

Citrate Synthase

Unidentified

Src kinases

Unknown

(Lewandrowski, Sickmann et al. 2008)

Ribosomal Proteins

Unidentified

Fyn kinase

Increases protein synthesis

(Koc, Miller-Lee et al. 2016)

CR6-interacting factor 1

Unidentified

Lck kinase

Decreases protein synthesis

(Vahedi, Chueh et al. 2015)

39kDa and 72kDa

Unidentified

Src kinases

Unknown

(Augereau, Claverol et al. 2005)

NDUFV2

Tyr193

c-Src kinase

Increases activity of CI

(Hebert-Chatelain, Jose et al. 2012)

NDUFB10

Unidentified

c-Src kinase

Increases activity of CI

OXPHOS complex II

SDHA

Unidentified

Src kinases

Unknown

OXPHOS complex III

Subunits I and II

Unidentified

Src kinases

Decreases activity of CIII

COII

Unidentified

c-Src kinase

Increases activity of CV

COII

Unidentified

Decreases activity of CIV

α-, β-, γ-, and ε-

Unidentified

c-Src kinase
and EGFR
Src kinases

ATP/ADP translocase 1 and 2

Unidentified

Src kinases

Unknown

(Hebert-Chatelain et al., 2012; Ogura et al.,
2012)
(Augereau et al., 2005; Ogura et al., 2012; Salvi
et al., 2007)
(Augereau et al., 2005; Hebert Chatelain et al.,
2011)
(Augereau et al., 2005; Miyazaki et al., 2003;
Miyazaki et al., 2006)
(Demory, Boerner et al. 2009, Boerner, Demory
et al. 2004)
(Augereau et al., 2005; Hebert-Chatelain et al.,
2012; Hebert Chatelain et al., 2011;
Lewandrowski et al., 2008)
(Lewandrowski, Sickmann et al. 2008)

Creatine kinase

Unidentified

Src kinases

Unknown

(Lewandrowski, Sickmann et al. 2008)

Carbohydrate metabolism
(glycolysis)

TCA cycle/CAC

Protein Synthesis

OXPHOS complex I

OXPHOS complex IV

OXPHOS complex V

Decreases activity of CV

Apoptosis (MPTP)

Table 2. Mitochondrial pathways that are regulated by Src family kinases. Individual targets, modified residues, the
respective modifying Src family kinase, and the physiological role from each modification is listed.
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2.5. SFK Signaling and Cancer
Alterations in the expression of SFKs have been shown to contribute to the initiation and
progression of multiple diseases including neurological disorders (Alzheimer’s and Parkinson’s
disease), metabolic syndrome, diabetes, and various types of cancer (Elias & Ditzel, 2015; Irby
& Yeatman, 2000; Lu et al., 2009; K. Yang et al., 2011; Yeatman, 2004). Many SFK members
have been established and characterized as proto-oncogenes (Brown & Cooper, 1996;
Czernilofsky et al., 1980; Irby & Yeatman, 2002; L. C. Kim, Song, & Haura, 2009; M. P. Kim,
Park, Kopetz, & Gallick, 2009; Stehelin et al., 1976). Surprisingly, to date, no somatic mutations
have been identified in SFK genes (Frame, 2004; Yeatman, 2004); therefore, dysregulation of
their activities play critical roles in the etiology of cancer. In fact, aberrant activation is
implicated in disease development, growth, and progression due to the induction of multiple
malignant properties of SFKs including proliferation, invasion, angiogenesis, and metastasis
(Elsberger, 2014; M. P. Kim et al., 2009; Yeatman, 2004), linking SFKs to both tumorigenicity
and metastasis (Brown & Cooper, 1996; Irby & Yeatman, 2000). c-Src kinase is the SFK
member most often implicated in cancer and increased expression and/or activity has been
reported in a variety of human cancers including ovarian, lung, breast, colorectal, pancreatic,
brain, gastric, liver, melanoma, and leukemia (Dai et al., 1998; Irby & Yeatman, 2002; Rosen et
al., 1986; Yeatman, 2004). Aberrant expression and activity of c-Src has been positively
correlated with cancer stage, disease recurrence, and adverse prognosis, and is frequently
associated with increased cancer metastasis and resistance to treatments (Elsberger, 2014; Irby &
Yeatman, 2000; E. L. Mayer & Krop, 2010; Yeatman, 2004; S. Zhang et al., 2011). These
findings demonstrate the need for a better understanding of the involvement of c-Src in cancer
types, which can be used for the development of novel treatments.
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Liver cancer is one of the most common cancer types that is increasing due to the rising
rates of obesity and metabolic syndrome and is the sixth major cause of cancer mortality in men
(Walker et al., 2019). Approximately 85-90% of primary liver cancers occurring are
hepatocellular carcinoma (HCC) (El-Serag & Rudolph, 2007; Ren, Fang, Ding, & Chen, 2016;
Torre et al., 2015). HCC is one of the most metastatic and malignant cancers and is strongly
associated with poor prognosis, recurrence, and resistance to treatments (Daher, Massarwa,
Benson, & Khoury, 2018; Pang et al., 2008; Ren et al., 2016). Due to the high recurrent and
metastatic nature of HCC, the five-year survival rate is low (R. Zhao et al., 2015); therefore, the
identification of oncogenes involved in HCC progression are essential to the prevention and
treatment.
The overexpression and/or increased activity of c-Src has been found in HCC (Masaki et
al., 1998; Sun et al., 2008; R. Zhao et al., 2015). Aberrant c-Src activity was suggested to
contribute to the malignant transformation of hepatocytes and the poor prognosis of patients
(Masaki et al., 1998). Interestingly, oxidative stress, which is strongly associated with
mitochondrial dysfunction, was indicated as a contributor to HCC carcinogenesis (Hsu, Lee, &
Wei, 2013; Klaunig & Kamendulis, 2004; Kumar, Zhao, & Wang, 2011), and is an activator of
c-Src kinase. In fact, c-Src has been shown to alter mitochondrial function and energy
metabolism by phosphorylating mitochondrial proteins and is implicated in promoting the
Warburg effect and malignant properties in various cancer types (Y. Jin et al., 2016; Wallace,
2012; J. Zhang et al., 2017). Previous studies have shown c-Src phosphorylation of HK1 and
HK2 at Tyr732 and Tyr686, respectively, in addition to PDH at Tyr289 in cancer cells which
inhibited their activities, promoted the glycolytic flux and increased glycolysis, impaired
OXPHOS function and ATP synthesis, and contributed to the Warburg effect and the
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development of cancer (Y. Jin et al., 2016; J. Zhang et al., 2017). Additionally, c-Src promoted
the metastatic phenotype by increasing cell proliferation and enhancing angiogenesis (Fleming et
al., 1997; W. Mao et al., 1997; Munshi et al., 2000) as well as stimulating the cell cycle
progression to prevent apoptosis by increasing the expression of B-cell lymphoma-extra-large
(Bcl-XL) (Karni, Jove, & Levitzki, 1999) and activating Stat3 (Bromberg et al., 1999; CatlettFalcone et al., 1999).
c-Src plays a critical role in cell growth and maintenance; however, the overactivation of
c-Src leads to malignant phenotypes found in cancer. The presence of c-Src and other SFKs
within the mitochondria in cancer cells not only implies their role in mitochondrial dysfunction
and cancer development (Demory et al., 2009; Hebert-Chatelain et al., 2012; E. C. Koc et al.,
2016), but it also demonstrates that mitochondrial metabolism is essential to cancer cell growth,
especially since mitochondria are also essential for the biosynthetic machineries of lipids,
proteins, and nucleic acids which are largely derived from the TCA cycle. Therefore, a better
understanding of the role of c-Src, and other SFKs, in mitochondrial energy metabolism in
different cancer cell types needs to be established. Furthermore, identifying direct pathways and
substrates regulated by SFKs can make them pharmacological tools for drug development to
allow for improved mitochondrial function. Aberrant expression of c-Src was clearly implicated
in the progression of HCC, which is also associated with high oxidative stress. Yet, the role of cSrc on mitochondrial dysfunction in liver cancer remains to be elucidated.
2.6. SFKs as Drug Targets
Due to the increased expression of SFKs in a large number of human cancers, they have
become promising targets for cancer therapies (Blake et al., 2000; Hanke et al., 1996; Roskoski,
2015; S. Zhang & Yu, 2012). To date, only five orally effective multi-kinase inhibitors have
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been approved by the Food and Drug Administration (FDA). In fact, Vandetanib and Sarcatinib
were initially developed as SFK inhibitors, while other inhibitors such as Bosutinib, Dasatinib,
and Ponatinib were developed as multi-kinase inhibitors and demonstrated to target SFKs
(Boschelli et al., 2004; Hennequin et al., 2006; W. S. Huang et al., 2010; Lombardo et al., 2004;
Nowak et al., 2007). Although Vandetanib, Ponatinib, and Sarcatinib were shown to target all
SFKs, Bosutinib and Dasatinib were shown to target specific SFKs c-Src, Lyn, and Hck and cSrc, Lck, Fyn, and Yes, respectively. These inhibitors have been used to target specific cancer
types, such as small cell lung, colorectal, and ovarian cancers; however, they are currently
undergoing additional clinical trials to be used for the treatments of other cancers.
In addition to these FDA-approved drugs for cancer treatments, other SFK inhibitors such
as 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2) and 2,3Dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1H-indole-5sulfonamide (SU6656) have been evaluated for their potential use in cancer treatments (Blake et
al., 2000; Finn et al., 2013; Hanke et al., 1996; Lau et al., 2009; E. L. Mayer & Krop, 2010). PP2
and SU6656 are small molecule inhibitors that block the ATP binding site of the ubiquitously
expressed SFK members c-Src, Yes, Fyn, and Lyn (Blake et al., 2000; Hanke et al., 1996). While
these inhibitors have been proven effective in reducing cell proliferation, and decreased cancer
progression by suppressing SFK activity (Finn et al., 2013; H. Guo et al., 2016; Zhu et al., 2018),
clinically significant data is limited. Unfortunately, breast cancer, HCC, and others are highly
metastatic and resistant to conventional cancer treatments, only providing the ability to
minimally extend the life expectancy of patients (E. L. Mayer & Krop, 2010; Salem, WhitakerMenezes, Howell, Sotgia, & Lisanti, 2012; Wu et al., 2018; S. Zhang et al., 2011; R. Zhao et al.,
2015). Currently, the multi-kinase inhibitor Sorafenib is the only approved drug for the systemic
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treatment of HCC; however, it only extends the life of patients by 3-4 months (Daher et al.,
2018; Llovet et al., 2008; Wilhelm et al., 2008), demonstrating a need for alternative treatment
options.
2.6.1. Natural Antioxidants as SFK Inhibitors
Increased levels of ROS have been found in various cancer types and are often associated
with mitochondrial OXPHOS dysfunction (Delmas, Jannin, Cherkaoui Malki, & Latruffe, 2000;
H. Guo et al., 2016; Liao et al., 2010; Zhu et al., 2018). Due to high levels of ROS in cancer and
the ability of ROS to activate SFKs, natural antioxidants such as kaempferol and resveratrol have
been evaluated as chemotherapeutic agents and Src kinase inhibitors. Kaempferol and resveratrol
are both naturally occurring antioxidants that have anti-tumor, anti-inflammatory, and chemopreventative pharmacological activities (H. Guo et al., 2016; Y. B. Huang et al., 2014; Liao et
al., 2010; M. Singh, Kaur, & Silakari, 2014; Udenigwe, Ramprasath, Aluko, & Jones, 2008; Zhu
et al., 2018). Kaempferol belongs to the flavonoid family that also has anti-diabetic effects (A. Y.
Chen & Chen, 2013). Our laboratory has previously demonstrated increased mitochondrial
complex II activity with kaempferol treatment, demonstrating improved mitochondrial function
(Cimen et al., 2010). Additionally, previous studies demonstrated reduced cell proliferation,
migration, invasion, and apoptosis in the liver cancer cell line, HepG2, when cells were treated
with kaempferol (H. Guo et al., 2016; Zhu et al., 2018). Resveratrol is a polyphenol that has
many protective effects against cardiovascular disease, age-related deterioration, and cancer
(Baur, 2010; Jang et al., 1997). Resveratrol has been shown to reduce cell growth and
proliferation by inhibiting the cell cycle and inducing apoptosis in various cancer types including
liver and breast cancer (Delmas et al., 2000; Kocsis, Marcsek, Jakab, Szende, & Tompa, 2005;
Liao et al., 2010; Nakagawa et al., 2001). Resveratrol induces apoptosis by stimulating the
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production of intracellular ROS to activate the ROS-dependent apoptotic pathways (Miki et al.,
2012). Similarly, resveratrol treatments have also been reported to increase mitochondrial
function in cancer cells (Haohao, Guijun, Juan, Wen, & Lulu, 2015; Lagouge et al., 2006).
Interestingly, both kaempferol and resveratrol have been shown to have inhibitory effects on Src
pathways (K. M. Lee et al., 2010; Oz et al., 2019). Kaempferol acts similarly to PP2 and SU6656
by blocking the ATP binding site of Src kinases, inhibiting the activity, and preventing
downstream signaling (K. M. Lee et al., 2010). Although these two antioxidants show promise as
SFK inhibitors, their effects on mitochondrial OXPHOS and energy metabolism remains to be
elucidated. Due to the aberrant expression of c-Src and its regulatory role in the metabolic
reprogramming of cancer cells by altering mitochondrial function, understanding the impact of
these inhibitors on mitochondrial energy metabolism will prove to be therapeutically beneficial.
2.7. Research Specific Aims and Hypotheses
Specific Aims
Mitochondrial translation is responsible for producing 13 essential subunits of oxidative
phosphorylation (OXPHOS) complexes in mammals. The mitochondria produce the majority of
the cell’s energy by OXPHOS; therefore, protein synthesis is critical for mitochondrial energy
production. Mitochondrial dysfunction is often found to be associated with obesity, type 2
diabetes (T2D), and cancer (Kelley et al., 2002; J. A. Kim et al., 2008; Wallace, 1999, 2012).
Although several studies have demonstrated diminished mitochondrial energy metabolism in
obesity and T2D subjects, the mitochondrial molecular pathogenesis of the disease remains to be
discovered. Sequence variants in mitochondrial genes involved in mitochondrial protein
synthesis, such as Dars2 and several mitochondrial proteins, along with variants in OXPHOS
complex subunits, Sdhc and Ndufs2, have been identified in the human obesity and type 2
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diabetes model, TALLYHO/Jng (TH) mice. For this reason, impaired mitochondrial protein
synthesis and oxidative energy metabolism results in mitochondrial dysfunction which can
contribute to the development of obesity and T2D in TH mice.
Post-translational modifications (PTMs) have been shown to be a regulatory mechanism
for many mitochondrial processes; however, the regulation of mitochondrial OXPHOS complex
expression and energy metabolism remains to be elucidated. The Src family kinases (SFKs) cSrc and Fyn are expressed in all cell types and have been located within the mitochondria where
they are involved in the phosphorylation and regulation of mitochondrial proteins (HebertChatelain, 2013; Miyazaki et al., 2006; Salvi et al., 2005). These kinases are activated by cellular
reactive oxygen species (ROS), a byproduct of OXPHOS (Giannoni et al., 2005). In fact, in one
of the most common and malignant cancers, human hepatocellular carcinoma (HCC), increased
c-Src expression and activity was reported and correlated with disease progression and cancer
metastasis (Masaki et al., 1998; Zhao et al., 2015). Although c-Src phosphorylates many
mitochondrial proteins, its role in the regulation of mitochondrial energy metabolism in health
and disease, such as liver cancer, has yet to be established. Therefore, due to the essential role
of mitochondria in energy metabolism, deregulation of mitochondrial OXPHOS complex
expression by increased c-Src expression and activation may result in dysfunctional energy
metabolism.
Additionally, elevated Fyn kinase expression has been reported in liver cancer and shown
to alter mitochondrial energy metabolism by stimulating mitochondrial protein synthesis (E. C.
Koc et al., 2016). Hyperactivation of Fyn, along with other SFKs, has contributed to the
development and progression of metabolic diseases such as neurodegeneration and cancer.
However, many patients are becoming resistant to available treatment options due to the
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increased activity of SFKs, leading to investigations in alternative treatments such as natural
antioxidants. Therefore, a better understanding of Fyn kinase in cellular signaling and the
regulation of mitochondrial energy metabolism is necessary for the development of novel
therapeutic strategies to improve disease prognosis. For this reason, the inhibition of Fyn
kinase activity may improve mitochondrial function and energy metabolism and slow
metabolic disease progression. Our studies will help devise mechanisms for how c-Src and Fyn
regulate mitochondrial energy metabolism and oxidative phosphorylation as well as the
development of therapeutic tools for combating mitochondrial dysfunction in metabolic diseases.

Aim 1: Determine the changes in oxidative phosphorylation and mitochondrial biogenesis
in human obesity and type 2 diabetes model, TALLYHO/Jng mice.
Previous studies have implicated mitochondrial dysfunction as an underlying factor in the
development of obesity, insulin resistance, and type 2 diabetes (T2D) (Kelley et al., 2002; J. A.
Kim et al., 2008; Petersen et al., 2003). Reduced energy expenditure and sequence variants in
mitochondrial proteins have been reported in the human obesity and T2D model TALLYHO/Jng
(TH) mice (Denvir et al., 2016; X. Mao, Dillon, McEntee, Saxton, & Kim, 2014), implying that
TH mice may have impaired mitochondrial function. We hypothesize that the mitochondrial
sequence variants identified in the whole genome analysis of TH mice would affect oxidative
phosphorylation and contribute to the obesity and insulin resistant phenotypes. In an effort to
uncover the role of mitochondrial function in TH mice, we will investigate differences in the
expression and activity of OXPHOS complexes. Additionally, the transcription and translation of
nuclear- and mitochondrial-encoded OXPHOS subunits will be evaluated in mitochondrial-rich
tissues (i.e. the liver and kidney) of TH and C57BL/6J (B6) mice. The role of the sequence
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variants identified in TH mice will be observed and discussed. The results from this aim will
identify factors that contribute to mitochondrial dysfunction in obesity and T2D and allow us to
improve disease prognosis and treatment.

Aim 2: Investigate the role of c-Src on mitochondrial OXPHOS complex expression and
activity in liver cancer.
Src family kinases (SFKs) have been shown to regulate mitochondrial energy metabolism in
normal and cancer cells. In fact, dysregulation of SFK activities have been shown to contribute
to the development and progression of cancer. Several studies have reported high c-Src
expression and activity in human hepatocellular carcinoma (HCC) which is correlated to disease
stage (Masaki et al., 1998; R. Zhao et al., 2015). c-Src kinase has also been shown to contribute
to mitochondrial dysfunction and the Warburg effect (Y. Jin et al., 2016; Wallace, 2005; J.
Zhang et al., 2017). We hypothesize that c-Src kinase expression and activity is increased in
metastatic liver cancer tissues and cell lines and is associated with decreased expression of
OXPHOS complex subunits, which can be reversed when treated with SFK inhibitors and c-Src
siRNA. To determine the role of c-Src on mitochondrial energy metabolism in liver cancer, noncancerous and cancerous liver biopsies from patients and common liver cancer cell lines, Hep3B
and HepG2, will be evaluated for the expression of c-Src and the phosphorylation and activation
of c-Src at Tyr416 (pSFK), along with changes in the expression and activity of OXPHOS
complexes. Once the association between c-Src and OXPHOS complex expression is determined
in the liver cancer tissues and cell lines, the cells will be treated with the SFK inhibitor PP2 and
transfected with c-Src specific siRNA to observe changes in c-Src phosphorylation, OXPHOS
complex expression and activity, and cell proliferation. Additionally, we will compare the results
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from the liver cancer studies to studies using multiple mouse embryonic fibroblast cell lines with
varying expressions of c-Src to observe if similar effects are found in normal cells. The results
from this aim will reveal the correlation between c-Src and mitochondrial OXPHOS complex
expression in both health and disease. The findings will also allow us to have a better
understanding of how c-Src kinase alters energy metabolism and responds to SFK inhibitors to
develop better treatment options for cancers with high c-Src expression and/or activity.

Aim 3: Identify the effects of Fyn kinase inhibition with natural antioxidants on
mitochondrial energy metabolism and oxidative phosphorylation in metabolic diseases.
SFK inhibitors, as well as natural antioxidants kaempferol and resveratrol which have also been
reported to have inhibitory effects on Src kinase pathways (Finn et al., 2013; Lau et al., 2009; K.
M. Lee et al., 2010; E. L. Mayer & Krop, 2010; Oz et al., 2019), have been investigated as
potential therapies. Interestingly, Fyn kinase was shown to be a contributing factor to several
metabolic disorders; however, the effects of Fyn kinase and mitochondrial energy metabolism
are largely unknown. Recently, our laboratory has shown Fyn kinase is associated with and
phosphorylates mitochondrial translation components and increased OXPHOS complex
expression (E. C. Koc et al., 2016). We hypothesize that treatment of liver cancer cell lines with
the SFK inhibitor, SU6656, and natural antioxidants, kaempferol and resveratrol, will impair Fyn
activity and OXPHOS expression while reducing oxidative stress and decrease cell proliferation.
To identify the effects of Fyn inhibition on OXPHOS complex expression, we will examine the
changes in the expression of OXPHOS complexes and cell proliferation when Hep3B and
HepG2 liver cancer cell lines are treated with SU6656, kaempferol, and resveratrol. The results
from this aim will identify the effects of Fyn inhibition on mitochondrial oxidative
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phosphorylation. These findings will also provide us with a better understanding of the effects of
Fyn inhibition on mitochondrial function and cell proliferation. In addition, the data will allow us
to better evaluate SU6656, kaempferol, and resveratrol as SFK inhibitors to help develop better
treatment options to improve mitochondrial function and prevent the progression of metabolic
disorders.
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Abstract
Type 2 diabetes has become an epidemic disease largely explained by the dramatic
increase in obesity in recent years. Mitochondrial dysfunction is suggested as an underlying
factor in obesity and type 2 diabetes. In this study, we evaluated changes in oxidative
phosphorylation and mitochondrial biogenesis in a new human obesity and type 2 diabetes
model, TALLYHO/Jng mice. We hypothesized that the sequence variants identified in the whole
genome analysis of TALLYHO/Jng mice would affect oxidative phosphorylation and contribute
to obesity and insulin resistant phenotypes. To test this hypothesis, we investigated differences in
the expression and activity of oxidative phosphorylation complexes, including the transcription
and translation of nuclear- and mitochondrial-encoded subunits and enzymatic activities, in the
liver and kidney of TALLYHO/Jng and C57BL/6J mice. A significant decrease was observed in
the expression of nuclear- and mitochondrial-encoded subunits of complex I and IV,
respectively, in TALLYHO/Jng mice, which coincided with significant reductions in their
enzymatic activities. Furthermore, sequence variants were identified in oxidative
phosphorylation complex subunits, a mitochondrial tRNA synthetase, and mitochondrial
ribosomal proteins. Our data suggested that the lower expression and activity of oxidative
phosphorylation complexes results in the diminished energy metabolism observed in
TALLYHO/Jng mice. Sequence variants identified in mitochondrial proteins accentuated a
defect in mitochondrial protein synthesis which also contributes to impaired biogenesis and
oxidative phosphorylation in TALLYHO/Jng mice. These results demonstrated that the
identification of factors contributing to mitochondrial dysfunction will allow us to improve the
disease prognosis and treatment of obesity and type 2 diabetes in humans.
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Highlights
Mitochondrial oxidative phosphorylation is impaired in TALLYHO/Jng mice.
Expression and activities of complex I and IV are diminished in TALLYHO/Jng mice.
Impaired mitochondrial protein synthesis is one of the contributing factors.
Mitochondrial sequence variants may contribute to mitochondrial biogenesis defects.

3.1. Introduction
Diabetes and obesity are two of the major metabolic diseases worldwide that are
becoming an epidemic due to an increase in sedentary lifestyles. Type 2 diabetes (T2D) accounts
for at least 90% of the diabetic cases and is commonly associated with an increased risk for
morbidity and mortality (Bouret, Levin, & Ozanne, 2015; Romao & Roth, 2008). The etiology of
obesity and T2D involves complex interactions of several susceptibility genes and environmental
factors, making disease prevention difficult (Bouret et al., 2015; Romao & Roth, 2008). Animal
models with both physiologic and genetic similarities to humans have become valuable resources
for obesity and T2D studies; however, to date, only a few polygenic animal models exist (Rees &
Alcolado, 2005). Recently, TALLYHO/Jng (TH) mice were developed as models for human
obesity and type 2 diabetes (J. H. Kim et al., 2001). The polygenic pattern of inheritance in TH
mice closely resembles the genetic inheritance in humans, making these mice ideal models for
the identification of underlying molecular defects in diabetes and obesity related abnormalities
(Grarup, Sandholt, Hansen, & Pedersen, 2014; J. H. Kim & Saxton, 2012).
TH mice encompass many aspects of the human T2D condition and are characterized by
obesity, glucose intolerance, insulin resistance, hyperinsulinemia, hyperlipidemia, and
hyperglycemia (in male mice) (J. H. Kim et al., 2006; J. H. Kim et al., 2005). Additionally, these
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mice are also accompanied by lower energy expenditure and locomotor activity (X. Mao et al.,
2014). Previous studies have suggested that the diet is an important modulator of susceptibility to
obesity and T2D when TH mice are fed a high fat diet (Parkman et al., 2016). Interestingly, the
diabetic condition was ameliorated and metabolic flexibility was significantly improved in TH
mice treated with Bezafibrate (BEZ), a pan PPAR (peroxisome proliferator-activated receptor)
activator (Franko et al., 2017). Several mapping studies were performed to identify significant
quantitative trait loci (QTLs) that are linked to the obesity, diabetes, and hyperlipidemia
phenotypes present in TH mice (J. H. Kim et al., 2005; Parkman et al., 2017; Stewart, Kim,
Saxton, & Kim, 2010). Additionally, whole genome sequencing was also performed to identify
causal variants of underlying metabolic diseases found in this animal model (Denvir et al., 2016).
Mitochondrial dysfunction, including impaired mitochondrial biogenesis, was established
as a contributing factor to insulin resistance in obesity and T2D (Kelley et al., 2002; Patti et al.,
2003; Petersen et al., 2003). Mitochondrial biogenesis relies on the coordinated regulation of
both nuclear and mitochondrial protein expression for energy metabolism via oxidative
phosphorylation (OXPHOS). In mammals, mitochondrial biogenesis is regulated by PPAR
coactivator-1 alpha (PGC-1α), a transcriptional coactivator that interacts with nuclear respiratory
factor 1 (NRF-1) and stimulates the transcription of nuclear-encoded mitochondrial genes
(Heilbronn et al., 2007; Mootha et al., 2003; Patti et al., 2003). A coordinated reduction of PGC1α and its responsive gene, NRF-1, were correlated with obesity, insulin resistance, and T2D
(Heilbronn et al., 2007; Mootha et al., 2003; Patti et al., 2003; Skov et al., 2007). Lower
expression of each of the five mitochondrial OXPHOS complexes, including the mitochondrialencoded subunit of complex IV, cytochrome c oxidase I (COI), was shown in subjects with
acquired obesity and insulin resistance (Heinonen et al., 2015; Morino et al., 2005; Perks et al.,
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2017). Interestingly, one of the most common pathogenic mutations in the mitochondrial genome
that is linked to T2D was found in the mitochondrial-encoded tRNA (Leu, UUR), which led to a
defect in oxidative phosphorylation (Esterhuizen et al., 2019), and the mutation was identified in
patients with impaired insulin secretion (Maassen et al., 2004; van den Ouweland et al., 1992).
The mitochondrial genome codes for 13 polypeptides that are essential subunits of
OXPHOS complexes, two ribosomal RNAs (rRNAs), and 22 transfer RNAs (tRNAs). These
essential subunits are synthesized by the mitochondrial transcription and translation machinery,
which also contribute to the impaired mitochondrial biogenesis identified in obesity and T2D.
Studies have demonstrated that the haploinsufficiency of pentatricopeptide repeat domain 1
(PTCD1) and the altered expression and/or mutation of mitochondrial ribosomal proteins
(MRPs) led to reduced mitochondrial energy metabolism via decreased RNA processing,
impaired mitochondrial protein synthesis, and the diminished expression of OXPHOS complexes
in obesity, insulin resistance, and T2D (Bains et al., 2004; Heinonen et al., 2015; Perks et al.,
2017; Rong et al., 2007). Additionally, the mitochondrial elongation factor Tu (EF-Tu) was also
identified as a possible factor responsible for impaired mitochondrial biogenesis following
exercise in an obese state (Greene et al., 2014) and has been recognized as one of the
mitochondrial genes most connected to the insulin signaling cascade (Mercader et al., 2012).
Taken together, these studies suggest that impaired mitochondrial biogenesis, including
diminished mitochondrial protein synthesis, may lead to the metabolic disturbances that are
characteristic of obesity, insulin resistance, and T2D. However, we still lack a thorough
understanding of mitochondrial biogenesis and the contribution of mitochondrial protein
synthesis and oxidative phosphorylation in obesity and T2D.

60

In this study, we investigated mitochondrial biogenesis, including the expression of
nuclear- and mitochondrial-encoded subunits of OXPHOS complexes and mitochondrial
translation machinery, in mitochondrial rich liver and kidney tissues of TH and C57BL/6J (B6)
mice. We discovered reduced expression of nuclear-encoded subunits of OXPHOS complex I,
NADH:ubiquinone oxidoreductase subunit B8 (NDUFB8) and NADH:ubiquinone
oxidoreductase core subunit S2 (NDUFS2), and mitochondrial-encoded subunits of OXPHOS
complex IV, COI and cytochrome c oxidase II (COII), along with diminished activities of the
corresponding complexes. Furthermore, we identified sequence variants in NDUFS2,
mitochondrial aspartyl-tRNA synthetase 2 (DARS2), and several MRPs in the whole genome
sequence database of TH mice previously published (Denvir et al., 2016). The potential
contribution of these sequence variants on mitochondrial biogenesis and oxidative
phosphorylation is also discussed. Our study strongly indicates that impaired mitochondrial
biogenesis could be one of the reasons for the lower mitochondrial oxidative energy metabolism
in TH mice.
3.2. Materials and Methods
3.2.1. TALLYHO/Jng and C57BL/6J Tissue Samples
Liver (18-20 weeks old) and kidney (25-27 weeks old) tissues were collected from male
TH and B6 mice fed standard rodent chow (Purina 5001, PMI Nutrition, Brentwood, MO, USA).
Breeding of TALLYHO/Jng mice was established as previously described (J. H. Kim & Saxton,
2012; X. Mao et al., 2014) and all animal studies were carried out with the approval of Marshall
University Animal Care and Use Committee.
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3.2.2. Western Blot Analyses
Tissue lysates from the liver of TH and B6 mice (n=5 in each group) and the kidney of
TH (n=3) and B6 (n=5) mice were obtained by sonication of samples in RIPA
(radioimmunoprecipitation assay) buffer containing 50 mM Tris-HCl (Tris-hydrochloride) (pH
7.6), 150 mM NaCl (sodium chloride), 1 mM EDTA (ethylenediaminetetraacetic acid), 1 mM
EGTA (ethylene glycol-bis (β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid), 1% NP40
(nonylphenoxypolyethoxylethanol), 0.1% SDS (sodium dodecyl sulfate), 0.5% DOC (sodium
deoxycholate), 1 mM PMSF (phenylmethylsulfonyl fluoride), and protease and phosphatase
inhibitor cocktails (Abcam, Cambridge, MA). Protein concentration of tissue lysates was
determined using the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, USA). Protein
lysates were separated by 12% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel
electrophoresis), and the gels were stained with Coomassie brilliant blue to ensure equal protein
loading. The lysates (5 – 40 µg) were then separated by 12% SDS-PAGE, transferred to
nitrocellulose membranes (Bio-Rad, Richmond, VA), stained with Ponceau S to check for equal
protein loading, and blocked with Tris-buffered saline (TBS) containing 0.05% Tween-20
(TBST), 5% (w/v) dry skim milk powder, and 1% BSA (bovine serum albumin). Membranes
were incubated with primary antibodies overnight against the following proteins: OXPHOS
cocktail from Mitosciences (Eugene, OR); ATP6 and COII from Abcam (Cambridge, MA); COI,
NDUFS2, NRF-1, TFAM, and citrate synthase from Santa Cruz (Dallas, TX); SDHA from
Novus Biologicals (Littleton, CO); GAPDH (glyceraldehyde 3-phosphate dehydrogenase) from
Fitzgerald Industries International Inc. (Acton, MA); PDH, PEPCK, and PDHK1 from Cell
Signaling Technology (Danvers, MA); MRPS29 and HSP60 from BD Biosciences (San Jose,
CA); MRPL11 and MRPS18-B from Sigma Aldrich (St. Louis, MO); DARS2 from Proteintech
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(Rosemont, IL); and MRPL15 and EF-Tu were a kind gift from Dr. Linda Spremulli. The protein
immunoreactivity was detected using the ECL chemiluminescent kit from Amersham (GE
Healthcare Life Sciences, Marlborough, MA), and the membranes were developed per the
manufacturer’s protocol. UN-Scan-It (Silk Scientific, Inc, Orem, UT) and ImageJ (Schneider,
Rasband, & Eliceiri, 2012) were used to quantify the protein band intensities detected by
Western blot analyses. The quantified values were normalized to the protein loading determined
by Ponceau S staining and GAPDH probing of each membrane. The expression of each protein
was quantified from each mouse sample from at least three independent experiments. The data
are the mean ± SD for each mouse strain, and the results are expressed as a percentage of B6
mice.
3.2.3. Mitochondrial Complex Activity Assays
Protein lysates used in the activity assays for mitochondrial OXPHOS complexes were
prepared in a buffer containing 10 mM Tris-HCl (pH 7.0), 250 mM sucrose, and phosphatase and
protease inhibitor cocktails. For complex I and III enzymatic activity assays, liver and kidney
protein lysates were further diluted in a 50 mM potassium phosphate (pH 7.5) buffer containing
1 mg/mL BSA, 1 mM potassium cyanide, and 100 µM cytochrome c. The protein concentration
was determined by using the BCA protein assay and protein amounts were normalized with
Coomassie brilliant blue stained gels. The reactions were started by adding 200 µM NADH and
the combined complex I and III assay was determined spectrometrically by measuring the
reduction of cytochrome c at 550 nm for 6 min. Each sample was run in triplicate (technical
replicates) and each assay was run at least three times (biological replicates). The average
absorbance values were calculated for both technical and biological replicates and were graphed
against the time points to determine the linear range of the assay. The rate of cytochrome c
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reduction was then calculated by a time-dependent change in the absorbance at the selected time
point for each TH and B6 sample using the formula: Rate = (Abs 1 – Abs 2) / (Time 1 – Time 2).
The data are the mean ± SD for each mouse strain and the results are presented as a percentage
of B6 mice.
Briefly, liver and kidney lysates for the complex IV enzymatic activity assay were further
diluted in a 50 mM phosphate buffer (pH 7.4) containing 1 mM EDTA and 100 µM reduced
cytochrome c. The complex IV activity was also measured spectrometrically by monitoring the
oxidation of cytochrome c at 550 nm, as previously described (Birch-Machin & Turnbull, 2001).
The rate of cytochrome c oxidation was calculated as described above for the complex I and III
assay.
3.2.4. Quantitative Real-time Polymerase Chain Reaction (qRT-PCR)
Total RNA was extracted from liver and kidney tissues in the presence of TRIzol
(Invitrogen, Carlsbad, CA) and converted to cDNA with the high capacity cDNA reverse
transcription kit using random primers (Applied Biosystems, Inc., Foster City, CA). Quantitative
real-time PCR (qRT-PCR) was carried out using the PowerUp SYBR green master mix (Applied
Biosystems, Inc.), and samples were run on an Applied Biosystems Step One Plus instrument.
The relative expression values were calculated using the ΔΔCt method for both biological and
technical replicates (Schmittgen & Livak, 2008). The transcript expression values were
normalized to GAPDH as the control. Results were presented as a percentage of B6 mice. The
following sequences were used as primers: 16S rRNA forward 5’TGAACGGCTAAACGAGGGTC-3’ and reverse 5’-TATTCTCCGAGGTCACCCCAA-3’;
ND6 forward 5’-TATATTGCCGCTACCCCAATCC-3’ and reverse 5’ATCCAGAGACTTGGGGATCT-3’; Cyt b forward 5’-TGCATACGCCATTCTACGCT-3’ and

64

reverse 5’-TGGGTGTTCTACTGGTTGGC-3’; COI forward 5’TCGGAGCCCCAGATATAGCA-3’ and reverse 5’-TTTCCGGCTAGAGGTGGGTA-3’; ATP6
forward 5’-ATCCACACACCAAAAGGACGA-3’ and reverse 5’GGAAGTGGGCAAGTGAGCTT-3’; and GAPDH forward 5’GGTGAAGGTCGGTGTGAACG-3’and reverse 5’-CTCGCTCCTGGAAGATGGTG-3’.
3.2.5. Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6.07. Statistically significant
differences between TH and B6 mice were detected using unpaired Student’s t-tests (2-tailed).
All data are expressed as the mean ± SD (standard deviation), unless otherwise stated.
3.3. Results
3.3.1. Mitochondrial Oxidative Phosphorylation is Impaired in TH Mice
Mitochondrial dysfunction was recognized as one of the key underlying factors in the
development of T2D and identified as a contributing factor to T2D-dependent liver and renal
failure (de Boer et al., 2011; El-Serag, Tran, & Everhart, 2004). In the initial characterization
studies of TH mice, altered energy balance was reported (X. Mao et al., 2014). Furthermore, data
mining of the whole genome sequencing analysis revealed the presence of several missense
variants in the genes of nuclear-encoded OXPHOS complexes I and II, Ndufs2 and Sdhc,
respectively (Parkman et al., 2017). To determine changes in mitochondrial energy metabolism
in this mouse model, we compared the expression and activity of mitochondrial OXPHOS
complexes in the liver (Figs. 7 and 8) and kidney tissues (Figs. 12 and 13) of TH and B6 mice
due to the high energy demands in these organs. We first evaluated the steady-state expression of
OXPHOS complexes by Western blot analyses using antibodies raised against several subunits at
varying protein amounts to determine the optimal amount for the consistent detection of
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OXPHOS subunits in the liver (Fig. 7A) and kidney (Fig. 12A) of several tissues from both
mouse strains. In the liver samples initially analyzed, the expression of nuclear-encoded subunits
of complex I, NDUFB8 and NDUFS2, and the mitochondrial-encoded subunits of complex IV,
COI and COII, was significantly lower at varying protein amounts in TH mice (Figs. 7A and 9).
The consistent detection of diminished OXPHOS subunit expression was observed at 15 µg (Fig.
7A) with significantly decreased expressions of NDUFB8, NDUFS2, COI, and COII by
approximately 55%, 40%, 60%, and 30%, respectively (Fig. 7A, bottom panel). Therefore, the
remainder of the liver samples were run at this optimal protein amount. Similar to Fig. 7A,
significant reductions were observed in the expression of NDUFB8 and NDUFS2 by
approximately 40% and 35%, respectively, in the liver of TH mice (Fig. 7B, P = 0.0002 and P =
0.0001). The mitochondrial-encoded subunits of complex IV, COI and COII, were also
decreased by 45% and 55%, respectively (Fig. 7B, P = 0.001). On the other hand, the expression
of complex II subunits, SDHA and SDHB (P = 0.4303 and P = 0.3027), complex III subunit,
UQCRC2 (P = 0.1881), and complex V subunits, ATP5A and ATP6 (P = 0.1790 and P =
0.2233), was comparable between the two mouse strains (Figs. 7B and 10A). The changes in
expression of OXPHOS complex subunits were normalized to the Ponceau S staining and
GAPDH probing of the membranes (Figs. 7 and 10B). To determine the effect of the impaired
NDUFB8, NDUFS2, COI, and COII expressions on oxidative phosphorylation activity and
energy metabolism, we performed complex I and III and complex IV enzymatic activity assays.
As shown in Fig. 8A, the complex I and III enzymatic activity was significantly decreased by
about 42% (P = 0.0001) in TH mice. Furthermore, a reduction of 25% (P = 0.0003) was clearly
observed in the activity of complex IV (Fig. 8B). An example of the calculation used to
determine the difference in enzymatic activities of OXPHOS complexes is described in the
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Materials and Methods and demonstrated in Fig. 11. The diminished activity of OXPHOS
complexes I, III, and IV coincided with the significantly lower expression of the NDUFB8,
NDUFS2, COI, and COII subunits in the TH mice liver.
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Figure 7. Mitochondrial OXPHOS is impaired in TH mice liver. A) To determine the
linear response range of the antibodies, the expression of OXPHOS subunits NDUFB8
and NDUFS2 (complex I), SDHA and SDHB (complex II), UQCRC2 (complex III), COI
and COII (complex IV), and ATP5A and ATP6 (complex V) was detected at varying
protein amounts by Western blot analyses of TH and B6 mice liver lysates (n=2 in each
group). The average quantitative analyses of the protein bands (15 µg) by densitometry
are shown in the bottom panel. B) The expression of OXPHOS complexes in TH and B6
mice liver (n=4 in each group). The graph (bottom panel) represents the average
quantitative analyses of the OXPHOS complex subunits with significant changes from
each mouse strain at the optimal protein amount determined in A. The mitochondrialencoded subunits COI, COII, and ATP6 are marked by arrows. Approximately 5 – 30 µg
of protein lysate was separated by 12% SDS-PAGE and equal protein loading was
evaluated by Ponceau S staining and GAPDH probing of the membranes. Results
represent the mean ± SD of at least three experiments for each mouse strain and are
presented as a percentage of B6 mice. Significant difference was observed between B6
and TH mice using an unpaired Student’s t-test (2-tailed), *P < 0.05.
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Figure 8. Mitochondrial complex I and III and IV activities are lower in TH mice
liver. A) Combined complex I and III activity was determined by measuring cytochrome
c reduction spectrometrically at 550 nm using equal amounts (~10 µg) of TH and B6
mice liver lysates. B) The rate of cytochrome c oxidation at 550 nm was determined as
the complex IV activity using equal amounts (~20 µg) of liver lysates for both mouse
strains. The data are the mean ± SD of at least three experiments for both mouse strains.
Results are represented as a percentage of B6 mice. Significant difference was observed
between B6 and TH mice using unpaired Student’s t-tests (2-tailed), *P < 0.05.
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Figure 9. Expression of mitochondrial OXPHOS complexes I and IV is diminished
at various protein concentrations in the liver of TH mice. A) Quantitation of
OXPHOS complex subunits NDUFB8 and NDUFS2 (complex I) and COI and COII
(complex IV) at 5 µg and 10 µg (B) in the liver of TH and B6 mice, Western blots shown
in Fig. 7A. Results are represented as mean ± SD of at least three experiments and
presented as a percentage of B6 mice. Statistical analyses were performed using the
unpaired Student’s t-test (2-tailed), *P < 0.05. See Figure 7 legend for details.
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Figure 10. Mitochondrial OXPHOS complex expression in the liver of TH mice. A)
Quantitation of OXPHOS complex expression in the liver of TH and B6 mice, shown in
Fig. 7B. Results are represented as the mean ± SD of at least three experiments and
presented as a percentage of B6 mice. The unpaired Student’s t-test (2-tailed) was
performed for statistical analysis, and no significant difference was observed in these
OXPHOS subunits between the two mouse strains. B) Whole Western blots and the
corresponding Ponceau S membrane stains for antibodies that show significant changes
in the expression between TH and B6 mice. Protein bands for COI and COII are indicated
by arrows. See Figure 7 legend for details.
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Figure 11. Sample calculation for complex I and III enzymatic activity assays. A)
Absorbance values of cytochrome c reduction measured at 550 nm over six min. The
values listed are from the control (without lysate), one TH, and one B6 mouse liver
sample run two times each. The absorbance values for each mouse strain were averaged
together and the percent difference was calculated. B) The plot represents the average TH
and B6 absorbance values graphed against each time point. The time point used to
calculate the percent difference is shown in the black box and bolded. C) The graph
represents the mean ± SD of the percent change at the third (3) timepoint between the TH
and B6 mice. This process was repeated for each TH and B6 mouse sample in both the
liver and the kidney, and each assay was run at least three times. The samples were
normalized to the control without lysate per assay. This normalization and calculations
were performed for both the liver and kidney tissues on every mouse sample for both
complex I and III and complex IV activity assays.
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Similar to the results obtained with liver tissues, the biggest difference between TH and
B6 mice kidney samples was observed in the expression of OXPHOS complexes I and IV (Figs.
12A and 12B). As shown in Figs. 12A and 14, the expression of NDUFB8, NDUFS2, COI, and
COII were significantly lower at varying protein amounts in the TH kidney, with the optimal and
consistent detection at 15 µg, similar to the liver lysates. Reductions of approximately 25% and
30% were detected in the expression of nuclear-encoded NDUFB8 and NDUFS2 subunits,
respectively (P = 0.0014 and P = 0.0009), followed by a 40% decrease in the expression of
mitochondrial-encoded complex IV subunits, COI and COII (P = 0.001 and P = 0.0008), in TH
mice kidney (Figs. 12B). The expression of complex II and III subunits was comparable in the
kidney of TH and B6 mice (Fig. 12B, P = 0.2609 and P = 0.9736 and Fig. 15A). The nuclearencoded subunit of complex V, ATP5A, also had a similar expression between the two mouse
strains (P = 0.5741); however, the expression of the mitochondrial-encoded subunit of complex
V, ATP6, was slightly lower in the TH mice kidney samples although not significant (Fig. 12B,
P = 0.2464 and Fig. 15A). The changes observed in the expression of OXPHOS complex
subunits were normalized to both the Ponceau S membrane staining and the expression of
GAPDH (Figs. 12 and 15B). We also performed OXPHOS complex activity assays to determine
the effect of the lower expression of OXPHOS complexes I and IV on oxidative phosphorylation
function in the kidney of these mice. Significant decreases of roughly 30% (P = 0.0113) and 27%
(P = 0.0005) were observed in the activities of complexes I and III (Fig. 13A) and complex IV
(Fig. 13B), respectively, in the TH mice compared to the B6 mice. These diminished activities of
OXPHOS complexes were associated with the reduced expression of their subunits. Together,
our findings show significant decreases in oxidative phosphorylation complex expression and
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activity which implies mitochondrial energy metabolism is impaired in both the liver and the
kidney of TH mice.
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Figure 12. Mitochondrial OXPHOS is reduced in TH mice kidney. A) The expression
of OXPHOS subunits in TH and B6 kidney tissue lysates (n=2 in each group) was
evaluated at various protein amounts by Western blot analyses and Ponceau S staining.
The average quantitative analyses by densitometry of OXPHOS subunits using 15 µg
total protein lysate is shown in the bottom panel. B) Western blots of the OXPHOS
subunit expression in TH (n=3) and B6 (n=4) mice kidney lysates. The graph in the
bottom panel represents the average quantitative analysis of OXPHOS subunits with
significant changes at the optimal protein amount determined in A. The expression of
mitochondrial-encoded subunits COI, COII, and ATP6 are marked by arrows. Results
represent the mean ± SD of at least three experiments for each mouse strain and are
presented as a percentage of B6 mice. Significant difference was observed between the
mouse strains using unpaired Student’s t-tests (2-tailed), *P < 0.05. See Figure 7 legend
for details.
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Figure 13. Mitochondrial complex I and III and IV activities are diminished in the
kidney of TH mice. A) Combined complex I and III activity was determined by
spectrometrically measuring the rate of cytochrome c reduction at 550 nm in TH and B6
mice kidney lysates. B) Complex IV activity was measured by the oxidation of
cytochrome c at 550 nm in the kidney lysates. Results represent the mean ± SD of at least
three experiments for each mouse strain and are expressed as a percentage of B6 mice. Pvalues were calculated using unpaired Student’s t-tests (2-tailed), *P < 0.05. See Figure 8
legend for details.
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Figure 14. Expression of mitochondrial OXPHOS complexes I and IV is diminished
at various protein concentrations in TH mice kidney. A) Quantitation of OXPHOS
complex subunits of complex I, NDUFB8 and NDUFS2, and complex IV, COI and COII,
at 5 µg and 10 µg (B) in the kidney of TH and B6 mice, Western blots shown in Fig.
12A. Results are represented as mean ± SD of at least three experiments and presented as
a percentage of B6 mice. Statistical significance was measured by the unpaired Student’s
t-test (2-tailed), *P < 0.05. See Fig. 12 legend for details.
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Figure 15. Expression of mitochondrial OXPHOS complexes in the kidney of TH
mice. A) Quantitation of OXPHOS complex expression in the kidney of TH and B6
mice, shown in Fig. 12B. Results are represented as mean ± SD of at least three
experiments and are presented as a percentage of B6 mice. The unpaired Student’s t-test
(2-tailed) was performed for statistical analysis, and no significant difference was
observed in these OXPHOS subunits between the two mouse strains. B) The full Western
blots and their corresponding Ponceau S stained membranes are shown for each
OXPHOS subunit with significant changes in expression. The arrows indicate the COI,
COII, and NDUFS2 protein bands for the TH and B6 mice kidney samples. See Fig. 12
legend for details.
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3.3.2. Citrate Synthase Expression is Elevated in TH Mice
Above, we demonstrated that oxidative phosphorylation is significantly impaired in TH
mice (Figs. 7-13). To further evaluate this decrease, we assessed the expression of several crucial
metabolic enzymes that control OXPHOS by regulating the citric acid cycle (CAC) and
gluconeogenesis, including citrate synthase (CS), pyruvate dehydrogenase (PDH), pyruvate
dehydrogenase kinase 1 (PDHK1), and mitochondrial phosphoenolpyruvate carboxykinase
(mtPEPCK). Interestingly, the expression of CS was increased by approximately 20-25% in the
liver (Fig. 16A) and kidney (Fig. 16B) of TH mice. CS is one of the major checkpoints for the
CAC and the increase in its expression suggests that the CAC activity is elevated in TH mice.
Since CS expression is higher, we further analyzed other metabolic pathways that converge onto
the CAC cycle. The expression of mtPEPCK, an enzyme that regulates the rate-controlling step
of gluconeogenesis is comparable between the TH and B6 mice in the liver (Fig. 16A) but has a
slight increase in expression in the kidney (Fig. 16B) of TH mice indicating that gluconeogenesis
may be slightly higher. Little difference was observed in the expression of PDH and PDHK1,
two critical enzymes involved in the regulation of pyruvate metabolism, in TH mice liver (Fig.
16A) and kidney (Fig. 16B) mitochondria. These findings imply that pyruvate metabolism and
gluconeogenesis functions are comparable in both tissues of the two mouse strains and are not
largely responsible for the increase in CS expression. Our results suggest that the lower oxidative
metabolism in TH mice is not caused by diminished activities of other metabolic pathways that
regulate OXPHOS complexes. Rather, the decrease is due to the reduced expression of OXPHOS
complexes I and IV, possibly by a defect in nuclear and mitochondrial protein synthesis.
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Figure 16. Citrate synthase is increased in TH mice liver and kidney. A) The
expression of various crucial metabolic enzymes involved in the citric acid cycle and
gluconeogenesis, including citrate synthase (CS), pyruvate dehydrogenase (PDH),
pyruvate dehydrogenase kinase 1 (PDHK1), and mitochondrial phosphoenolpyruvate
carboxykinase (mtPEPCK), was assessed in TH and B6 mice liver and kidney (B) by
Western blot analyses. The quantitative analyses of metabolic enzymes by densitometry
were normalized to the expression of GAPDH and Ponceau S stained membranes (bottom
panels) as equal loading controls. Results are expressed as the mean ± SD for each mouse
strain and presented as a percentage of B6 mice. Unpaired Student’s t-tests (2-tailed)
were performed to for statistical analyses and no significant difference was observed
between TH and B6 mice.
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3.3.3. Mitochondrial Transcription Machinery and Translation Components
Remain Unaltered in TH mice
In mammals, OXPHOS complexes are encoded by approximately 85 nuclear and 13
mitochondrial genes. Mitochondrial biogenesis, mainly via transcription and translation of these
genes, is essential for energy generation by oxidative phosphorylation. We observed a
diminished protein expression of OXPHOS subunits NDUFB8, NDUFS2, COI, and COII in the
liver and kidney of TH mice (Figs. 7 and 12). Since COI and COII are two of the 13 crucial
mitochondrial-encoded subunits, we performed quantitative RT-PCR analyses on several
mitochondrial-encoded transcripts to determine if a defect is present in the expression of
mitochondrial genes in TH mice. Despite a lower protein expression of COI in the liver (Fig. 7)
and kidney (Fig. 12) of TH mice, the mRNA expression of COI was comparable in both tissues
between the two mouse strains (Figs. 17A and 18A). Furthermore, minor reductions were
observed in the mRNA expression of mitochondrial-encoded 16S rRNA and OXPHOS subunits
ND6 (complex I), cyt b (complex III), and ATP6 (complex V) between the TH and B6 mice liver
(Fig. 19A) and kidney (Fig. 18A). To further evaluate this slight reduction, we performed
Western blot analyses to assess the protein expression of two major transcription factors
responsible for the synthesis of both mitochondrial- and nuclear-encoded proteins. The
expression of mitochondrial transcription factor A (TFAM) and NRF-1 was comparable between
TH and B6 mice in both the liver (Fig. 17B) and kidney (Fig. 18B). These results suggest that
changes in the expression of mitochondrial transcription factors is not responsible for the slight
reduction observed in the mitochondrial-encoded transcripts and further implies that there is no
defect in the mitochondrial transcription of TH mice.
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The minor differences found in the expression of mitochondrial-encoded rRNA/mRNA
transcripts without changes in the expression of transcription factors, prompted us to analyze two
essential mitochondrial translation factors, EF-Tu and DARS2, and ribosomal proteins that are
responsible for the synthesis of the 13 mitochondrial-encoded proteins of the OXPHOS
complexes in TH and B6 mice. Although EF-Tu has been associated with insulin signaling and
the obesity phenotype (Greene et al., 2014; Mercader et al., 2012), the expression of EF-Tu in
the obesity and insulin resistant TH mouse model is comparable to the B6 mice in both the liver
(Fig. 17C) and kidney (Fig. 18C) tissues. In the whole genome sequencing analysis of TH mice,
mitochondrial aspartyl-tRNA synthetase, DARS2, was shown to have a C370R mutation.
Although this variant introduces a positively charged residue into the protein sequence in a
highly conserved region, the difference in the expression of the mitochondrial DARS2, was
negligible between the two mouse strains in both the liver and kidney (Figs. 17C and 18C,
respectively). Interestingly, this C370R variant is also found in Myotis lucifugus (little brown
bat) and Equus caballus (horse) sequences. Thus, the defect we observed in mitochondrial
translation, indicated by the significantly diminished expression of mitochondrial-encoded COI
and COII without changes in transcription, could not be exclusively dependent on the DARS2
variant.
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Figure 17. Mitochondrial transcription and translation are comparable between TH
and B6 mice liver. A) Relative changes in mitochondrial transcripts, including 16S
rRNA (39S subunit), ND6 (complex I), cyt b (complex III), COI (complex IV), and
ATP6 (complex V) were determined by quantitative RT-PCR and reported as fold
changes with respect to GAPDH mRNA expression in the liver of TH and B6 mice.
Results represent the mean ± SD of at least three experiments for each mouse strain.
Unpaired Student’s t-tests (2-tailed) were performed for statistical analyses and no
significant difference was shown between TH and B6 mice. B) Expression of
mitochondrial transcription factors, TFAM and NRF-1, and translation factors, EF-Tu
and DARS2 (C), were evaluated in the liver of both mouse strains by Western blot
analyses. Equal protein loading was determined by Ponceau S staining and probing
membranes with mitochondrial matrix marker, HSP60.
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Figure 18. Mitochondrial transcription and translation are unaltered in TH mice
kidney. A) Relative changes in 16S rRNA and mitochondrial-encoded mRNA expression
were determined by quantitative RT-PCR in the kidney of TH and B6 mice and reported
as fold changes with respect to GAPDH mRNA expression as a control. Results represent
the mean ± SD of at least three experiments for each mouse strain. B) The expression of
mitochondrial transcription and translation (C) factors were evaluated in TH and B6 mice
kidney by Western blot analyses. See Figure 17 legend for details.
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3.3.4. Expression of Mitochondrial Ribosomal Proteins are Comparable
Mitochondrial ribosomes, 55S, are composed of small (28S) and large (39S) subunits
with two mitochondrial encoded rRNAs, 12S and 16S, respectively, and approximately 80
nuclear-encoded ribosomal proteins (E. C. Koc et al., 2013). These MRPs are essential to the
synthesis of the 13 mitochondrial-encoded subunits of OXPHOS complexes in mammals. To
identify changes in MRPs that could contribute to the impaired protein synthesis in TH mice, we
analyzed several MRPs in both the 28S (MRPS18B and MRPS29) and 39S (MRPL11 and
MRPL15) ribosomal subunits by Western blot analyses (Fig. 19). The expression of the majority
of the MRPs analyzed, MRPS18B, MRPL11, and MRPL15, were comparable between the TH
and B6 mice in both tissues (Figs. 19A and 19B) relative to GAPDH as a loading control.
Surprisingly, the expression of MRPS29 was approximately 20% lower in the TH mice in both
the liver (Fig. 19A) and kidney (Fig. 19B); however, the decrease was not statistically significant
(P = 0.0628 and P = 0.0558).
The slight reduction observed in the expression of MRPS29 encouraged us to search for
MRP variants in the whole genome sequence database previously published (Denvir et al., 2016),
which is archived at the Sequence Read Archive (SRA) at the National Center for Biotechnology
Information (NCBI) via accession number SRP067703. Our data mining revealed the presence of
16 sequence variants in 11 MRPs in TH mice (Table 3). To predict the amino acid substitution
on MRP function, the ‘Sorting Intolerant From Tolerant’ (SIFT) scores were calculated (Table
3). The majority of the SIFT scores for the MRP sequence variants identified were greater than
0.05, indicating that the variants were tolerated (Zerbino et al., 2018). The majority of significant
amino acid replacements were found at the N-terminal signal sequences of MRPs (Table 3). One
of the most remarkable variants was identified in MRPL20. The missense sequence variant found

85

in MRPL20 caused the loss of a stop codon (Table 3), which introduces an additional nine amino
acid residues into the protein sequence. The possible effect of this insertion at the C-terminus of
MRPL20 is unknown. Although the sequence variants identified in mitochondrial ribosomal
proteins in TH mice were possibly ineffective in altering the protein expression of other MRPs
(Figs. 19A and 19B), the variants may still interfere with the translocation of MRPs into the
mitochondria and the function of the ribosome.

86

Figure 19. Mitochondrial ribosomal protein expression remains unchanged in TH
and B6 mice. A) Relative expression of mitochondrial ribosomal proteins (MRPs) of the
small (28S) and large (39S) subunits were detected in TH and B6 mice liver and kidney
lysates (B) by Western blot analyses. The average quantitative analyses by densitometry
of MRPs in TH and B6 mice normalized to GAPDH and Ponceau S staining is shown in
the bottom panels. Results represent the mean ± SD of at least three experiments in each
mouse strain and are presented as a percentage of B6 mice. No statistical difference was
shown between TH and B6 mice using unpaired Student’s t-tests (2-tailed). See Figure 7
legend for details.
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Gene
MRPL20
MRPS11
MRPL22
MRPL49
MRPL48
MRPS35

MRPL3
MRPL19
MRPL39
MRPL55

AA B6/TH
AA position
UniProtKB
Mitochondrial ribosomal protein mutations
stop lost
97
Q9CQL4
R/L
L/R
A/T
L/F
I/V
T/S
C/Y
I/V
I/T
C/R
E/Q
K/R
V/A
L/F

13
70
4
6
148
11
216
293
32
39
72
133
280
19

Q9DCA2
Q8BU88
Q9CQ40
Q8JZS9
Q8BJZ4

Q99N95
Q9D338
Q9JKF7
Q9CZ83

SIFT score

0.12
0.06
0.26
1.00
1.00
0.37
1.00
1.00
0.48
0.35
0.20
0.49
0.52
0.65

Table 3. Sequence variants of mitochondrial ribosomal proteins (MRPs) in TH mice
(Denvir et al., 2016).
AA: amino acid. Mitochondrial ribosomal small (MRPS) and (MRPL) subunit proteins.
Sorting intolerant from tolerant (SIFT) scores are shown to predict if the amino acid
substitution is deleterious (SIFT < 0.05) or tolerated/neutral (Zerbino et al., 2018).
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3.4. Discussion
Obesity and T2D are two metabolic diseases that are becoming more prevalent
worldwide. Recent evidence implies that mitochondrial dysfunction is an underlying defect in
the development of obesity, insulin resistance, and T2D (Kelley et al., 2002; Patti et al., 2003;
Petersen et al., 2003). The TH mouse has recently been developed as a polygenic model for
obesity, insulin resistance, and T2D (J. H. Kim & Saxton, 2012; J. H. Kim et al., 2001).
Metabolic characterization, gene mapping, and whole genome sequencing analyses of TH mice
have revealed an altered energy balance (Franko et al., 2017; X. Mao et al., 2014; Parkman et al.,
2017; Parkman et al., 2016); however, the mechanism is largely unknown. In this study, we
evaluated mitochondrial biogenesis including the expression of mitochondrial- and nuclearencoded OXPHOS complex subunits in mitochondrial rich tissues of TH and B6 mice.
Additionally, we analyzed mitochondrial energy metabolism by observing changes in oxidative
phosphorylation activity. In conjunction with the whole genome sequencing information, our
results allowed us to correlate the biogenesis of OXPHOS complexes with mitochondrial
translation, oxidative phosphorylation, and energy metabolism in TH mice (Fig. 20).
One of our most compelling observations was the significant reduction in the expression
of nuclear-encoded complex I subunits, NDUFS2 and NDUFB8, and mitochondrial-encoded
complex IV subunits, COI and COII, which coincided with diminished enzymatic activities of
these OXPHOS complexes in TH mice liver and kidney tissues (Figs. 7-13). Strikingly,
NDUFS2 carries an R8G variant which is located within the mitochondrial targeting sequence in
TH mice. This variant can interfere with the translocation of NDUFS2 into the mitochondria. In
fact, NDUFS2 is one of the largest and highly conserved subunits in complex I and its mutations
have resulted in the disruption of the subunit as well as an absence in the formation of the
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peripheral arm of complex I (Guenebaut, Vincentelli, Mills, Weiss, & Leonard, 1997). Complex
I is the major entry point into the OXPHOS complexes and plays a pivotal role in mitochondrial
energy metabolism. Several mutations found in complex I subunits and assembly factors were
shown to cause a variety of clinical symptoms (Ugalde, Janssen, van den Heuvel, Smeitink, &
Nijtmans, 2004). For example, mutations in NDUFA4 caused a reduction in mitochondrial
function, impaired insulin release in the pancreas, and led to the development of diabetes (Yagil,
Varadi-Levi, & Yagil, 2018). The diminished expression of NDUFS2 could disrupt the subunit,
inhibit the assembly of the peripheral arm of complex I, impair its function, significantly lower
mitochondrial oxidative phosphorylation and energy metabolism, and contribute to the obesity
and insulin resistant phenotypes observed in TH mice.
In addition to defects in complex I, the reduced expression of mitochondrial-encoded
COI and COII and the diminished activity of complex IV were evident in TH mice. Interestingly,
the expression of complex IV is required for the assembly and stability of complex I (Diaz,
Fukui, Garcia, & Moraes, 2006); therefore, the diminished expression of complex IV subunits
may contribute to the reduced expression of complex I observed in TH mice. Previous studies
have also shown a lower expression of COI in obesity and insulin-resistant subjects (Heinonen et
al., 2015; Morino et al., 2005; Perks et al., 2017). These results further implied that metabolic
alterations could lead to the development of obesity-related diseases, such as T2D, and may be
caused by impaired mitochondrial biogenesis and oxidative phosphorylation, as demonstrated in
TH mice. Mitochondrial biogenesis relies on the coordinated expression of both nuclear- and
mitochondrial-encoded OXPHOS subunits for energy metabolism. More significantly,
complexes I and IV consist of 10 of the 13 mitochondrial-encoded essential subunits synthesized
by the mitochondrial translation machinery. Thus, their expression is more susceptible to the
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changes in mitochondrial protein synthesis. Although we observed minor differences in the
expression of mitochondrial transcription and translation factors, the reduction in the expression
of COI and COII subunits indicated that mitochondrial protein synthesis is impaired in TH mice.
One of the possible candidates for the defect in mitochondrial translation was the DARS2
variant, C370R, identified in TH mice. The variant introduced a positive charge into a highly
conserved region of DARS2 near the tRNA binding site, which can alter aminoacylation of
mttRNAAsp and impair mitochondrial protein synthesis (Fig. 20). However, the presence of this
variant in M. lucifugus and E. caballus DARS2 gene, demonstrated that the diminished
mitochondrial protein synthesis observed in TH mice is not exclusively caused by the C370R
conversion.
A negligible difference was observed in the expression of the majority of the MRPs
analyzed, except a slightly lower expression of MRPS29 in TH mice. MRPS29 provides the only
GTPase activity to the 28S subunit, making its expression essential for ribosome function and the
regulation of mitochondrial protein synthesis (Cavdar Koc, Ranasinghe, et al., 2001; O'Brien,
O'Brien, & Norman, 2005). Although the reduction observed in TH mice is not statistically
significant, the decreased expression of MRPS29 can impair the ribosome assembly and function
reducing protein synthesis and oxidative phosphorylation activity. The probability of defects in
mitochondrial translation machinery compelled us to search for sequence variants in translation
factors and MRPs in the whole genome sequence database of TH mice. The sequence variants
found in 11 MRPs of TH mice were not predicted to be deleterious based on the SIFT scores (>
0.05) (Table 3). In fact, the majority of the variants were either at the less conserved N-terminus
of the MRPs or the amino acid substitutions were conservative replacements with similar amino
acid residues (Table 3). The variants at the N-terminus could interfere with the translocation of
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MRPs into the mitochondria, which may impair the assembly and function of the mitochondrial
ribosome and inhibit protein synthesis. Perhaps the most compelling variant found in TH mice
was in MRPL20. The loss of the stop codon and the nine residue extension of MRPL20 may alter
the folding, structure, and/or activity of the protein, in addition to its ability to interact with other
MRPs in the mitochondrial ribosome. Moreover, these extra residues make MRPL20 a viable
candidate for the defect found in mitochondrial protein synthesis contributing to impaired
mitochondrial biogenesis and oxidative phosphorylation in TH mice.
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Figure 20. A schematic synopsis of OXPHOS and mitochondrial translation
component variants found in TH mice. Mammalian mitochondria have a ~16.5 kb
circular genome (mtDNA) that encodes two rRNAs, 22 tRNAs, and 13 mRNAs (nine
monocistronic and two dicistronic). The mammalian mitochondrial 55S ribosome (28S
and 39S subunits), are responsible for the synthesis of the 13 mitochondrial-encoded
subunits of complexes I, III, IV, and ATP synthase (complex V). The expression of
mitochondrial-encoded subunits COI, COII, and ATP6 detected in TH mice are bolded.
The expression of nuclear-encoded mitochondrial OXPHOS complex subunits NDUFB8
and NDUFS2 (complex I), SDHA, SDHB, and SDHC (complex II), UQCRC2 (complex
III), ATP5A (complex V) were also detected in TH mice. The expression of nuclearencoded NDUFB8 and NDUFS2 and mitochondrial-encoded COI and COII were lower
in TH mice, indicated by red arrows. Missense variants found in OXPHOS complexes,
MRPs, and mitochondrial aspartyl-tRNA synthetase 2 (DARS2) in TH mice are shown
by asterisks (*). Bovine mtEF-Tu (PDB #1XB2) and E. coli aminoacyl-tRNACys (PDB
#IB23) were modeled to demonstrate the interaction of tRNA with mtEF-Tu and shown
in violet and blue, respectively. The bovine 55S mammalian ribosome (PDB #3J9M) was
also modeled and shown in light purple, with the mitochondrial rRNAs highlighted in
green.
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3.5. Conclusions
In summary, our data clearly demonstrated a significant impairment of mitochondrial
energy metabolism, observed through a significant reduction in oxidative phosphorylation in TH
mice. The sequence variants discussed in this study may be contributing factors to the
diminished mitochondrial biogenesis by inhibiting protein synthesis in TH mice. Further studies
need to be performed to determine the contribution of mitochondrial defects to the development
of obesity, insulin resistance, and T2D in this animal model.
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CHAPTER 4
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Abstract
Src family kinases (SFKs) play a crucial role in the regulation of multiple cellular
pathways, including mitochondrial oxidative phosphorylation (OXPHOS). Aberrant activities of
one of the most predominant SFKs, c-Src, was identified as a fundamental cause for
dysfunctional cell signaling and implicated in cancer development and metastasis, especially in
human hepatocellular carcinoma (HCC). However, the role of c-Src in mitochondrial energy
metabolism in liver cancer remains to be elucidated. In this study, we investigated the effect of cSrc expression on mitochondrial energy metabolism by examining changes in the expression and
activities of OXPHOS complexes in liver cancer biopsies and cell lines. An increased expression
of c-Src was correlated with an impaired expression of nuclear- and mitochondrial-encoded
subunits of OXPHOS complexes I and IV, respectively, in metastatic biopsies and cell lines.
Additionally, we observed a similar association between high c-Src and reduced OXPHOS
complex expression and activity in mouse embryonic fibroblast (MEF) cell lines. Interestingly,
the inhibition of c-Src kinase activity with the SFK inhibitor PP2 and c-Src siRNA stimulated the
expression of complex I and IV subunits and increased their enzymatic activities in both cancer
and normal cells. Evidence provided in this study reveals that c-Src impairs the expression and
function of mitochondrial OXPHOS complexes, resulting in a significant defect in mitochondrial
energy metabolism, which can be a contributing factor to the development and progression of
liver cancer. Furthermore, our findings strongly suggest that SFK inhibitors should be used in the
treatment of HCC and other cancers with aberrant c-Src kinase activity to improve mitochondrial
energy metabolism.
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4.1. Introduction
Src family kinases (SFKs) are a major group of tyrosine (Tyr) kinases that are essential
for the regulation of a large number of intracellular signaling pathways, including cell growth
and proliferation, differentiation, motility, adhesion, cell death, and survival, in a variety of cell
types (Parsons & Parsons, 2004; Thomas & Brugge, 1997). Aberrant expression of SFK
members, such as c-Src, have been shown to induce malignant properties in cells, thereby
establishing them as proto-oncogenes (Blume-Jensen & Hunter, 2001; Irby & Yeatman, 2002;
M. P. Kim et al., 2009). In fact, the increased expression and/or activity of c-Src kinase has been
observed in colorectal, ovarian, lung, breast, and liver cancer (Djeungoue-Petga et al., 2019; Irby
& Yeatman, 2000; Rosen et al., 1986; Yeatman, 2004), including human hepatocellular
carcinoma (HCC) which is the most common type of liver cancer and one of the most malignant
and metastatic cancers worldwide (Masaki et al., 1998; R. Zhao et al., 2015).
c-Src is one of the ubiquitously expressed SFK members with a high sequence homology
to Yes and Fyn and, consequently, has overlapping functions in cellular pathways (E. C. Koc et
al., 2016; Thomas et al., 1995). c-Src, as well as several other SFKs, Fyn, Fgr, Lyn, and Lck, are
localized to the mitochondria and regulate mitochondrial pathways (Hebert-Chatelain, 2013;
Salvi et al., 2002; Tibaldi et al., 2008; Vahedi et al., 2015), such as pyruvate decarboxylation (Y.
Jin et al., 2016), the tricarboxylic acid (TCA) cycle (Lewandrowski et al., 2008; Salvi et al.,
2007), apoptosis (Lopez et al., 2012), and oxidative phosphorylation (OXPHOS) (Acin-Perez et
al., 2014; Augereau et al., 2005; Demory et al., 2009; Hebert-Chatelain et al., 2012;
Lewandrowski et al., 2008; Miyazaki et al., 2003; Ogura et al., 2012; Salvi et al., 2007).
OXPHOS is supported by four electron transfer chain complexes, complex I-IV and ATP
synthase, complex V. The majority of these complexes have been shown to be Tyr
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phosphorylated by SFKs; however, c-Src was identified as the kinase responsible for the
phosphorylation of two nuclear-encoded subunits, NDUFB10 and NDUFV2, of complex I,
SDHA of complex II, and the mitochondrial-encoded subunit, COII, of complex IV (Demory et
al., 2009; Hebert-Chatelain et al., 2012; Miyazaki et al., 2003; Ogura et al., 2012). The
phosphorylation of COII by c-Src kinase and the epidermal growth factor receptor (EGFR) were
shown to regulate the activity of complex IV as well as cellular ATP synthesis in several normal
and cancer cell lines (Demory et al., 2009). In addition to the alteration of OXPHOS activity by
SFK phosphorylation of its complexes, our laboratory recently demonstrated the implication of
Fyn with mitochondrial translation which is responsible for the synthesis of the 13 core subunits
of OXPHOS complexes I, III, IV, and V (E. C. Koc et al., 2016). Although reduced
mitochondrial function and c-Src activity have been implicated in promoting the Warburg effect
in various cancer types (Y. Jin et al., 2016; Wallace, 2005, 2012), the role of c-Src in
mitochondrial energy metabolism in liver cancer still remains to be established.
In this study, we investigated the role of c-Src on mitochondrial energy metabolism by
studying the steady-state expression of OXPHOS complex subunits. We observed increased
expression of c-Src in metastatic liver tumors and the metastatic liver cancer cell line, Hep3B,
which was correlated with significant reductions in the expression and activity of OXPHOS
complex I and IV subunits. Additionally, we observed the same association between high c-Src
expression and impaired OXPHOS complex expression and activity in mouse embryonic
fibroblast (MEF) cell lines. Interestingly, the inhibition of c-Src with the SFK inhibitor PP2
stimulated the expression of complex I and IV subunits, improved their enzymatic activities, and
significantly reduced cell proliferation in both cancer and normal cell lines. The suppression of
c-Src using c-Src siRNA was also shown to increase mitochondrial OXPHOS expression. Our
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studies strongly indicate that c-Src impairs the expression and function of OXPHOS complexes,
which can be one of the underlying factors for the development and progression of liver cancer.
Furthermore, our findings provide evidence that the inhibition of SFKs with PP2 can be used as
possible therapeutic strategies to inhibit cell proliferation and improve mitochondrial function
and energy metabolism in liver cancers.
4.2. Materials and Methods
4.2.1. Liver Tumor Samples
Liver tissue biopsies, five cancerous and four non-cancerous, were derived from patients
treated at the Pennsylvania State University Health Milton S. Hershey Medical Center. Protein
lysates used in Western blot analyses were obtained by the resuspension and sonication of tissues
in RIPA buffer containing 1% SDS. Lysates were then separated by 12% SDS-PAGE,
transferred to nitrocellulose membranes, and probed with various antibodies, as described below.
4.2.2. Cell Culture
Human liver cancer Hep3B and HepG2 cell lines and mouse embryonic fibroblast (MEF)
cells with endogenous expression of c-Src, Yes, and Fyn (WT), MEF cells with functional null
mutations in both alleles of c-Src, Yes, and Fyn kinases (SYF), MEF cells with an endogenous
expression of c-Src kinase and null mutations in Yes and Fyn (Src++), and SYF cells with a stable
over expression of c-Src kinase (Src) were purchased from the American Type Culture
Collection (ATCC). Monolayer cultures of each cell line were maintained in Dulbecco’s
modified Eagles Medium (DMEM) (Hyclone, Thermo-Scientific, Waltham, MA) with 4.5 g/L
glucose and adjusted to contain 10% fetal bovine serum (FBS) (Rocky Mountain Biologicals,
Missoula, MT), 4 mM glutamine, 1 mM pyruvate, and 1% penicillin/streptomycin (P/S)
(Corning Cellgro, Manassas, VA). The cells were grown in a humidified incubator at 37 °C with
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5% CO2. Collected cells were treated with sodium orthovanadate to preserve Tyr
phosphorylation (Hebert Chatelain et al., 2011; Nishikawa et al., 2009).
Transfections of small interfering ribonucleic acids (siRNAs) were performed using
Lipofectamine transfection reagent according to the manufacturer’s protocols (Thermo Fisher
Scientific). Partial knock down of human and mouse c-Src were performed using control and cSrc siRNAs obtained from Santa Cruz Biotechnology Inc. (Dallas, TX). The Hep3B, HepG2,
WT, SYF, Src++, and Src cell lines were also treated with the Src family kinase inhibitor PP2 (4amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine) (EMD Chemicals,
Gibstown, NJ) (Hanke et al., 1996), dissolved in dimethyl sulfoxide (DMSO), at concentrations
ranging from 0 to 10 µM. Briefly, cells were seeded at 25x104 cells/mL in DMEM containing
0.2% FBS and incubated for 24 h. The media was then replaced with fresh DMEM containing
10% FBS and cells were treated with PP2 for 24 to 72 h. To measure cell proliferation, cells
were grown as described above and counted using the Trypan blue exclusion assay. For reactive
oxygen species (ROS) generation assays, cells were grown as described above and the amount of
ROS produced by the Hep3B and HepG2 cells was measured using Amplex Red assays (Thermo
Fisher Scientific) according to the manufacturer’s protocol. The results for cell proliferation and
ROS generation assays are represented as the mean ± SD of at least three experiments for each
group and presented as a percentage of the control cells (HepG2 cells = 100%; control cells for
treatments = 100%).
4.2.3. Western Blot Analyses
Whole cell lysates obtained from liver biopsies and cell lines were lysed in RIPA buffer
containing 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP40,
0.1% SDS, 0.5% DOC, 1 mM PMSF, and protease and phosphatase inhibitor cocktails. Protein
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concentrations were determined using the bicinchoninic protein assay (BCA) (Pierce, Rockford,
USA). The protein lysates (10 – 40 µg) were separated by 12% SDS-PAGE, transferred to
nitrocellulose membranes (Amersham, GE Healthcare, Pittsburg, PA), stained with Ponceau S to
ensure equal protein loading, blocked in a Tris-buffered saline (TBS) containing 0.05% Tween20 (TBST), 5% (w/v) dry skim milk, and 1% BSA, and incubated with the corresponding
primary antibodies overnight. Human and rodent OXPHOS complex cocktails and SDHA
antibodies were purchased from Sigma Aldrigh (St. Louis, MO). Citrate synthase (CS), acylcoenzyme A oxidase 1 (ACOX1), and c-Src kinase antibodies were purchased from Santa Cruz
(Dallas, TX). Phosphotyrosine (PY-100), phospho-Src family (pSFK), LDHA, and PDH
antibodies were purchased from Cell Signaling Technologies (Danvers, MA). The pSFK
antibody detects the phosphorylation of c-Src and other family members Fyn, Lyn, Lck, Yes, and
Hck at the kinase activation site Tyr416 (pTyr416) or the equivalent residue. The loading control
antibody GAPDH was purchased from Fitzgerald (Acton, MA). Mitochondrial EF-Tu and
TFAM antibodies were kind gifts from Dr. Linda Spremulli and Dr. Craig Cameron,
respectively. The protein immunoreactivity was detected using the ECL Western blotting
detection kit from Amersham (GE Healthcare, UK) and the membranes were developed per the
manufacturer’s protocol. The membranes were exposed to autoradiography films and band
intensities were quantified using UN-Scan-It (Silk Scientific, Inc, Orem, UT) and ImageJ
(Schneider, C. A., Rasband, & Eliceiri, 2012). The quantified values were normalized to the
protein loading determined by Ponceau S staining and GAPDH antibody probing of the
membranes. The expression of each protein was quantified from individual tissue and cell lysates
from at least three independent experiments. The results represent the mean ± SD for each
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quantified sample and are expressed as a percentage of the control cells (non-cancerous liver
tissues = 100%; HepG2 cells = 100%; SYF cells = 100%; control cells for treatments = 100%).
4.2.4. Mitochondrial OXPHOS Complex Enzymatic Activity Assays
Cell pellets were dissolved in a buffer containing 10 mM Tris-HCl (pH 7.0), 250 mM
sucrose, and phosphatase and protease inhibitor cocktails. Briefly, for the complex I and III
enzymatic activity assay, cell lysates were further diluted in a 50 mM phosphate buffer (pH 7.4)
containing 1 mM potassium cyanide, 1 mg/mL BSA, and 100 µM cytochrome c. Protein
concentrations were determined using the BCA protein assay and protein amounts were
normalized by Ponceau S staining and GAPDH antibody probing of the membranes. The
reactions were started by adding 200 µM NADH and the combined activity of complex I and III
was determined spectrometrically by measuring the reduction of cytochrome c at 550 nm. The
complex IV enzymatic activity protein lysates were diluted in a 50 mM phosphate buffer (pH
7.4) containing 1 mM EDTA and 100 µM reduced cytochrome c. The activity of complex IV
was also measured spectrometrically by monitoring cytochrome c oxidation at 550 nm, as
previously described (Birch-Machin & Turnbull, 2001). The rate of cytochrome c reduction and
oxidation were calculated by dividing the change in absorbance at 550 nm between two linear
points by the difference in time using the formula: Rate = (Abs 1 – Abs 2) / (Time 1 – Time 2).
Each sample was run in triplicate for each experiment. The data are expressed as the mean ± SD
of at least three experiments and are presented as a percentage of the control (HepG2 cells =
100%; SYF cells = 100%; control for treated cells = 100%).
4.2.5. Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6.07. Statistically significant
differences between non-cancerous/cancerous liver biopsies, HepG2/Hep3B cell lines, MEF
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(WT/SYF//Src++/Src) cell lines, and control/treated cells were detected using unpaired Student’s
t-tests (2-tailed), *P < 0.05. The non-cancerous tissues, HepG2, SYF, and control cells for
treatments were set to 100% during statistical analyses. All data are expressed as mean ± SD,
unless otherwise described.
4.3. Results and Discussion
4.3.1. c-Src is Overexpressed in Metastatic Liver Cancers
Aberrant expression and activity of c-Src was reported in patients with HCC and was
positively correlated with tumor stage and metastasis. Thus, c-Src is believed to play an
important role in the malignant transformation of hepatocytes (Masaki et al., 1998; R. Zhao et
al., 2015). Although c-Src has been located in the mitochondria and established as one of the
major regulators of mitochondrial energy metabolism and OXPHOS in various cell lines (Salvi
et al., 2002; Tibaldi et al., 2008) and has been identified as a promoter of the aggressiveness of
breast cancer cells by reduced mitochondrial activity (Djeungoue-Petga et al., 2019), the effects
of c-Src on the expression of OXPHOS complexes in liver cancer have yet to be determined.
Therefore, a better understanding of c-Src signaling and mitochondrial energy metabolism in
liver cancer is essential to improve disease prognosis and treatments. To investigate c-Src kinase
in liver cancer, we examined and compared the expression of c-Src in two groups of liver
biopsies, cancerous and non-cancerous (patient tissue characteristics described in Table 4), by
Western blot analyses. The expression of c-Src was detected in all liver tissues with a
significantly higher expression of approximately 61% in the cancerous tissues compared to the
non-cancerous tissues (Fig. 21). We also assessed the activation of c-Src by observing its
phosphorylation at Tyr416, which is located in the activation loop of the kinase domain and is
responsible for the enzymatic activity of c-Src when phosphorylated (T. Hunter, 1987; Thomas
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& Brugge, 1997). The phospho-Src family (pSFK) antibody detects the endogenous c-Src
phosphorylation at Tyr416, in addition to the phosphorylation of other SFK members, Lyn, Fyn,
Lck, Yes, and Hck, at equivalent activation sites. An increase in SFK phosphorylation was also
detected in liver cancer biopsies with an increased phosphorylation in cancerous tissues,
especially those correlated with a higher c-Src expression (Fig. 21). The SFK phosphorylation
was increased in the non-cancerous tissue from patient 7; however, this increase in pSFK may be
due to the detection of another active SFK member. Interestingly, the tissues with the highest
expression of c-Src and pSFK were metastatic adenocarcinomas (Table 4) from patients 2, 3, and
5 (Fig. 21), implying that increased c-Src expression and activity may contribute to the
metastatic state of the tumors.
Subsequently, the steady-state expression of OXPHOS complex subunits was also
examined in the two tissue groups using an antibody cocktail that detects the nuclear-encoded
subunits of complex I (NDUFB8), II (SDHB), III (UQCRC2), and V (ATP5A) and the
mitochondrial-encoded subunit of complex IV (COII) (Fig. 21), along with an antibody for
complex II (SDHA). The lysates were also probed with GAPDH antibody as a protein loading
control. Compared to the non-cancerous biopsies, the expression of complex III and V subunits
(UQCRC2 and ATP5A, respectively) were reduced in the cancerous tissues, while the subunits
of complexes I (NDUFB8) and II (SDHA and SDHB) were significantly decreased by roughly
55%, 45%, and 25%, respectively, as shown in Fig. 21. The expression of the mitochondrialencoded complex IV subunit (COII) was also substantially decreased by approximately 35% in
the cancerous liver tissues (Fig. 21). Surprisingly, the lowest expression of OXPHOS complexes
was also identified in the metastatic tissues from patients 2, 3, and 5 (Fig. 21), potentially
implicating impaired OXPHOS complex expression in cancer metastasis. The altered expression
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of both nuclear- and mitochondrial-encoded OXPHOS subunits implies that there may be a
possible defect in protein synthesis. Due to these findings, we investigated two factors essential
to the synthesis of mitochondrial proteins. The expression of both mitochondrial transcription
factor A (TFAM) and mitochondrial elongation factor Tu (EF-Tu) was comparable between the
two tissue types, signifying that the synthesis of nuclear- and mitochondrial-encoded OXPHOS
subunits may be regulated by c-Src kinase. These results strongly suggest that increased c-Src
expression is correlated with reduced OXPHOS subunit expression and may play a role in liver
cancer.
To further examine the impaired OXPHOS complex expression observed in the
cancerous liver tissues above, we analyzed the expression of several crucial metabolic enzymes
that control OXPHOS by regulating pathways such as the citric acid cycle (CAC), fatty acid beta
oxidation, and pyruvate metabolism, including peroxisomal acyl-coenzyme A oxidase 1
(ACOX1), citrate synthase (CS), pyruvate dehydrogenase (PDH), as well as mitochondrial
markers heat shock protein 60 (HSP60) and voltage-dependent anion channel (VDAC)/porin.
The expression of ACOX1, the first enzyme of the fatty acid beta oxidation pathway, is
significantly decreased in the cancerous tissues from patients 2, 3, and 5, indicating that fatty
acid beta oxidation is reduced in these patients which possibly implies lower energy production
through oxidative phosphorylation, as observed by reduced expression of OXPHOS complexes
(Fig. 22). Next, we also examined the expression of citrate synthase, one of the major
checkpoints for the CAC. CS expression was comparable between the cancerous and noncancerous liver tissues (Fig. 22) suggesting that the CAC activity is relatively equal between the
two tissue types. Due to these findings, we further analyzed other metabolic pathways and
enzymes that converge onto the CAC, such as PDH. The expression of PDH, which is a critical
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enzyme involved in the regulation of pyruvate metabolism by catalyzing the conversion of
pyruvate to acetyl-CoA and connecting glycolysis to the CAC and mitochondrial oxidative
metabolism. The expression of PDH was higher in the cancerous tissues of patients 2, 3, and 5
(Fig. 22), implying that pyruvate metabolism is high in liver cancer tissues. Interestingly, c-Src
expression, which has been shown to phosphorylate, inactivate PDH, and cause a restraint on the
pyruvate flux into mitochondrial metabolism (Y. Jin et al., 2016), was increased in these
cancerous liver tissues (Fig. 21). Therefore, although the expression of PDH was increased, the
presence of high c-Src expression may inhibit the activity of PDH, causing these metastatic
tissues to rely more on glycolysis than mitochondrial oxidative metabolism, the Warburg effect.
Combined, our results suggest that c-Src may be contributing to the metabolic reprogramming of
cancer tissues and inducing cancer metastasis by impairing mitochondrial oxidative
phosphorylation.
To ensure the reduction in the expression of OXPHOS complexes was not a result of
decreased mitochondrial presence, we assessed the expression of two mitochondrial markers,
VDAC/porin and HSP60. The expression of VDAC/porin, found in the mitochondrial outer
membrane, was comparable between cancerous and non-cancerous tissues, implying comparable
amounts of mitochondria between each liver tissue analyzed (Fig. 22). The expression of HSP60,
a mitochondrial chaperone protein that is responsible for the folding and assembly of newly
imported proteins in the mitochondria, is reduced (Fig. 22). Additionally, minor differences were
observed in the expression of mitochondrial matrix protein, CS, between the cancerous and noncancerous liver tissues, demonstrating that mitochondrial content was almost equal levels in both
tissue types. These findings suggest that the decrease in OXPHOS complex expression was
largely a result of the expression and activation of c-Src kinase.
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Patient

Age

Tissue type

Metastasis

Disease state

1

18

T

+

Adenocarcinoma

2

20

T

+

Adenocarcinoma

3

28

T

+

Adenocarcinoma

4

31

T

-

Adenoma

5

43

T

+

Adenocarcinoma

6

58

N

-

Benign cyst

7

36

N

-

Hyperplasia

8

69

N

-

Bilary cystadenoma

9

73

N

-

Macrovesicular
steatosis

Table 4. Characterization of liver tumor and non-cancerous tissues.
T: primary tumor
N: non-cancerous tissue
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Figure 21. c-Src expression is increased in metastatic liver cancer tissues. The
expression of OXPHOS subunits, including NDUFB8 (complex I), SDHA and SDHB
(complex II), UQCRC2 (complex III), COII (complex IV), and ATP5A (complex V)
were detected by Western blot analyses. The expression of c-Src kinase, mitochondrial
transcription factor A (TFAM), and mitochondrial elongation factor Tu (EF-Tu) were
also detected. Approximately 30 µg of whole cell lysates from each tissue was separated
by 12% SDS-PAGE, and equal protein loading was determined by GAPDH antibody and
Ponceau S staining of the membranes. The bar graphs represent the average quantitative
analyses from densitometry of the expression of c-Src (top right panel) and the OXPHOS
complex subunits (bottom right panel) of the two groups. Significant differences were
identified in c-Src (P=0.0488), COII (P=0.0028), SDHA (P=0.0253), SDHB (P=0.0001),
and NDUFB8 (P=0.0001). The data is represented as the mean ± SD of at least three
experiments for each tissue group and are presented as a percentage of the non-cancerous
tissues (non-cancerous tissues = 100%) (see Table 4 for details). Significant differences
were observed between the non-cancerous and cancerous tissues via unpaired Student’s ttests (2-tailed), *P < 0.05.
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Figure 22. Metabolic pathways are altered between cancerous and non-cancerous
liver tissues. The expression of peroxisomal acyl-coenzyme A oxidase (ACOX1), citrate
synthase (CS), pyruvate dehydrogenase (PDH), heat shock protein 60 (HSP60), and
voltage-dependent anion channel (VDAC)/porin were detected by Western blot analyses.
See Fig. 21 legend for details.
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4.3.2. c-Src is Expressed in Metastatic Liver Cancer Cell Line
The findings from the liver biopsies led us to further explore the relationship between cSrc and OXPHOS complex expression by studying their expressions in whole cell lysates from
two of the most common liver cancer cell lines, Hep3B and HepG2, which are isolated from
patients with primary HCC and hepatoblastoma (HB), respectively (Lopez-Terrada, Cheung,
Finegold, & Knowles, 2009; Qiu et al., 2015; Slany et al., 2010). HepG2 cells express proteins
that are characteristic of normal hepatocytes, while proteins expressed in Hep3B cells are
involved in the induction of the epithelial mesenchymal transition (EMT) (Slany et al., 2010).
Due to the increased expression of c-Src in the metastatic liver biopsies, we first assessed its
expression in both cell lines. c-Src expression was clearly increased in Hep3B cells compared to
almost no expression in HepG2 cells (Fig. 23A). Surprisingly, we found relatively similar SFK
phosphorylation between Hep3B and HepG2 cell lines (Fig. 23A), indicating other SFK
members are active in the two cell lines. Since a handful of SFKs have been located in the
mitochondria (Salvi et al., 2002; Tibaldi et al., 2008), we analyzed the expression of some of
these kinases. The expression of Lyn was comparable between the two cell lines (data not
shown), while the expression of Lck and Fyn (data not shown) were increased in HepG2 cells, as
previously described (E. C. Koc et al., 2016). Therefore, the expression of Lyn, Lck, Fyn, c-Src,
and other SFKs contribute to the pSFK signal detected in Hep3B and HepG2 cells. Yet, our
results clearly show c-Src expression is only found in the metastatic Hep3B cell line.
The mitochondrial localization of c-Src has been shown to increase (Arachiche et al.,
2008; Ogura et al., 2012) or decrease (Demory et al., 2009; Y. Jin et al., 2016) the OXPHOS
activity and expression in various cell lines. Due to our findings in the liver biopsies and the
expression of c-Src in the Hep3B liver cancer cell line only, we investigated the relationship
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between c-Src and changes in mitochondrial energy metabolism by observing the expression of
OXPHOS subunits. Similar to what was found in the metastatic cancerous liver tissues from
patients 2, 3, and 5 (Fig. 21), the subunits of complexes II, III, and V were decreased in Hep3B
cells compared to HepG2 cells (Fig. 23A), with significant reductions in the expression of the
nuclear-encoded subunit of complex I and the mitochondrial-encoded subunit of complex IV
(NDUFB8 and COII, respectively) in Hep3B cells (Fig. 23A). Even with a lower expression of
mitochondrial-encoded COII, the expression of EF-Tu and TFAM were comparable between the
two cell lines (Fig. 23A). These results imply that c-Src may regulate the expression of both
nuclear- and mitochondrial-encoded OXPHOS subunits in liver cancer tissues and cell lines.
Next, we determined the effects of the reduced expression of NDUFB8 and COII on
mitochondrial oxidative phosphorylation and energy metabolism by performing complex I and
III and complex IV enzymatic activity assays in both cell lines. As shown in Fig. 23B, a
significant decrease of approximately 60% was observed in the complex I and III activity and a
reduction of about 50% was found in the complex IV activity in Hep3B cells compared to
HepG2 cells. The impaired mitochondrial enzymatic activities of complexes I and III and
complex IV in Hep3B cells can be attributed to the reduction of the expression of nuclearencoded NDUFB8 and mitochondrial-encoded COII, which are two core subunits of complexes I
and IV, respectively. The reduced COII expression and activity are in agreement with previous
studies that demonstrate reduced complex IV activity due to the phosphorylation of COII by cSrc and EGFR (Boerner et al., 2004; Demory et al., 2009). Since reactive oxygen species (ROS)
are major byproducts of oxidative phosphorylation, we examined the ROS production between
Hep3B and HepG2 cell lines. ROS generation was significantly reduced in Hep3B cells, which is
possibly a result of the decreased OXPHOS expression and activity found in Hep3B cells.
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Although Hep3B cells have significantly lower OXPHOS function, cell proliferation was
increased compared to HepG2 cells.
To further study the decrease in OXPHOS in Hep3B cells, we analyzed the expression of
several metabolic enzymes that control OXPHOS. The expression of ACOX1 was increased in
Hep3B cells compared to HepG2 cells, demonstrating increased fatty acid oxidation in these
cells (Fig. 23C). The expression of CS, PDH, and lactate dehydrogenase A (LDHA) were
decreased in Hep3B cells implying that the reduction in oxidative phosphorylation may be a
result of impaired CAC and pyruvate metabolism and further suggesting that Hep3B cells may
rely more on anaerobic glycolysis for energy metabolism. In fact, both PDH and LDHA have
known to be phosphorylated by c-Src and induce a more metastatic phenotype in various cancers
(L. Jin et al., 2017; Y. Jin et al., 2016; J. Zhang et al., 2017), similar to our observation in Hep3B
cells. Reductions in the expression of these metabolic enzymes could be caused by the
diminished OXPHOS subunit expression and/or activity in the Hep3B cell line. Although the
expression of mitochondrial marker, HSP60, is comparable between Hep3B and HepG2 cells
indicating similar mitochondrial presence in the two cell lines, mitochondrial OXPHOS is
regulated by c-Src kinase expression and activity. Along with an aberrant activity of c-Src,
decreased expression of OXPHOS complexes I and IV and reduced mitochondrial function have
been correlated with cancer metastasis and the induction of EMT (Gaude & Frezza, 2016;
Porporato et al., 2014). The expression of several EMT factors analyzed were increased in
Hep3B compared to HepG2 cell lines (data not shown), confirming the metastatic state of Hep3B
cells, as previously described (Qiu et al., 2015; Slany et al., 2010). Furthermore, our findings
suggest that increased c-Src expression may impair OXPHOS expression and activity which
could contribute to the metastatic phenotype of the Hep3B cell line.

112

Figure 23. c-Src is overexpressed in liver cancer cell lines. A) The expression of OXPHOS complex
subunits, c-Src kinase, and mitochondrial proteins TFAM and EF-Tu were detected by Western blot
analyses in Hep3B and HepG2 cell lines. Additionally, the phosphorylation of SFK members at the
activation site, Tyr416 (pSFK), was also observed. Equal protein concentration was determined by
GAPDH antibody expression and Ponceau S staining of the membranes. Quantification of the average
expression of OXPHOS complex subunits between the two cell lines is shown in the bar graph (right
panel). The results represent the mean ± SD of at least three independent experiments. Significant
difference was observed between HepG2 and Hep3B cells in OXPHOS subunits COII (P = 0.0104) and
NDUFB8 (P = 0.0001). The data is presented as a percentage of HepG2 protein expression (HepG2 cells
= 100%). B) HepG2 and Hep3 cells were grown for 48 h and proliferation was measured by the Trypan
blue exclusion assay (cell proliferation). Combined complex I and III activity was determined by
measuring the rate of cytochrome c reduction at 550 nm using equal amounts (10 µg) of whole cell
lysates obtained from HepG2 and Hep3B cells. Complex IV enzymatic activity was determined by
measuring the rate of cytochrome c oxidation spectrometrically at 550 nm using equal amounts of HepG2
and Hep3B whole cell lysates. ROS generation was assessed with the Amplex Red assay using equal
concentrations of HepG2 and Hep3B cell lysates. Significant differences were observed between Hep3B
and HepG2 cells in complex I and III activity (P = 0.0001), complex IV activity (P = 0.0139), cell
proliferation (P = 0.013), and ROS generation (P = 0.0002). C) The expression of metabolic enzymes
peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), citrate synthase (CS), pyruvate dehydrogenase
(PDH), lactate dehydrogenase A (LDHA), and heat shock protein 60 (HSP60) were detected by Western
blot analyses of HepG2 and Hep3B cell lines. See Fig. 21 legend for details. Values are presented as
mean ± SD for at least three experiments and presented as a percentage of HepG2 (HepG2 = 100%).
Significant differences were observed between Hep3B and HepG2 cells via unpaired student’s t-test (2tailed) with Welch’s correction, *P < 0.05.
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4.3.3. Inhibition of c-Src Stimulates the Expression of OXPHOS Subunits
Our data provide strong evidence that c-Src expression is associated with impaired
OXPHOS complex expression and activity in liver cancer cells. Since aberrant expression of cSrc was shown in metastatic liver cancer tissues and cell lines (Figs. 21 and 23) and has been
correlated with cancer metastasis, recurrence, adverse prognosis, and resistance to therapies
(Yeatman, 2004; S. Zhang et al., 2011; R. Zhao et al., 2015), we investigated c-Src kinase as a
potential target for liver cancer therapies by treating Hep3B and HepG2 cell lines with the
selective SFK inhibitor PP2 at concentrations ranging from 0 – 10 µM for 72 h and investigated
the steady-state expression of OXPHOS complex subunits. PP2 is a membrane-permeable
inhibitor that blocks the ATP binding site of c-Src and prevents activation without altering its
expression (Hanke et al., 1996; Hebert-Chatelain, 2013).
We first determined the effect of PP2 treatments on c-Src kinase in Hep3B cells and
observed a substantial decrease of approximately 40% in phosphorylation at Tyr416 (pSFK)
using the pSFK and the phospho-Tyr antibody, along with a reduction in the overall Tyr
phosphorylation at PP2 concentrations ranging from 0 to 5 µM (Fig. 24A). Although SFK
phosphorylation was lower, minor differences in the expression of c-Src were observed in the
presence of PP2 (Fig. 24A). Interestingly, the suppression of c-Src kinase stimulated the
expression of nuclear-encoded NDUFB8 and mitochondrial-encoded COII in a concentrationdependent manner, with a significant increase of approximately 50% in their expression at 5 µM
PP2, as shown in Fig. 24A. However, minor changes were found in most of the nuclear-encoded
OXPHOS complex subunits, SDHB, UQCRC2, and ATP5A in the presence of PP2 (Fig. 24A).
Despite the higher expression of COII and NDUFB8, the expression of EF-Tu and TFAM were
comparable between the treated and control cells (Fig. 24A), demonstrating that the increased
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expression of OXPHOS subunits may be a result of c-Src inhibition and decreased Tyr
phosphorylation. To determine if the increases in the expression of NDUFB8 and COII altered
the function of complexes I and IV, respectively, we performed complex I and III and complex
IV enzymatic activity assays. Significant increases were measured in the complex I and III
activity of Hep3B cells treated with 2.5 and 5 µM PP2 (Fig. 24B). Similar increases were found
in the complex IV activity of PP2 treated Hep3B cells (Fig. 24B). Additionally, the proliferation
of Hep3B cells was decreased by approximately 65% and 80% at 2.5 and 5 µM PP2, respectively
(Fig. 24B). The results of these studies demonstrated that the inhibition of c-Src kinase by PP2
stimulated OXPHOS complex expression which may be therapeutically beneficial to increase
mitochondrial energy metabolism and possibly contribute to the decrease in cell proliferation.
In addition to Hep3B cells, we treated the HepG2 cell line with PP2 at concentrations
ranging from 0 to 10 µM for 72 h. Minor differences were found in the expression of OXPHOS
complex subunits in HepG2 treated cells compared to the control cells (Fig. 25). Yet, we showed
a clear reduction in the proliferation of HepG2 cells, which was associated with reduced SFK
phosphorylation at increasing concentrations of PP2 (data not shown). Although PP2 treatments
reduced cell proliferation in both Hep3B and HepG2 cell lines by suppressing phosphorylation at
Tyr416, the increase in OXPHOS complex subunits COII and NDUFB8 were only observed in
Hep3B cells. These findings strongly imply that c-Src impairs OXPHOS expression, which can
be alleviated when c-Src activity is suppressed.
As shown in Fig. 24C, siRNA mediated knock down of c-Src kinase reduced c-Src
expression and activity relative to the cells transfected with control siRNA in Hep3B cells. The
expression of NDUFB8 and COII of complexes I and IV, respectively, were slightly increased by
approximately 40% in cells transfected with c-Src siRNA (Fig. 24C). The expression of SDHB

115

and UQCRC2, of complexes II and III, respectively, were also increased; however, the
expression of ATP5A of complex V remained unchanged (Fig. 24C). Minor differences were
observed in the expression of TFAM and EF-Tu (data not shown), implying that the increase
found in the expression of OXPHOS complexes may be a result of the suppression of c-Src. The
increase in the expression of NDUFB8 and COII in Hep3B cells transfected with c-Src siRNA is
similar to what was observed in PP2 treated Hep3B cells (Fig. 24A). These findings provide
further evidence that c-Src inhibition stimulates OXPHOS expression and increases
mitochondrial energy metabolism. Therefore, c-Src should be closely evaluated as a therapeutic
agent for cancers with increased c-Src expression and activity.
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Figure 24. Inhibition of c-Src increases OXPHOS expression in the Hep3B cell line. A) Hep3B cells
were treated with 0 – 5 µM Src family kinase (SFK) inhibitor PP2 for 72 h before collection. Changes in
the expression of OXPHOS complex subunits, c-Src, pSFK, Tyr phosphorylation (pTyr), EF-Tu, and
TFAM were measured by Western blot analyses with respect to GAPDH antibody probing and Ponceau S
staining of the membranes as equal protein loading controls. The phosphorylation of SFK members
(pSFK) was detected by the pTyr antibody, indicated by an arrow, as well as the pSFK antibody that
detects phosphorylation at Tyr416. The quantitative analyses of the expression of OXPHOS subunits are
represented as mean ± SD of at least three experiments for each group (bar graph, right panel). Significant
differences were observed in the expression of COII (P = 0.0091) and NDUFB8 (P = 0.024) at 5 µM PP2.
B) Cell proliferation of PP2 treated Hep3B cells were measured with the Trypan blue exclusion assays
after 72 h treatment. Statistical difference was shown between the control and 2.5 µM (P = 0.001) and 5
µM (P = 0.0001) PP2. Complex I and III and complex IV activities were measured by determining the
rates of cytochrome c reduction and oxidation, respectively, at 550 nm. Significant differences were
observed in the complex I and III activity at 2.5 µM (P = 0.0122) and 5 µM (P = 0.0006) PP2 and
complex IV activity at 2.5 µM (P = 0.0002) and 5 µM (P = 0.0001) PP2. C) Western blot analyses were
used to identify changes in Hep3B cells transfected with with c-Src siRNA (c-Src) relative to control
siRNA (cont). The quantitative analyses of OXPHOS expression are represented as the mean ± SD of at
least three experiments for each group (bar graph, right panel). Significant differences were observed in
the expression of COII (P = 0.0397) and NDUFB8 (P = 0.0022) between the control and c-Src siRNA
transfected Hep3B cells. Data represents the mean ± SD of at least three independent experiments. The
results are presented as a percentage of the control cells (cont = 100%). Statistical difference was
observed between the control and treatment groups via unpaired Student’s t-test (2-tailed), *P < 0.05.
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Figure 25. PP2 treatments of HepG2 cells reduce cell proliferation without altering
OXPHOS expression. HepG2 cells were treated with 0 – 10 µM PP2 for 72 h before
collection. Expression of OXPHOS complex subunits, including NDUF8 (complex I),
SDHA and SDHB (complex II), UQCRC2 (complex III), COII (complex IV), and
ATP5A (complex V) were detected by Western blot analyses. Approximately 30 µg of
protein lysates from HepG2 cells treated with PP2 were separated by 12% SDS-PAGE
and equal protein loading was assessed by Ponceau S staining and GAPDH antibody
probing of the membranes.
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4.3.4. c-Src Expression Impairs the Expression of OXPHOS Complexes
Above, we clearly showed increased c-Src expression was associated with impaired
OXPHOS expression and activity, especially complexes I and IV, in metastatic liver cancer
tissues and cell lines which was alleviated when c-Src activity was suppressed. Our findings
imply that c-Src kinase regulates mitochondrial oxidative phosphorylation by altering the
expression and activity of its complexes. To further examine the functional significance of c-Src
on mitochondrial energy metabolism, we investigated changes in the expression of OXPHOS
complexes in more homogenous cellular system. For this purpose, we used the mouse embryonic
fibroblast (MEF) cell line (WT cells), MEF cells with functional null mutations in both alleles of
c-Src, Yes, and Fyn (SYF cells), MEF cells with an endogenous expression of wild-type c-Src
and null mutations in Yes and Fyn (Src++ cells), and SYF cells with a stable over expression of
wild-type c-Src kinase (Src cells). Detection of c-Src expression by Western blot analyses in all
four cell lines revealed varying expression of c-Src in WT, Src++ and Src cells (Fig. 26A)
compared to its complete knock down in SYF cells. The pSFK level was significantly higher in
Src++ and Src cells compared to SYF cells with the highest phosphorylation in WT cells (Fig.
26A). The phosphorylation of Tyr416 in WT cells could be a result of the activation of c-Src as
well as Yes, Fyn, and other SFKs expressed in WT cells. The levels of pSFK detection in WT,
Src++, and Src cell lines can also be correlated to the level of Tyr phosphorylation in these cell
lines (Fig. 27) confirming both c-Src expression and activity in Src++, Src, and WT cells
compared to SYF cells.
We assessed the steady-state expression of OXPHOS subunits in the four cell lines using
an OXPHOS antibody cocktail that detects subunits from nuclear-encoded complex I
(NDUFB8), II (SDHB), III (UQCRC2), V (ATP5A), and the mitochondrial-encoded complex IV
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(COI) (Fig. 26A). Significant reductions were observed in the expression of the nuclear-encoded
complex I (NDUFB8) and mitochondrial-encoded complex IV (COI) subunits with increasing cSrc expression in WT, Src++, and Src cells compared to the SYF cells (Fig. 26A). On the
contrary, the expression of complex II, III, and V subunits were comparable among all the cell
lines (Fig. 26A). These results strongly suggest that c-Src expression impairs the expression of
complex I and IV subunits in mouse embryonic fibroblast cells.
To determine the effect of reduced NDUFB8 and COI expressions, we performed
mitochondrial complex I and III and complex IV enzymatic activity assays in WT, SYF, Src++,
and Src cells. The activity of complex I and III was significantly decreased with an increasing
expression of c-Src found in WT, Src++, and Src cells compared to SYF cells (Fig. 26B).
Similarly, the complex IV activity was also decreased in WT, Src++, and Src cells compared to
the SYF cell line (Fig. 26B). Therefore, the impaired mitochondrial function and diminished
complex I and III and complex IV activities can be attributed to the reduced expression of the
core subunits, NDUFB8 and COI, and the associated increase in the expression of c-Src in these
cells.
c-Src kinase has also been shown to control cell proliferation, migration, and adhesion;
consequently, we examined the cell proliferation of fibroblast cells with and without c-Src
expression. In cells expressing c-Src, cell proliferation was significantly higher compared to SYF
cells (Fig. 26B). Increased cell proliferation and c-Src activity are correlated with high glycolytic
metabolism by inhibiting PDH activity and OXPHOS, as previously described (Y. Jin et al.,
2016). Therefore, the increased c-Src expression could also cause inhibition of PDH activity,
resulting in diminished OXPHOS as observed in MEF cell lines (Fig. 26). These findings are in
agreement with our Hep3B cell line data shown above and further imply that c-Src alters the
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enzymatic activity of OXPHOS complexes, possibly by changing the expression of their
subunits. Together, our results obtained with liver biopsies and cell lines suggest that c-Src
expression regulates mitochondrial function in both normal and cancerous cells.
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Figure 26. c-Src expression reduces OXPHOS expression in fibroblast cells. A) Mouse embryonic
fibroblast (MEF) cells with functional null mutations in both alleles of three SFK members, c-Src, Yes,
and Fyn (SYF), MEF cells with the endogenous expression of c-Src and null mutations in Yes and Fyn
(Src++), SYF cells with the overexpression of c-Src (Src), and wild-type embryonic fibroblast cells (WT)
were cultured. Expression of OXPHOS complex subunits, including NDUFB8 (complex I), SDHB
(complex II), UQCRC2 (complex III), COI (complex IV), and ATP5A (complex V) were detected by
Western blot analyses of WT, SYF, Src++, and Src cell lines. The expression of c-Src and pSFK were
also detected with respect to GAPDH and Ponceau S staining as a control for equal protein loading.
Quantification of the average expression of OXPHOS complex subunits between SYF and WT, Src++,
and Src cells is shown in the bar graph (right panel). Significant differences were observed in the
expression of COI between SYF and WT (P = 0.0426), Src++ (P = 0.0017), and Src (P = 0.0001) and in
the expression of NDUFB8 between SYF and WT (P = 0.0163), Src++ (P = 0.0033), and Src (P =
0.0016). B) WT, SYF, Src++, and Src cells were grown for 24 h and proliferation was measured by the
Trypan blue exclusion assay (cell proliferation). Significant differences were observed in the cell
proliferation between SYF and WT (P = 0.0007), Src++ (P = 0.0018), and Src (P = 0.0014). The complex
I and III and complex IV enzymatic activities were determined by measuring the reduction and oxidation
rate, respectively, of cytochrome c using equal amounts of whole cell lysates obtained from WT, SYF,
Src++, and Src cells. Significant differences were observed in the complex I and III activity between SYF
and WT (P = 0.0071), Src++ (P = 0.0001), and Src (P = 0.0002) and complex IV activity (P = 0.0001).
Results are expressed as mean ± SD for at least three experiments and are presented as a percentage of
SYF cells (SYF = 100%). Significant differences were observed between SYF, WT, Src++, and Src cells
via unpaired student’s t-tests (2-tailed) to measure statistical significance, *P < 0.05. See Fig. 23 legend
for details.
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Figure 27. Increased tyrosine phosphorylation is correlated with increased c-Src.
The overall tyrosine phosphorylation and the expression of citrate synthase (CS) and
pyruvate dehydrogenase (PDH) were detected by Western blot analyses in WT, SYF,
Src++, and Src cells. See Fig. 26 legend for details.
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4.3.5. c-Src Inhibition with PP2 Stimulates the Expression of OXPHOS Subunits
Our data provide strong evidence that c-Src expression is associated with impaired
OXPHOS complex expression and activity in normal and cancerous cells. To investigate if the
inhibition of c-Src kinase activity could improve OXPHOS subunit expression and function, we
first treated MEF cell lines expressing the highest c-Src kinase, Src cells, with PP2 for 24 to 48
h. As expected, PP2 treatments decreased overall Tyr phosphorylation and the phosphorylation
of c-Src at Tyr416 without influencing the c-Src expression (Fig. 28A). Interestingly, the steadystate expression of nuclear-encoded NDUFB8 and mitochondrial-encoded COI subunits of
complexes I and IV, respectively, were significantly increased with PP2 treatments compared to
the control cells, while minor changes were observed in the expression of the remainder of the
OXPHOS subunits detected by the rodent antibody cocktail (Fig. 28A). Despite the higher
expression in COI and NDUFB8, the expression of EF-Tu and TFAM (data not shown) were
comparable, suggesting that the increase in the expression of OXPHOS subunits may be a result
of the inhibition of c-Src kinase activity and the associated changes in Tyr phosphorylation.
Subsequently, significant increases of roughly 40% and 50% were observed in the
enzymatic activities of complexes I and III and complex IV in PP2 treated Src cells, respectively,
which may be a result of the stimulated expression of the NDUFB8 and COI subunits (Fig. 28B).
In fact, the OXPHOS subunit expression and activity found in PP2 treated Src cells was
comparable to the subunit expression of the SYF cell line (Figs. 26 and 28). The morphology of
PP2 treated Src cells became similar to SYF cells (data not shown). Clearly, cell proliferation
was also reduced by approximately 50% in PP2 treated Src cells compared to the control cells
(Fig. 28B), further demonstrating the role of c-Src on cell proliferation and morphology.
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In addition to the treatment of Src cells with PP2, we also treated the WT, Src++, and SYF
cell lines with PP2. Similar to what was observed in Src cells, we detected an increase in the
expression of NDUFB8 and COI of complexes I and IV, respectively, in PP2 treated Src++ cells
(Fig. 29) and WT cells (data not shown). The increases in the expression of NDUFB8 and COI
were correlated with a decrease in c-Src activity, determined by the changes in the pSFKs at
Tyr416 and total Tyr phosphorylation. Additionally, increasing concentrations of PP2 were also
correlated with significant decreases in cell proliferation in Src++ (Fig. 29) and WT (data not
shown) cell lines. To ensure the increases in the expression of OXPHOS complexes I and IV
were a result of reduced c-Src activity, we treated SYF cell lines with PP2 for 48 h and observed
the effects on OXPHOS complexes. Although the cell proliferation was diminished in SYF cells
treated with PP2, the OXPHOS subunit expressions were comparable between the control and
PP2 treated SYF cells (Fig. 30). Combined, these results demonstrate the negative effects of cSrc on mitochondrial OXPHOS and energy metabolism, cell proliferation, and cell morphology
which can be alleviated in the presence of an SFK inhibitor, such as PP2.
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Figure 28. Inhibition of c-Src stimulates mitochondrial OXPHOS expression in Src
cells. A) Src cells were treated with DMSO (cont) or 5 µM Src family kinase (SFK)
inhibitor PP2 (PP2) for 24 h before collection. Changes in OXPHOS complex subunits,
c-Src, and EF-Tu expression were measured by Western blot analyses with respect to
GAPDH as a loading control. The phosphorylation of SFK members (pSFK), around 60
kDa, detected by the pTyr antibody, is indicated by an arrow. Quantitation of
mitochondrial protein expression of OXPHOS complex subunits are represented as the
mean ± SD of at least three experiments (right panel) and expressed as a percentage of
the control cells (cont = 100%). Significant difference was observed between PP2 treated
Src cells in mitochondrial-encoded COI and nuclear-encoded NDUFB8 subunits via an
unpaired student’s t-test (2-tailed), *P-value < 0.05. B) Cell proliferation, complex I and
III activity, and complex IV enzymatic activity of PP2 treated Src cells were measured
after 24 h treatments. Significant differences were observed between the cont and PP2
treated Src cells in the cell proliferation (P = 0.0003), complex I and III activity (P =
0.0001), and complex IV activity (P = 0.0001). Results are presented as the mean ± SD of
at least three experiments and expressed as a percentage of the control cells (cont =
100%). The statistical significance was analyzed by unpaired student’s t-tests (2-tailed),
*P < 0.05. See Fig. 26 legend for details.
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Figure 29. Inhibition of c-Src with PP2 stimulates OXPHOS expression in Src++
cells. A) Src++ cells were treated with 0 – 5 µM PP2 for 24 h before collection. The
expression of OXPHOS complex subunits were detected by Western blot analyses with
respect to GAPDH as a loading control. The quantitation of the protein expression of
OXPHOS subunits are represented as the mean ± SD of at least three experiments (right
panel) and are expressed as a percentage of the control cells (cont = 100%). Significant
difference was observed between PP2 treated Src++ cells in mitochondrial-encoded COI
(P = 0.0084) and nuclear-encoded NDUFB8 (P = 0.0022) subunits. B) Cell proliferation
was measured between the control and PP2 treated Src++ cells and significant difference
was observed (P = 0.0003). Results are presented as the mean ± SD of at least three
experiments and expressed as a percentage of the control cells (cont = 100%). The
statistical significance was analyzed by unpaired student’s t-tests (2-tailed), *P < 0.05.
See Fig. 28 legend for details.
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Figure 30. PP2 treatments of SYF cells reduce cell proliferation without changing
the expression of OXPHOS complexes. SYF cells were treated with 0 – 10 µM PP2 for
48 h before collection. Expression of OXPHOS complex subunits were detected by
Western blot analyses with respect to Ponceau S staining of the membrane. See Fig. 28
legend for details.
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4.3.6. c-Src Knock Down Increases OXPHOS Complex Expression
Above, we demonstrated that the increasing expression of c-Src was correlated with a
decrease in OXPHOS subunit expression and activity in cells treated with PP2. To further
investigate c-Src inhibition, we transfected WT, Src++, and Src cell lines with mouse specific cSrc siRNA. The c-Src expression was significantly reduced in WT, Src++, and Src cell lines
(Figs. 31A, 31B, and 31C, respectively) transfected with c-Src siRNA relative to cells treated
with control siRNA. A significant increase was observed in the expression of NDUFB8 and COI
of complexes I and IV, respectively, in all three cell lines transfected with c-Src siRNA (Fig. 31).
The remainder of the OXPHOS complexes analyzed, were comparable between the cells
transfected with the control and c-Src siRNAs. Clearly, the increases in OXPHOS complex
expression was a result of the c-Src knock down in these MEF cell lines expressing c-Src to
varying degrees. Therefore, our findings strongly suggest that c-Src regulates mitochondrial
energy metabolism by inhibiting the expression and activity of OXPHOS complexes, specifically
complexes I and IV. Furthermore, our results demonstrate that therapies targeting c-Src kinase
alleviate the inhibition on mitochondrial oxidative phosphorylation and could be beneficial for
the treatment of cancers with elevated c-Src expression and activity.

129

Figure 31. c-Src knock down increases the expression of OXPHOS complexes. A)
WT, Src++ (B), and Src (C) cells were transfected with c-Src specific siRNA (c-Src) and
control siRNA (cont). The expression of OXPHOS complex subunits were detected by
Western blot analyses with respect to GAPDH antibody probing and Ponceau S
membrane staining as loading controls. Quantitation of the expression of OXPHOS
complex subunits are represented as the mean ± SD of at least three experiments (right
panel) and expressed as a percentage of the control siRNA cells (cont = 100%).
Significant difference was observed between c-Src and control siRNA transfected cells in
the expression of NDUFB8 and COI in WT cells (P = 0.0001 and P = 0.0029,
respectively), Src++ cells (P = 0.0020 and P = 0.0056, respectively), and Src cells (P =
0.0004 and P = 0.0356, respectively). Statistical differences were analyzed between the
cont and c-Src siRNA transfected cells with the unpaired student’s t-tests (2-tailed), *P <
0.05.
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4.4. Conclusions
Increased c-Src expression and activity are recognized as major underlying factors in the
development of various diseases, including cancer, and is also suggested to contribute to
increased metastatic, recurrence, and resistance rates in HCC (Masaki et al., 1998; R. Zhao et al.,
2015). Although many systemic agents have been studied, to date, Sorafenib is the only
approved drug for the systemic treatment of HCC, which has been shown to only extend the life
of patients by 3-4 months (Daher et al., 2018; Llovet et al., 2008; Wilhelm et al., 2008).
Interestingly, c-Src is located in the mitochondria and shown to alter mitochondrial energy
metabolism via regulating OXPHOS complexes (Demory et al., 2009; Hebert-Chatelain et al.,
2012; Miyazaki et al., 2003; Ogura et al., 2012). In some cases, c-Src has also been shown to
induce the Warburg effect by inhibiting mitochondrial energy metabolism (Y. Jin et al., 2016;
Wallace, 2012). Therefore, due to the various functions of c-Src in cell signaling, a better
understanding of its role in mitochondrial energy metabolism in cancer and normal cells is
essential.
In this study, we examined the effects of aberrant c-Src expression on mitochondrial
energy metabolism by determining the relative changes in the expression of OXPHOS subunits
in human liver cancer biopsies and cell lines. We clearly demonstrated that increased expression
of c-Src was associated with an impaired expression of OXPHOS complex subunits in metastatic
liver cancer biopsies and the Hep3B cell line. More importantly, we showed diminished
OXPHOS complex expression and activity in mouse embryonic fibroblast cells expressing c-Src
kinase alone. These results exhibited an inhibitory effect of c-Src on mitochondrial OXPHOS
expression in both health and disease.
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Both c-Src kinase and mitochondrial energy metabolism have become important targets
for cancer therapy. We investigated the effects of c-Src inhibition on mitochondrial energy
metabolism by treating cells with the SFK inhibitor PP2 as well as transfecting cells with c-Src
siRNA. A significant increase in the expression of complex I and IV and their corresponding
activities was shown in the metastatic Hep3B cell line in addition to c-Src expressing mouse
fibroblast, WT, Src++, and Src, cell lines treated with PP2 and c-Src siRNA. Interestingly, the
inhibition of c-Src was also shown to reduce cell proliferation in Hep3B and c-Src expressing
MEF cells, suggesting that c-Src regulates by modulating OXPHOS. Our results provide a better
understanding of the relationship between c-Src and OXPHOS expression in normal and
cancerous cells. Additionally, our results indicate that c-Src inhibition should be utilized in anticancer therapies to reduce cell proliferation and improve mitochondrial function.
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Abstract
Mitochondrial dysfunction plays a role in the development and progression of many
different diseases, including cancer. The mitochondrion is not only important for energy
production via oxidative phosphorylation (OXPHOS), but it also plays a major role in the
production of reactive oxygen species (ROS), a byproduct of OXPHOS. Aberrant levels of ROS
are major characteristics of mitochondrial dysfunction and the development and progression of
various diseases and cancers. Fyn kinase, a Src family tyrosine (Tyr) kinase (SFK), is activated
by oxidative stress and has been reported in various diseases. Additionally, Fyn was found in the
mitochondria and shown to regulate mitochondrial OXPHOS. However, inhibitors that target
both Fyn and mitochondrial OXPHOS have yet to be identified. In this study, we examined the
role of Fyn kinase, along with the effect of the SFK inhibitor, SU6656, and natural antioxidants,
kaempferol and resveratrol, on the expression of OXPHOS complexes. Fyn expression was
correlated with high OXPHOS complex expression, which was reduced when cells were treated
with SU6656 and kaempferol. Furthermore, the treatment of these cells with SU6656,
kaempferol, and resveratrol significantly reduced cell proliferation. Evidence provided in this
study reveals that Fyn regulates mitochondrial energy metabolism by altering the expression of
OXPHOS complex subunits, which can be contributing factors to the development and
progression of cancer. Our findings strongly suggest that the suppression of Fyn significantly
reduces cell proliferation, implying that targeting the regulation of mitochondrial function by
SFK inhibitors and natural antioxidants could prove valuable in cancer treatments.
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5.1. Introduction
Mitochondria are unique organelles that are responsible for producing over 90% of the
cell’s energy in the form of ATP via oxidative phosphorylation (OXPHOS). The mitochondria
also play essential roles in various cellular processes such as energy metabolism, cell survival
and death, calcium homeostasis, and the generation of free radicals (Bhatti, Bhatti, & Reddy,
2017; J. A. Kim et al., 2008; Osellame et al., 2012). Reactive oxygen species (ROS), a family of
free radicals (Halliwell, 2006), are produced as a byproduct of OXPHOS through leakage at
complexes I and III (Q. Chen, Vazquez, Moghaddas, Hoppel, & Lesnefsky, 2003; Turrens, 2003;
Turrens & Boveris, 1980). An uncontrolled production of ROS can contribute to oxidative stress
which leads to cell damage, altered mitochondrial redox signaling, damage to regulatory
proteins, mitochondrial membranes, and DNA, and mitochondrial dysfunction (Bhatti et al.,
2017; Duchen, 2004; Finkel & Holbrook, 2000; Murphy, 2009). Interestingly, both
mitochondrial dysfunction and oxidative stress have been reported as contributing factors in the
development of a number of diseases including cancer (Bhatti et al., 2017; Dalle-Donne et al.,
2006; Dhalla et al., 2000; Mitchell & Darley-Usmar, 2012; Petersen et al., 2003; Roberts &
Sindhu, 2009; Sayre et al., 2001). Both genetic predisposition and environmental factors
contribute to the development of diseases, which is attributed to oxidative stress generated
through mitochondrial dysfunction. Although mitochondrial dysfunction has been established as
a key factor in disease states, regulatory mechanisms for mitochondrial energy metabolism and
ROS generation are not well understood.
Fyn kinase, a non-receptor Src family tyrosine (Tyr) kinase has emerged as a regulator of
diverse pathological processes including the immune response, cell proliferation and adhesion,
and has been shown to play a major role in metabolism and insulin signaling (Cary, Chang, &
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Guan, 1996; T. W. Lee et al., 2013; Saito, Jensen, Salgia, & Posadas, 2010; Thomas & Brugge,
1997). Fyn was also reported as an inhibitor of AMP-activated protein kinase (AMPK) and fatty
acid oxidation in the mitochondria (Bastie et al., 2007; Yamada, Pessin, Kurland, Schwartz, &
Bastie, 2010). More importantly, Fyn is activated by oxidative stress and was located within the
mitochondria where it regulates mitochondrial pathways (Lewandrowski et al., 2008; Salvi et al.,
2002; Salvi et al., 2005). Recently, our laboratory has demonstrated the implication of Fyn with
mitochondrial translation which is responsible for the synthesis of the 13 core subunits of
OXPHOS complexes I, III, IV, and V and established the association of Fyn with increased
mitochondrial translation and OXPHOS complex expression (E. C. Koc et al., 2016). As a result
of its involvement in various cellular pathways, the hyperactivation of Fyn has contributed to the
development of neurodegenerative diseases and multiple types of cancers (Elias et al., 2015;
Saito et al., 2010; Schenone et al., 2011) indicating the need for novel therapeutic strategies.
Although SFK inhibitors have been tested as potential cancer therapies (Finn et al., 2013; Lau et
al., 2009; E. L. Mayer & Krop, 2010), the clinical data are limited. Due to the high levels of ROS
found in cancer cells (Delmas et al., 2000; H. Guo et al., 2016; Liao et al., 2010; Zhu et al.,
2018), natural antioxidants, kaempferol and resveratrol, have also been studied as
chemotherapeutic agents. Even though these two antioxidants reduce cell proliferation in some
studies and were reported to have inhibitory effects on Src kinase pathways (K. M. Lee et al.,
2010; Oz et al., 2019), their role on the inhibition of Fyn and effects on mitochondrial OXPHOS
remains to be elucidated.
In this study, we investigated the role of Fyn kinase on mitochondrial energy metabolism
by analyzing the expression and activity of OXPHOS complexes. Additionally, we studied the
effects of Fyn inhibition on mitochondrial energy metabolism and cell proliferation to examine
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Fyn kinase as a potential target for the treatment of metabolic diseases with high Fyn kinase
activity. Our studies strongly indicate that Fyn regulates the expression of OXPHOS complexes.
Furthermore, our findings provide evidence that Fyn inhibition can be used as possible
therapeutic strategies to prevent the progression of cancer by regulating mitochondrial energy
metabolism and reducing cell proliferation.
5.2. Materials and Methods
5.2.1. Cell Culture
Monolayer cultures of HepG2 and Hep3B cell lines purchased from the American Type
Culture Collection (ATCC) were maintained in DMEM medium (HyClone, Thermo-Scientific,
Waltham, MA) adjusted to contain 4 mM glutamine, 1 mM pyruvate, 10% fetal bovine serum
(FBS) (Rocky Mountain Biologicals, Missoula, MT), and 1% penicillin/streptomycin (P/S)
(Corning Cellgro, Manassas, VA). The cells were grown in a humidified incubator at 37 °C and
5% CO2. Collected cells were treated with sodium orthovanadate to preserve Tyr
phosphorylation (Hebert Chatelain et al., 2011; Nishikawa et al., 2009).
For treatments, HepG2 and Hep3B cells were seeded at 25 x 104 cells/mL in DMEM
containing 0.2% FBS and incubated for 24 h. The media was then replaced with fresh DMEM
containing 10% FBS and cells were treated for 48 – 72 h. The two cell lines were treated with the
Src kinase inhibitor SU6656 (2,3-Dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol2-yl)methylene]-1H-indole-5-sulfonamide) (Millipore Sigma, St. Louis, MO) (Blake et al., 2000)
dissolved in dimethyl sulfoxide (DMSO) at concentrations ranging from 0 – 10 µM.
Additionally, both cell lines were treated with natural antioxidants kaempferol and resveratrol
(Calbiochem, EMD Millipore, Burington, MA), also dissolved in DMSO), at concentrations
ranging from 0 – 50 µM, as previously described by our laboratory (Cimen et al., 2010). For cell
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proliferation, cells were counted using the Trypan blue exclusion assay. The results are
represented as the mean ± SD of triplicates from at least three experiments for each group and
are presented as a percentage of the control (DMSO treated) cells.
5.2.2. Western Blot Analysis
Cell pellets were lysed in RIPA buffer containing 50 mM Tris-HCl (pH 7.6), 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP40, 0.1% SDS, 0.5% DOC, 1 mM PMSF, and protease
and phosphatase inhibitor cocktails. Protein concentrations were determined by BCA assays
(Pierce, Rockford, USA) using bovine serum albumin (BSA) as a standard. The protein lysates
were separated by 12% SDS-PAGE, transferred to nitrocellulose membranes (Amersham, GE
Healthcare, Pittsburg, PA) and stained with Ponceau S to ensure equal protein loading. The
membranes were blocked in 5% (w/v) dry skim milk powder and 1% BSA dissolved in Trisbuffered saline (TBS) containing 0.05% Tween20 (TBST) and incubated with the corresponding
primary antibodies overnight at 4 °C. The antibody for the OXPHOS complex cocktail was
obtained from Mitosciences (Eugene, OR). The Fyn and phosphotyrosine (PY-20) antibodies
were purchased from Sigma Aldrich (St. Louis, MO). The GAPDH antibody used as the protein
loading control was obtained from Fitzgerald (Acton, MA). The phospho-Src family (pSFK) at
Tyr416 (pTyr416) and phosphotyrosine (PY-100) antibodies were purchased from Cell Signaling
Technologies (Danvers, MA). The pSFK antibody detects the phosphorylation of Fyn and other
family members, c-Src, Lyn, Yes, Hck, and Lck, at the kinase activation site, Tyr416, or the
equivalent residue. Mitochondrial elongation factor Tu (EF-Tu) and mitochondrial transcription
factor A (TFAM) antibodies were kind gifts from Dr. Linda Spremulli and Dr. Craig Cameron,
respectively. The protein immunoreactivities were detected using the protocols provided by the
manufacturer. Un-Scan-It (Silk Scientific Inc., Orem, UT) and ImageJ (Schneider et al., 2012)
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were used to quantify protein band intensities. Quantified protein values were normalized to the
protein loading determined by GAPDH antibody probing and Ponceau S staining of the
membranes. The expression of each protein was quantified from individual cell lysates from at
least three independent experiments. The results of the protein quantifications represent the mean
± SD for each sample and are expressed as a percentage of the control.
5.2.3. Mitochondrial Complex IV Enzymatic Activity Assays
Cell pellets from HepG2 and Hep3B cell lines were dissolved in a 50 mM phosphate
buffer (pH 7.4) containing 1 mM EDTA and 100 µM reduced cytochrome c. The assay was
performed by monitoring cytochrome c oxidation at 550 nm, as previously described (BirchMachin & Turnbull, 2001). The rate was calculated by dividing the difference in absorbances
between two linear points by the difference in time points: Rate = (Abs 1 – Abs 2)/(Time 2 –
Time 1). The enzymatic data are expressed as the mean ± SD of at least three experiments and
are presented as a percentage of the control.
5.2.4. Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6.07. Statistically significant
differences were determined between HepG2 and Hep3B cell lines as well as control and treated
cells using unpaired student’s t-tests (2-tailed), *P < 0.05. All data are expressed as the mean ±
SD, unless otherwise specified.
5.3. Results and Discussion
5.3.1. Fyn Kinase is Expressed in HepG2 Cells and Associated with Increased
OXPHOS
Fyn kinase is expressed in a variety of cell types and has therefore been identified as a
factor in the involvement of numerous diseases (Bastie et al., 2007; Elias & Ditzel, 2015;
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Matsushima et al., 2016; Saito et al., 2010). Additionally, Fyn kinase is one of the few SFK
members found within the mitochondria (Lewandrowski et al., 2008; Salvi et al., 2002; Salvi et
al., 2005) and has recently been shown to regulate mitochondrial protein synthesis and OXPHOS
expression (E. C. Koc et al., 2016). We evaluated two human liver cancer cell lines to study the
role of Fyn expression on mitochondrial OXPHOS expression and energy metabolism. An
increased expression of Fyn kinase was found in HepG2 cells compared to almost no expression
in the Hep3B cell line (Fig. 32A). Although Fyn kinase expression was absent in Hep3B cells,
the phosphorylation of SFK members at the activation site, Tyr416 (pSFK), was comparable
between the two cell lines (data not shown). Tyr416 is located within the activation loop of the
kinase domain and is therefore responsible for the activity of Fyn and other SFK members when
phosphorylated (T. Hunter, 1987; Thomas & Brugge, 1997). Since the phospho-Src family
kinase (pSFK) antibody detects endogenous Fyn phosphorylation at Tyr416, as well as other
family members at equivalent activation sites, these findings imply that other SFKs besides Fyn
are active in Hep3B cells.
The differential endogenous expression of Fyn kinase between HepG2 and Hep3B cell
lines allowed us to investigate its role on the expression of OXPHOS complexes. Reduced
expression of OXPHOS subunits of complexes II, III, and V, as well as a significant decrease of
approximately 80% in the expression of subunits of OXPHOS complexes I and IV, were
associated with the absence of Fyn kinase in Hep3B cells relative to the expression of OXPHOS
complexes found in HepG2 cells (Fig. 32A). To determine the effect of endogenous Fyn kinase
expression on mitochondrial function, complex IV enzymatic activity assays were performed in
the two cell lines. The activity of complex IV was significantly lower by roughly 40% in Hep3B
cells (Fig. 32B). This impaired activity could be a result of the reduced expression of one of the
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core subunits of complex IV, COII. Due to the decreased expression in one of the essential 13
mitochondrial-encoded proteins COII, we analyzed the expression of mitochondrial transcription
factor A (TFAM) and mitochondrial elongation factor Tu (EF-Tu) to determine if changes in two
of the main transcription and translation factors contributed to the decreased expression of COII.
However, minor differences were observed in the expression of TFAM (data not shown) and EFTu (Fig. 33A). To further evaluate the reduction in COII, we performed quantitative RT-PCR
analyses on several mitochondrial-encoded transcripts to determine if a defect is present in the
expression of mitochondrial genes. The mRNA expression of COII, and other mitochondrialencoded genes analyzed, were comparable between HepG2 and Hep3B cells (data not shown).
Together, these results suggest that the reduction in mitochondrial-encoded COII was possibly a
result of the absence of Fyn kinase expression and the associated reduction in Tyr
phosphorylation in the Hep3B cell line. These findings are also in agreement with results
previously published by our group (E. C. Koc et al., 2016) and imply that Fyn kinase regulates
mitochondrial energy metabolism, possibly by increasing the expression of OXPHOS
complexes.
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Figure 32. Fyn increases OXPHOS expression in the HepG2 liver cancer cell line. A)
The relative expression of Fyn kinase, OXPHOS complex subunits, and mitochondrial
proteins TFAM and EF-Tu were detected by Western blot analyses and compared
between the HepG2 and Hep3B cell lines. The expression of OXPHOS subunits,
including NDUF8 (complex I), SDHB (complex II), UQCRC2 (complex III), COII
(complex IV), and ATP5A (complex V) were detected. Equal protein loading was
determined by GAPDH antibody expression and Ponceau S staining of the membranes.
Quantification of the average expression of OXPHOS complex subunits between the two
cell lines is shown in the bar graph (right panel). The results represent the mean ± SD of
at least three independent experiments. Significant difference was observed in OXPHOS
subunits COII (P=0.001) and NDUF8 (0.0001) of complexes IV and I respectively
between HepG2 and Hep3B cells. The protein quantitation data is presented as a
percentage of HepG2 protein expression. B) Complex IV enzymatic activity was
determined by spectrometically measuring the rate of cytochrome c oxidation at 550 nm
using equal amounts of whole cell lysates from HepG2 and Hep3B cells. Enzymatic
activity assay values are presented as mean ± SD for at least three experiments and
presented as a percentage of the HepG2 complex IV activity. Significant difference was
observed between HepG2 and Hep3B cells via unpaired student’s t-test (2-tailed) with
Welch’s correction, *P < 0.05.
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5.3.2. SU6656 Inhibits SFKs and Decreases OXPHOS Complex Expression
In an effort to further identify the role of Fyn in mitochondrial OXPHOS and energy
metabolism, we treated HepG2 and Hep3B cell lines with the SFK inhibitor SU6656 and
monitored the differences in the expression of OXPHOS complexes. SU6656 is a small
molecule, potent inhibitor of ubiquitously expressed SFK members Fyn, c-Src, Yes, and Lyn
(Blake et al., 2000). We first treated HepG2 cells with SU6656 and observed a decrease in Tyr
phosphorylation with increasing concentrations of SU6656 (Fig. 33A). This reduction was
associated with a decrease in the phosphorylated SFK band at Tyr416 (pSFK, pTyr416) implying
that the SU6656 treatment inhibits the activation of SFKs in HepG2 cells (Fig. 33A). Although
Tyr and SFK phosphorylation were reduced when cells were exposed to SU6656, the expression
of Fyn was comparable to cells without treatment (Fig. 33A).
Subsequently, in addition to lower SFK and Tyr phosphorylation, reductions were
observed in the expression of the mitochondrial-encoded subunit of complex IV and the nuclearencoded subunit of complex II, COII and SDHB respectively, by approximately 25% with a
more substantial reduction of roughly 45% found in the expression of complex I subunit NDUF8
at the highest SU6656 concentration (Fig. 33A). The expression of the remainder of OXPHOS
subunits, UQCRC2 and ATP5A (Fig. 33A), along with EF-Tu and TFAM (data not shown) were
comparable between the treated and control HepG2 cells. Our findings with SU6656 treatments
are supported by previous studies by our laboratory demonstrating reduced mitochondrial
translation with Fyn inhibition by siRNA (E. C. Koc et al., 2016), implying the effect of SU6656
treatment is a result of reduced Fyn kinase activity. Additionally, due to the role of Fyn activity
on cell growth and proliferation (Cary et al., 1996; Schlessinger, 2000; Thomas & Brugge,
1997), we assessed the effect of Fyn inhibition by SU6656 on cell proliferation and observed a
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significant reduction in HepG2 cell proliferation with increasing concentrations of SU6656 (Fig.
33B). Together our data further suggests that Fyn regulates mitochondrial energy metabolism by
stimulating OXPHOS complex expression. Furthermore, treatment with SU6656 reduces
OXPHOS expression as well as cell proliferation, implying a potential role of Fyn in cell growth
in health and disease.
As a result of the impaired expression of OXPHOS complexes and the significant
reduction in the proliferation of HepG2 cells treated with SU6656, we also treated the Hep3B
cell line with SU6656 to observe possible changes in energy metabolism since it has a
comparable expression of pSFK to HepG2 cells. Similar to HepG2 cells, lower SFK
phosphorylation which coincided with reduced Tyr phosphorylation was found in Hep3B cells
treated with SU6656, yet minor differences were observed in the expression of mitochondrial
OXPHOS complexes (data not shown). Interestingly, a clear reduction in cell proliferation was
shown in SU6656 treated Hep3B cells in a concentration-dependent manner (data not shown).
The differences in the expression of OXPHOS complexes in SU6656 treated HepG2 and Hep3B
cells are possibly due to the endogenous expression of Fyn kinase in HepG2 cells compared to
almost no expression in Hep3B cells. These findings further imply that Fyn regulates
mitochondrial energy metabolism by altering the expression of OXPHOS complexes and suggest
that SFK inhibition can be beneficial for the treatment of diseases with high Fyn activity.
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Figure 33. SU6656 inhibits SFKs and decreases OXPHOS expression HepG2 cells.
HepG2 cells were treated with 0 – 10 µM SFK inhibitor SU6656 for 72 h before
collection. A) The expression of OXPHOS complex subunits, Fyn, pTyr, EF-Tu, and
TFAM were measured by Western blot analyses with respect to GAPDH antibody
probing and Ponceau S staining of the membranes as controls for equal protein loading.
The phosphorylation of SFKs (pSFK) was detected by the pTyr antibody and indicated
by an arrow. The quantification of OXPHOS subunits is represented in bar graph (right
panel). B) Cell proliferation of SU6656 treated HepG2 cells were measured with the
Trypan blue exclusion assays after 72 h treatment and is shown as the mean ± SD of at
least three experiments with statistical significance between the control and 5 µM
(P=0.001) and 10 µM (P=0.001) SU6656. The results are represented as a percentage of
the control. Statistical difference was observed between the control and treatment groups
via unpaired Student’s t-test (2-tailed), *P < 0.05.
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5.3.3. Kaempferol Impairs OXPHOS Expression by Inhibiting SFKs
Kaempferol and resveratrol have anti-oxidant, chemo-preventative, anti-tumor, and antiinflammatory pharmacological activities (H. Guo et al., 2016; Y. B. Huang et al., 2014; Liao et
al., 2010; M. Singh et al., 2014; Udenigwe et al., 2008; Zhu et al., 2018) and have been shown to
improve mitochondrial function in various cancer types (Cimen et al., 2010; Haohao et al., 2015;
Lagouge et al., 2006). In addition to its many beneficial properties, kaempferol was shown to act
as a c-Src kinase inhibitor by blocking the ATP-binding site of Src kinases and inhibiting their
downstream signals (K. M. Lee et al., 2010). Fyn has been reported to be activated when
exposed to oxidative stress. Since mitochondria produce the majority of ROS via oxidative
phosphorylation to meet biosynthetic demands for cell proliferation (Wallace, 2012), we treated
HepG2 and Hep3B cells with natural antioxidants kaempferol and resveratrol to observe their
effects on Fyn kinase activity and OXPHOS complex expression.
A reduction in SFK phosphorylation was observed in a concentration-dependent manner
with a decrease of approximately 35% at the highest kaempferol concentration (Fig. 34A). This
decrease in SFK phosphorylation was associated with a reduction in the Tyr phosphorylation of
proteins in HepG2 cells treated with kaempferol (Fig. 34A). Although kaempferol was identified
as a c-Src kinase inhibitor (K. M. Lee et al., 2010), the high sequence conservation between Fyn
and c-Src makes Fyn a likely target for kaempferol’s inhibitory effect. Therefore, our results
imply kaempferol acts as an SFK inhibitor in HepG2 cells and reduces the activity of SFKs by
decreasing phosphorylation at the activation site, Tyr416 (pSFK).
Along with reduced SFK phosphorylation, a clear decrease was observed in the nuclearencoded subunits of complexes I, NDUF8, and II, SDHA/SDHB, and the mitochondrial-encoded
subunits of complex IV, COII, with increasing concentrations of kaempferol (Fig. 34A). The
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expression of the remainder of the complex III, UQCRC2, and complex V, ATP5A, subunits
analyzed were comparable to the control cells (Fig. 34A). To determine if the decrease in the
expression of mitochondrial-encoded COII was due to changes in mitochondrial transcription
and/or translation, we studied the mRNA expression of mitochondrial-encoded transcripts and
the protein expression of TFAM and EF-Tu. Minor differences were found in the mRNA
transcript expression (data not shown) and the expression of TFAM (data not shown) and EF-Tu
(Fig. 34A), indicating the decreases in OXPHOS expression were a result of changes in Tyr
phosphorylation by SFK inhibition. These results are in agreement with our SU6656 treatment
data above. Our findings further demonstrate the possible regulation of mitochondrial OXPHOS
by Fyn kinase. Furthermore, a significant reduction in cell proliferation was observed in a
concentration-dependent manner (Fig. 34B). These findings reveal that kaempferol acts as an
SFK inhibitor to reduce OXPHOS expression and lower cell proliferation. Therefore, kaempferol
could potentially be used as a therapeutic tool to prevent the progression of cancer.
To observe if kaempferol had similar effects on Hep3B cells, the Hep3B cell line was
also treated with kaempferol, which did not cause major changes in the expression of OXPHOS
complexes under these conditions (Fig. 35A). Interestingly, a reduction in SFK phosphorylation,
as shown with the pTyr antibody, and a correlated decrease in Tyr phosphorylation was found
when Hep3B cells were treated with kaempferol (data not shown). However, similar to HepG2
cells, Hep3B cell proliferation was significantly decreased with increasing concentrations of
kaempferol (Fig. 35B). Our findings were also supported by previous studies demonstrating that
kaempferol-mediated reduction of the proliferation of Hep3B cells (Berger et al., 2013).
Together, these results suggest that kaempferol acts as an SFK inhibitor in both cell lines and
dramatically reduces cell proliferation.
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Figure 34. Kaempferol impairs OXPHOS, reduces cell proliferation, and inhibits
SFK activity in the HepG2 cell line. HepG2 cells were treated with 0 – 50 µM
kaempferol for 48 h before collection. A) The expression of OXPHOS subunits,
phosphorylated Src at Tyr416 (pSFK), pTyr, EF-Tu, and TFAM were detected by
Western blot analyses in three cell lysates with equal protein loading was evaluated by
GAPDH antibody probing and Ponceau S staining of the membranes. The average
quantitative analyses of the expression of OXPHOS subunits in the triplicates is shown in
the bar graph (right panel) and statistical difference was observed in the expression of
NDUF8 (P=0.001), SDHA (P=0.0007), SDHB (0.0135), and COII (0.0001) between the
control and 50 µM kaempferol treatment (Kaemp). The results are represented as the
mean ± SD of at least three experiments. B) Cell proliferation of kaempferol treated
HepG2 cells was measured with the Trypan blue exclusion assays after 48 h treatment.
Data is represented as the mean ± SD and statistical significance was found at 50 µM
(P=0.0001) kaempferol. The results are represented as a percentage of the control.
Statistical difference was observed between the control and treatment groups via unpaired
Student’s t-test (2-tailed), *P < 0.05.
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Figure 35. Kaempferol suppresses cell proliferation in the Hep3B cell line. Hep3B
cells were treated with 0 – 50 µM kaempferol for 48 h before collection. A) The
expression of OXPHOS complex subunits were measured by Western blot analyses with
respect to GAPDH antibody probing and Ponceau S staining of the membranes as equal
loading controls for the control (0) and 25 µM (25) kaempferol treatments. B) Cell
proliferation of kaempferol treated Hep3B cells was measured with the Trypan blue
exclusion assays after 48 h treatment. Statistical significance was observed between the
control and 50 µM kaempferol treatment (P=0.0001). Results represent the mean ± SD of
at least three experiments and are presented as a percentage of the control cells.
Significant difference was analyzed by unpaired Student’s t-tests (2-tailed), *P < 0.05.
See Figure 34 legend for details.
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5.3.4. Resveratrol Reduces Cell Proliferation
The natural antioxidant kaempferol showed promise as a potential therapeutic agent to
improve cellular stress by decreasing OXPHOS expression in HepG2 cells and inhibiting cell
proliferation in both HepG2 and Hep3B cell lines. To determine whether other natural
antioxidants can be used as a treatment for metabolic disorders and mitochondrial dysfunction,
we treated the two liver cancer cell lines with resveratrol for 48 h. In HepG2 cells, we found
minor differences in the expression of nuclear- and mitochondrial-encoded OXPHOS subunits
when treated with resveratrol (Fig. 36A); however, a significant decrease in the cell proliferation
was observed (Fig. 36B). Similar results were obtained in Hep3B cells treated with resveratrol
with the expression of OXPHOS subunits comparable between the control and treated cells (Fig.
37A) while the cell proliferation was substantially diminished in a concentration-dependent
manner (Fig. 37B). Resveratrol has been shown to inhibit Src kinase pathways in cell cultures
(Oz et al., 2019), yet its role as an SFK inhibitor and the effects on mitochondrial OXPHOS have
not been identified. Under these conditions, resveratrol did not alter the steady-state expression
of OXPHOS subunits, but it clearly decreased cell proliferation in both HepG2 and Hep3B cell
lines, as demonstrated previously (Delmas et al., 2000; Udenigwe et al., 2008). Together, our
findings suggest that SFK inhibitors and natural antioxidants kaempferol and resveratrol should
be utilized in treatment regiments to prevent the progression of liver cancer by impairing cell
proliferation.
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Figure 36. Resveratrol treatment inhibits cell proliferation in the HepG2 cell line.
HepG2 cells were treated with 0 – 40 µM resveratrol for 48 h before collection. A) The
expression of OXPHOS complex subunits were measured by Western blot analyses with
respect to GAPDH antibody probing and Ponceau S staining of the membranes as equal
loading controls. B) Cell proliferation of resveratrol treated HepG2 cells was measured
with the Trypan blue exclusion assays after 48 h treatment. Significant reduction was
observed at 20 µM (P=0.0269) and 40 µM (P=0.0089) resveratrol concentrations. Results
represent the mean ± SD of at least three experiments and are presented as a percentage
of the control (0). Statistical differences were analyzed by unpaired student’s t-tests (2tailed) for statistical significance, p-value < 0.05 (*).

151

Figure 37. Resveratrol impairs cell proliferation in the Hep3B liver cancer cell line.
Hep3B cells were treated with 0 – 40 µM resveratrol for 48 h before collection. A) The
changes in OXPHOS complex subunit expression was measured by Western blot
analyses with respect to GAPDH antibody probing and Ponceau S staining of the
membranes as equal loading controls. B) Cell proliferation of resveratrol treated Hep3B
cells was measured with the Trypan blue exclusion assays after 48 h treatment.
Significant reduction was observed at both 20 µM (P=0.02) and 40 µM (P=0.0001)
resveratrol treatments. The results represent the mean ± SD of at least three independent
experiments and are presented as a percentage of the control (0). Statistical significance
was analyzed between the control and treatment groups via unpaired Student’s t-test (2tailed), *P < 0.05. See Fig. 36 legend for details.
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5.4. Conclusions
Mitochondria are essential for energy metabolism and ATP production via oxidative
phosphorylation and are also major contributors to the generation of ROS. Uncontrolled ROS
production can be detrimental to the cell and lead to mitochondrial dysfunction, which has been
reported as a factor in the development and progression of numerous diseases including cancer
(Bhatti et al., 2017; Dalle-Donne et al., 2006; Dhalla et al., 2000; Mitchell & Darley-Usmar,
2012; Petersen et al., 2003; Roberts & Sindhu, 2009; Sayre et al., 2001). Fyn kinase was located
in the mitochondria, shown to regulate mitochondrial translation and OXPHOS, and activated by
oxidative stress (E. C. Koc et al., 2016; Lewandrowski et al., 2008; Salvi et al., 2002; Salvi et al.,
2005). Aberrant activation of Fyn contributed to the development of many diseases and has been
reported as a key player in cancer resistance (Elias et al., 2015; Saito et al., 2010; Schenone et
al., 2011), yet to date, no Fyn inhibitors are currently available. Therefore, understanding the role
of Fyn and its inhibition on cell signaling and mitochondrial OXPHOS and energy metabolism is
crucial for the treatment of metabolic diseases.
In this study, we demonstrated that Fyn kinase expression was associated with increased
expression of OXPHOS complexes in liver cancer cell lines. These results suggested that the
aberrant activation of Fyn could result in the continual stimulation of OXPHOS and
mitochondrial dysfunction. To alleviate these effects and improve mitochondrial energy
metabolism, we treated cells with the SFK inhibitor, SU6656, and observed decreased OXPHOS
complex expression and cell proliferation. Additionally, we treated the cells with the natural
antioxidants, kaempferol and resveratrol, and found a significant reduction in cell proliferation
with both antioxidant treatments. A reduction in OXPHOS expression was only found in HepG2
cells treated with kaempferol. These findings suggest Src-dependent pathways promote cell
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proliferation in the two cell lines. Our data clearly show that Fyn regulates mitochondrial energy
metabolism by increasing OXPHOS complex expression, which can be alleviated when cells are
treated with SFK inhibitors. More significantly, our results highlight the importance of Fyn
inhibition in the treatment of cancer to slow disease progression and improve mitochondrial
energy metabolism.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS
6.1. Conclusions
Mitochondria are the metabolic hub of the cell and therefore, are responsible for
producing most of the cellular energy, ATP, through oxidative phosphorylation (OXPHOS) and
activating numerous cellular pathways. In mammals, the majority of OXPHOS complex subunits
are encoded in the nuclear genome and translocated into the mitochondria; however, 13 core
enzymatic subunits are encoded in the mitochondrial genome and synthesized within the
mitochondria by their own translation machinery. Changes in the expression of mitochondrial
proteins, including OXPHOS complexes, can be detrimental to many cellular pathways and more
importantly, mitochondrial biogenesis and energy metabolism. In fact, mitochondrial dysfunction
impacts cellular and whole-body metabolism and has been identified as the cause for several
metabolic diseases such as T2D and cancer. Therefore, a better understanding of key players
involved in the regulation of mitochondrial functions in health and disease is essential. In these
studies, we investigated mitochondrial biogenesis and energy metabolism by observing changes
in OXPHOS expression and activity and evaluated potential targets and therapies in two major
metabolic diseases, type 2 diabetes (T2D) and liver cancer. Together, our studies clearly
demonstrated that changes in the expression of OXPHOS complexes can significantly impair
mitochondrial energy metabolism and may contribute to the development of T2D and liver
cancer.
6.1.1. Mitochondrial Biogenesis is Impaired in TALLYHO/Jng Mice
The TALLYHO/Jng (TH) mouse is a polygenic model for human obesity and T2D (J. H.
Kim & Saxton, 2012; J. H. Kim et al., 2001). Gene mapping, whole genome sequencing, and
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metabolic characterizations have been performed and altered energy balance has been reported
(Franko et al., 2017; J. H. Kim et al., 2005; X. Mao et al., 2014; Parkman et al., 2017; Parkman
et al., 2016); however, the mechanism is largely unknown. Additionally, the role of
mitochondrial biogenesis and oxidative phosphorylation has yet to be identified in TH mice. In
this study, we investigated mitochondrial biogenesis by analyzing the expression of nuclear- and
mitochondrial-encoded translation machinery and OXPHOS complex subunits in mitochondrial
rich liver and kidney tissues of TH and B6 mice. We observed a significant decrease in the
expression of nuclear-encoded complex I subunits, NDUFS2 and NDUFB8, in the liver and
kidney of TH mice. These decreases in the expression were correlated with reduced complex I
and III enzymatic activity. Interestingly, a sequence variant was identified in the NDUFS2
subunit that may be related to the impaired expression and activity of complex I. We also found a
significant decrease in the mitochondrial-encoded subunits of complex IV, COI and COII, which
were correlated with diminished activity of complex IV. The expression of complex IV is
required for the stability and assembly of complex I (Diaz et al., 2006); therefore, the reduced
expression of the subunit of complex IV may contribute to the reduced complex I expression
observed in TH mice.
The reduction in COI and COII expression in TH mice indicated impaired mitochondrial
protein synthesis, since it is responsible for the synthesis of the 13 mitochondrial-encoded core
OXPHOS subunits. Although the expression of translation machinery was comparable between
TH and B6 mice, a sequence variant was identified in DARS2 which was predicted to alter the
tRNA binding during protein synthesis and inhibit OXPHOS expression in TH mice. Other
translation components, such as MRPL20 and other MRPs, were also reported to have sequence
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variants that may influence the mitochondrial protein synthesis and OXPHOS. We identified
factors that may contribute to the impaired mitochondrial biogenesis found in TH mice.
6.1.2. c-Src Impairs OXPHOS Expression and Activity
Aberrant expression of c-Src has been shown to induce malignant properties in various
cancer types including increased resistance, metastasis, and recurrence in HCC (Blume-Jensen &
Hunter, 2001; Irby & Yeatman, 2000, 2002; M. P. Kim et al., 2009; Masaki et al., 1998;
Yeatman, 2004). c-Src is located within the mitochondria and regulates mitochondrial energy
metabolism by phosphorylating enzymes in carbohydrate metabolism, pyruvate decarboxylation,
TCA cycle, and more important, OXPHOS complexes (Augereau et al., 2005; Hebert-Chatelain
et al., 2012; Y. Jin et al., 2016; Lewandrowski et al., 2008; Miyazaki et al., 2003; Salvi et al.,
2007). Interestingly, c-Src was shown to induce the Warburg effect by impairing mitochondrial
energy metabolism (Y. Jin et al., 2016; Wallace, 2012). Although c-Src is reported as a major
contributing factor to the development of HCC, its role in mitochondrial energy metabolism in
liver cancer is currently unknown. In this study, we investigated the role of c-Src on
mitochondrial energy metabolism in liver cancer and MEF cell lines. We clearly demonstrated
that reduced mitochondrial OXPHOS expression was correlated with an increased expression of
c-Src in metastatic liver cancer tissues and the metastatic HCC cancer cell line, Hep3B. The
decrease in OXPHOS expression was associated with impaired activity of OXPHOS complexes I
and III and complex IV. More importantly, we observed reduced OXPHOS complex expression
and activity in MEF cell lines expressing varying levels of c-Src kinase. Our data signifies an
inhibitory effect of c-Src on mitochondrial OXPHOS expression in health and disease.
Since c-Src and mitochondrial energy metabolism are currently targets for cancer
therapies, we treated liver cancer and MEF cell lines with the SFK inhibitor PP2 to investigate
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the inhibition of c-Src on mitochondrial energy metabolism. A significant increase was observed
in the expression of OXPHOS complexes I and IV and their activities with increased
concentrations of PP2 in both cell types. Interestingly, treatments with PP2 reduced cell
proliferation in Hep3B and MEF cells. Since PP2 inhibits multiple SFKs, we studied the direct
effect of c-Src inhibition on mitochondrial OXPHOS by transfecting Hep3B and MEF cells with
c-Src siRNA. Similar to PP2 treatments, cells transfected with c-Src siRNA showed increased
expression of OXPHOS complexes I and IV. These results indicate that c-Src inhibition should
be utilized as anti-cancer therapies to improve mitochondrial function while slowing cell growth
and proliferation. More importantly, our results clearly show the role of c-Src in the regulation of
energy metabolism and provide a better understanding of the relationship between c-Src and
OXPHOS in normal and cancerous cells.
6.1.3. Fyn Inhibition Reduces OXPHOS Expression and Cell Proliferation
Mitochondria are not only important for energy production via oxidative phosphorylation
(OXPHOS), but it also plays a major role in the production of reactive oxygen species (ROS), a
byproduct of OXPHOS. Uncontrolled ROS generation can be detrimental to the cell and has
been identified as a major characteristic of mitochondrial dysfunction (Bhatti et al., 2017; DalleDonne et al., 2006; Dhalla et al., 2000; Mitchell & Darley-Usmar, 2012; Petersen et al., 2003;
Roberts & Sindhu, 2009; Sayre et al., 2001). Fyn kinase, a Src family tyrosine (Tyr) kinase
(SFK), is activated by oxidative stress and is located within the mitochondria and shown to
regulate protein synthesis and OXPHOS (E. C. Koc et al., 2016; Lewandrowski et al., 2008;
Salvi et al., 2002; Salvi et al., 2005). Aberrant activation of Fyn contributed to the development
of many metabolic diseases and has been reported as a key player in cancer resistance (Elias et
al., 2015; Saito et al., 2010; Schenone et al., 2011). Inhibitors that target both Fyn and
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mitochondrial energy metabolism and OXPHOS have yet to be identified. In this study, we
examined the role of Fyn kinase, along with the effect of the SFK inhibitor, SU6656, and natural
antioxidants, kaempferol and resveratrol, on the expression of OXPHOS complexes. Increased
Fyn expression was correlated with high OXPHOS complex expression. These results suggested
that the aberrant activation of Fyn could result in the continual stimulation of OXPHOS and lead
to increased ROS production and mitochondrial dysfunction. The increase in OXPHOS was
alleviated when cells were treated with SU6656 and kaempferol. Furthermore, the treatment of
these cells with SU6656, kaempferol, and resveratrol significantly reduced cell proliferation.
Evidence provided in this study reveals that Fyn regulates mitochondrial energy metabolism by
altering the expression of OXPHOS complex subunits, which can be a contributing factor to the
development and progression of metabolic diseases such as cancer. Additionally, these results
suggest Src-dependent pathways promote cell proliferation in the two cell lines. Our findings
strongly suggest that the suppression of Fyn significantly reduces cell proliferation, implying that
improving mitochondrial function by SFK inhibitors and natural antioxidants could prove
valuable in the treatment of metabolic diseases.
6.2. Future Directions
In chapter 3, we reported impaired mitochondrial biogenesis, protein synthesis and
OXPHOS activity in TH mice. We identified sequence variants in the previously published
whole genome database for TH mice NDUFS2, DARS2, and MRPL20 as possible candidates for
reduced mitochondrial protein synthesis. To further examine the role of mitochondrial biogenesis
and energy metabolism in TH mice, mitochondria should be isolated from fresh liver and kidney
tissues of TH and B6 mice. Similar experiments should be performed to observe the expression
of mitochondrial proteins and measure the activity of OXPHOS complexes in isolated
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mitochondria instead of whole cell lysates. In addition to animal tissues, changes in
mitochondrial biogenesis and OXPHOS can be observed in various cell lines treated with very
high glucose concentrations to mimic hyperglycemic conditions found in insulin resistance and
T2D. The changes in the expression of OXPHOS complexes, as well as other mitochondrial
proteins involved in biogenesis, can be evaluated at different glucose concentrations. The
enzymatic activities of mitochondrial OXPHOS complexes should also be measured.
Additionally, site-directed mutagenesis should be used to create the major protein variants found
in TH mice to express within the cell culture models. Changes in the expression of OXPHOS
complexes and their enzymatic activities should be observed. By altering the sequences of
NDUFS2, DARS2, and MRPL20, we can evaluate the effects of these sequence variants on
mitochondrial biogenesis and energy metabolism, as well as determine any changes in the
metabolic activity that reflect changes observed in the obesity and T2D phenotypes of TH mice.
Resveratrol has been shown to activate mitochondrial biogenesis by altering the expression and
activity of PGC-1α and has been shown to improve glucose tolerance and oxygen consumption
(Lagouge et al., 2006). Therefore, the effects of resveratrol on glucose tolerance and
mitochondrial energy metabolism should be investigated by treating the cell lines with varying
concentrations of resveratrol and observing changes in the expression and activity of OXPHOS
complexes. These studies would provide a better understanding of the factors involved in
changes in mitochondrial biogenesis that may lead to mitochondrial dysfunction in obesity and
T2D and could provide therapeutic targets for improving disease prognosis and treatments.
In chapter 4, we determined the role of c-Src in the regulation of mitochondrial OXPHOS
in cancerous and normal cells. To better understand the relationship, further studies need to be
performed to identify c-Src targets within the mitochondria. Since complex IV subunits COI and
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COII are mitochondrial-encoded and are significantly reduced in the presence of c-Src and
mitochondrial proteins were shown to be associated with Fyn kinase, another SFK member
closely related to c-Src (E. C. Koc et al., 2016), the phosphorylation of MRPs by c-Src should be
evaluated. In vitro phosphorylation assays should be performed with isolated c-Src kinase and
cell lysates from MEF cells overexpressing c-Src kinase (Src cells). After identification of
phosphorylation sites, site-directed mutagenesis can then be performed to alter the Tyr residue to
mimic phosphorylation, which can then be transfected into cells overexpressing c-Src to examine
the effects on OXPHOS expression and activity. By identifying c-Src targets within the
mitochondria, we can get a better understanding of the effects c-Src has on more mitochondrial
pathways than OXPHOS, which should provide more targeted therapy options. Additionally, the
liver cancer cell lines Hep3B and HepG2, as well as the MEF cells with varying expressions of
c-Src, should be treated with FDA-approved multi-kinase inhibitors to observe their effects on
mitochondrial OXPHOS expression. These findings would allow us to better understand the
effects of these inhibitors on c-Src and how they alter mitochondrial energy metabolism.
In chapter 5, we evaluated the association of Fyn kinase with OXPHOS expression and
its effects when liver cancer cell lines were treated with the SFK inhibitor SU6656 and natural
antioxidants kaempferol and resveratrol. To better determine the effects of SU6656 and
kaempferol on mitochondrial oxidative energy metabolism, cells should be treated with the two
compounds and changes in mitochondrial biogenesis should be investigated. First, OXPHOS
complex enzymatic activity should be measured with the whole cell lysates obtained from liver
cancer cell lines treated with the two compounds. Furthermore, changes in the expression of
other mitochondrial components involved in mitochondrial biogenesis and OXPHOS regulation
should be observed in whole cell lysates treated with SU6656 and kaempferol compared to the
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control cells. Due to the association between increased Fyn and OXPHOS expression,
mitochondrial biogenesis and OXPHOS should be further evaluated in additional cell lines with
high Fyn expression. Once the correlation between Fyn and OXPHOS expression is identified,
cell lines should be treated with SU6656 and kaempferol to determine if these treatments can
potentially be used to inhibit cell growth and proliferation and improve mitochondrial function in
other cancer types. Fyn was also shown to phosphorylate MRPs (E. C. Koc et al., 2016);
therefore, identifying more Fyn targets within mitochondrial energy metabolism will be
beneficial to better understand the role of Fyn kinase on mitochondrial OXPHOS. In vitro
phosphorylation assays should be performed to identify Fyn-specific mitochondrial targets,
which can then be altered with site-directed mutagenesis, and transfected into various cell lines
with Fyn overexpression to determine the effects of the variants on Fyn activity and
mitochondrial energy metabolism. The results from these phosphorylation studies should provide
phosphorylation targets for further analyses and investigation.
Although our laboratory has clearly demonstrated the role of mitochondrial dysfunction
by impaired OXPHOS expression in T2D and liver cancer, further studies are needed to better
understand the involvement of the sequence variants identified in TH mice as well as c-Src and
Fyn kinase in the regulation of mitochondrial energy metabolism in T2D and liver cancer,
respectively.
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APPENDIX B: ABBREVIATIONS
5’-UTR…5’-untranslated region
A…adenine
AA…amino acid
aa-tRNA…aminoacyl-tRNA
ACOX1…acyl-coenzyme A oxidase 1
ADP…adenosine diphosphate
AKAP121/84…protein kinase A anchoring protein
AMPK…activated protein kinase
ANT1…ATP/ADP translocase 1
ANT2…ATP/ADP translocase 2
ARS2…amino acyl-tRNA synthetases
A-site…aminoacyl-site
ATCC…American Type Culture Collection
ATP…adenosine triphosphate
ATP5A…adenosine triphosphate subunit alpha
ATP6…adenosine triphosphate synthetase subunit 6
ATP8…adenosine triphosphate synthetase subunit 8
AUA…adenine, uracil, adenine
AUG…adenine, uracil, guanine
B6…C57BL/6J mice
BCA…bicinchoninic acid
BCL-xL…B-cell lymphoma-extra large
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BEZ…bezafibrate
BSA…bovine serum albumin
Ca2+…calcium
CAC…citric acid cycle
cDNA…complementary deoxyribonucleic acid
CO2…carbon dioxide
CO…cytochrome c oxidase
COBRE ACCORD…Center of Biomedical Research Excellence named Appalachian Center for
Cellular transport in Obesity Related Disorders
COI…cytochrome c oxidase subunit I
COII…cytochrome c oxidase subunit II
COIII…cytochrome c oxidase subunit III
Cont…control
CRIF1…CR6-interacting factor 1
CS…citrate synthase
Csk…C-terminal Src kinase
Cys (C)…cysteine
Cys245…cysteine 245
Cys487…cysteine 487
Cyt…cytochrome
Cyt b…cytochrome b
DARS2…aspartyl-tRNA synthetase 2
Dars2…aspartyl-tRNA synthetase 2 gene
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D-loop…displacement loop
DMEM…dulbecco’s modified eagle’s medium
DMSO…dimethyl sulfoxide
DNA…deoxyribonucleic acid
DOC…sodium deoxycholate
Dok4…downstream of tyrosine kinase docking protein 4
ECL…enhanced chemiluminescence
EDTA…ethylenediaminetetraacetic acid
EF-Tu…mitochondrial elongation factor Tu
EGFR…epidermal growth factor receptor
EGTA…ethylene glycol-bis (β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid
EMT…epithelial mesenchymal transition
FATP…fatty acid transport protein
FBS…fetal bovine serum
FDA…U.S. Food and Drug Administration
fMet-tRNA…formylmethionine-tRNA
FOXO1…forkhead box O1
FH…fumarate hydratase
GABC…Genomics and Bioinformatics Core
GAPDH…glyceraldehyde 3-phosphate dehydrogenase
GDP…guanosine diphosphate
GLUT4…glucose transporter 4
GTP…guanosine triphosphate
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G…guanine
H2O…water
H2O2…hydrogen peroxide
H-strand…heavy strand
HB…hepatoblastoma
HCC…hepatocellular carcinoma
HCl…hydrochloride
Hep3B…human hepatocellular carcinoma cell line 3B
HepG2…human hepatocellular carcinoma cell line G2
HER2…human epidermal growth factor receptor 2
HGF…hepatocyte growth factor
HK1…hexokinase 1
HK2…hexokinase 2
HSP1…H-strand promoter 1
HSP2…H-strand promoter 2
HSP60…heat shock protein 60
IDH1…isocitrate dehydrogenase 1
IDH2…isocitrate dehydrogenase 2
IGF-1R…insulin-like growth factor-1 receptor
IL-8…interleukin-8
IM…inner membrane
IMS…inter membrane space
IRS1…insulin receptor substrate 1
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IRS2…insulin receptor substrate 2
K+…potassium
Kaemp…kaempferol
kDa…kiloDalton
L-strand…light-strand
LDHA…lactate dehydrogenase A
Leu…leucine
LSP…light-strand promoter
LSU…large subunit
MEF…mouse embryonic fibroblast
Met…methionine
Mfn2…mitofusin 2
MM…mitochondrial matrix
MMPs…matrix metalloproteinases
MTERF1…mitochondrial termination factor 1
mRNA…messenger ribonucleic acid
MRP…mitochondrial ribosomal protein
MRPL…mitochondrial ribosomal proteins of the large subunit
MRPL11…mitochondrial ribosomal protein of the large subunit 11
MRPL15…mitochondrial ribosomal protein of the large subunit 15
MRPS…mitochondrial ribosomal proteins of the small subunit
MRPS18-B…mitochondrial ribosomal protein of the small subunit 18-B
MRPS29…mitochondrial ribosomal protein of the small subunit 29
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MRPS30…mitochondrial ribosomal protein of the small subunit 30
mt…mitochondria
mtDNA…mitochondrial deoxyribonucleic acid
mtEF-G1…mitochondrial elongation factor G1
mtEF-Ts…mitochondrial elongation factor Ts
mtEF-Tu…mitochondrial elongation factor Tu
mtEF-Tu:GTP:aa-tRNA…mitochondrial elongation factor Tu, GTP, and aa-tRNA complex
mtIF2…mitochondrial initiation factor 2
mtIF3…mitochondrial initiation factor 3
mtPEPCK…mitochondrial phosphoenolpyruvate carboxykinase
mtRF1a…mitochondrial translation release factor 1a
mtRRF1…mitochondrial ribosome recycling factor 1
mtRRF2…mitochondrial ribosome recycling factor 2
mTOR…mammalian target of rapamycin
N…normal tissue
NaCl…sodium chloride
NADH…nicotinamide adenine dinucleotide plus hydrogen
NASA…National Aeronautics and Space Administration
NCBI…National Center for Biotechnology Information
ND…NADH dehydrogenase
ND1…NADH dehydrogenase core subunit 1
ND2…NADH dehydrogenase core subunit 2
ND3…NADH dehydrogenase core subunit 3
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ND4…NADH dehydrogenase core subunit 4
ND4L…NADH dehydrogenase core subunit 4L
ND5…NADH dehydrogenase core subunit 5
ND6…NADH dehydrogenase core subunit 6
NDUFA4…NADH:ubiquinone oxidoreductase 1 alpha subcomplex 4
NDUFA13…NADH:ubiquinone oxidoreductase subunit A13
NDUFB8…NADH:ubiquinone oxidoreductase subunit B8
NDUFB10…NADH:ubiquinone oxidoreductase subunit B10
NDUFS2…NADH:ubiquinone oxidoreductase core subunit 2
Ndufs2… NADH:ubiquinone oxidoreductase core subunit 2 gene
NDUFS3…NADH:ubiquinone oxidoreductase core subunit A13
NDUFV1…NADH:ubiquinone oxidoreductase core subunit V1
NDUFV2…NADH:ubiquinone oxidoreductase flavoprotein 2
NIH…National Institute of Health
NP40…nonyl phenoxypolyethoxylethanol
NRF-1… nuclear respiratory factor-1
NRF-2…nuclear respiratory factor-2
OM…outer membrane
OPA1…optic atrophy 1
OXPHOS…oxidative phosphorylation
P/S…penicillin/streptomycin
PDGFR…platelet-derived growth factor receptor
PDH…pyruvate dehydrogenase
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PDHK1…pyruvate dehydrogenase kinase 1
PEP…phosphoenolpyruvate phosphatase
PGC-1α… peroxisome proliferator-activated receptor gamma coactivator 1-alpha
PGC-1β… peroxisome proliferator-activated receptor gamma coactivator 1-beta
PKA…protein kinase A
PMSF…phenylmethylsulfonyl fluoride
POLRMT…mitochondrial DNA-dependent RNA polymerase
PP2…(4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine)
pSFK…phosphorylated Src Family Kinases at Tyr416
PTEN…phosphatase and tensin homolog
PTMs…post-translational modifications
PTPα…protein tyrosine phosphatase alpha
PTCD1… pentatricopeptide repeat domain 1
PTPD1…protein tyrosine phosphatase D1
pTyr416…phosphorylated tyrosine 416
pTyr527…phosphorylated tyrosine 527
PY-20…phosphotyrosine antibody
PY-100…phosphotyrosine antibody
pYEEI…phosphotyrosine motif, phosphor Tyrosine-Glutamic acid-Glutamic acid-Isoleucine
qRT-PCR…quantitative real-time polymerase chain reaction
QTLs…quantitative trait loci
RIPA…radioimmunoprecipitation assay
RNA…ribonucleic acid
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ROS…reactive oxygen species
rRNA…ribosomal ribonucleic acid
RSV…Rous sarcoma virus
RTK…receptor tyrosine kinase
SAT…subcutaneous adipose tissue
SD…standard deviation
SDH…succinate dehydrogenase
SDHA…succinate dehydrogenase complex flavoprotein subunit A
SDHB…succinate dehydrogenase complex flavoprotein subunit B
SDHC…succinate dehydrogenase complex flavoprotein subunit C
Sdhc…succinate dehydrogenase complex subunit c gene
SDHD…succinate dehydrogenase complex flavoprotein subunit D
SDS…sodium dodecyl sulfate
SDS-PAGE…sodium dodecyl sulfate-polyacrylamide gel electrophoresis
Ser…serine
SFK…Src family kinases
SH…Src homology
SH1…Src homology domain 1, protein kinase domain
SH2…Src homology domain 2
SH3…Src homology domain 3
SH4…Src homology domain 4
SHP1…Src homology 2 domain-containing protein tyrosine phosphatase 1
SHP2…Src homology 2 domain-containing protein tyrosine phosphatase 2
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SIFT…sorting intolerant from tolerant
siRNA…small interfering ribonucleic acid
SRA…Sequence Read Archive
Src cells…MEF cells with null mutations in Yes and Fyn, overexpressing c-Src
Src++ cells…MEF cells with null mutations in Yes and Fyn, endogenous expression of c-Src
SSU…small subunit
Stat3…signal transducer and activator of transcription 3
SU6656…(2,3-Dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]
1H-indole-5-sulfonamide)
SYF cells…MEF cells with functional null mutations in Src, Yes, and Fyn
T…primary tumor
T2D…type 2 diabetes
TBS…Tris-buffered saline
TBST…Tris-buffered saline with Tween-20
TCA…tricarboxylic acid
TEFM…mitochondrial transcription elongation factor
TFAM…mitochondrial transcription factor A
TFB2M…mitochondrial transcription factor B2
TH…TALLYHO/Jng mice
Thr…threonine
Tris-HCl…Tris-hydrochloride
tRNA…transfer ribonucleic acid
Trp…tryptophan
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TUFM…Tu translation elongation factor, mitochondrial
Tyr…tyrosine
Tyr416…tyrosine 416
Tyr527…tyrosine 527
UAA… uracil, adenine, adenine
UGA…uracil, guanine, adenine
UQCRC2…ubiquinol-cytochrome c reductase core protein 2
VDAC…voltage-dependent anion channel
VEGF…vascular endothelial growth factor
WT cells…wild-type MEF cells with endogenous expression of all SFKs
WV…West Virginia
WV-INBRE…West Virginia IDeA Network of Biomedical Research Excellence

207

APPENDIX C: CURRICULUM VITAE

Caroline Hunter
Phone: 540-589-8280
Email: cahunter589@gmail.com

Address: 903 Saddle Drive
Salem, VA 24153

EDUCATION_________________________________________________________________
Marshall University – Huntington, WV
• Biomedical Sciences (Research) Graduate Program
• Ph.D. Candidate – Cardiovascular, Obesity, and Diabetes Research
Roanoke College – Salem, VA
• Bachelor of Science, Biochemistry
RESEARCH EXPERIENCE_____________________________________________________
Graduate Researcher – Huntington, WV
May 2013 – Present
• Department of Biomedical Research, Koc Laboratory
Piedmont Eye Center – Lynchburg, VA
• Department of Clinical Research
• Data Specialist

Jan. 2012 – Aug. 2012

Student Researcher – Salem, VA
• Roanoke College, Department of Chemistry
• Sarisky Laboratory

May 2011 – Dec. 2011

Student Researcher – Salem, VA
• Roanoke College, Department of Chemistry
• Steehler Laboratory

Sept. 2010 – April 2011

LABORATORY SKILLS_______________________________________________________
Experimental Techniques
• Cell/ Tissue Culture
• Gene Silencing/Overexpression
• End point and real-time PCR
• PCR Primer Design
• DNA/RNA/Protein Extraction
• Western Blot Analysis
• Various Toxicity Assays
• Cell Viability Assays
• Protein Immunoprecipitation
• Enzymatic Assays
• Wes automated protein analysis system
208

•
•
•
•
•

Mitochondrial OXPHOS complex activity assays
Bacterial Cultures
Molecular Cloning
Site-directed Mutagenesis
Protein Expression and Purification

Software
• Proficient in Microsoft Office, Adobe Design, ImageJ, UN-Scan-IT, and GraphPad Prism

HONORS AND AWARDS_______________________________________________________
2017 Outstanding Poster Presentation Award
• Appalachian Regional Cell Conference
• Best Poster Presentation for Basic Science Category
2015

Travel Award
• Post-Doctorate/Graduate Travel Award from American Society of
Biochemistry and Molecular Biology (ASBMB)

2015

Selected for an Oral Presentation
• Marshall University School of Medicine Research Day

2014

Selected for an Oral Presentation
• Appalachian Regional Cell Conference

2014

Best Presentation Award
• Marshall University School of Medicine Research Day
• Best Poster Presentation for Basic Science Category

2013

Second Place Poster Presentation Award
• Appalachian Regional Cell Conference
• Second Place for Poster Presentation for Basic Science Category

FUNDING____________________________________________________________________
Graduate Research Fellowship Award
2015
• NASA West Virginia Space Grant Consortium

PROFESSIONAL AFFILIATIONS______________________________________________
• American Society of Biochemistry and Molecular Biology (ASBMB)
• American Chemical Society (ACS)
• American Association for Advancement of Science (AAAS)

209

PUBLICATIONS_____________________________________________________________
Lawag AA, Napper JM, Hunter CA, Bacon NA, Deskins S, El-Hmdani M, Govender
SL, Koc EC, Sollars VE. 2017 HSP90 Inhibition and Cellular Stress Elicits Phenotypic
Plasticity in Hematopoietic Differentiation. Cell Reprogram. Oct; 19(5):311-323. Doi:
10.1089/cell.2017.0001.
Hunter CA, Kartal F, Koc ZC, Murphy T, Kim JH, Denvir J, Koc EC. 2019
Mitochondrial oxidative phosphorylation is impaired in TALLYHO mice, a new obesity
and type 2 diabetes animal model. Int J Biochem Cell Biol. Nov; 116 Doi:
10.1016/j.biocel.2019.105616
Hunter CA, Koc H, Koc EC. 2020. c-Src kinase impairs the expression of mitochondrial
OXPHOS complexes in liver cancer. Cell Signal, 72, p. 109651.
doi:10.1016/j.cellsig.2020.109651. Epub 2020 April 23.
Hunter CA, Plymale NI, Smee KM, Sarisky CA. 2019. Experimental characterization of
two archaeal inosine 5'-monophosphate cyclohydrolases. PLOS One. Oct.
https://doi.org/10.1371/journal.pone.0223983
Hunter CA, Koc H, Koc EC. Fyn kinase inhibition impairs mitochondrial energy
metabolism and reduces cellular proliferation. In Preparation
PRESENTATIONS___________________________________________________________
Hunter, C.A., Kartal F, Koc ZC, Murphy T, Kim JH, Denvir J, Koc EC. (November
2017). Mitochondrial oxidative metabolism is impaired in TALLYHO mice, a new
obesity and type 2 diabetes animal model. ARCC. Athens, OH. Basic Sciences Poster
Presentation Award (1st).
Hunter, C.A., Koc, H. and Koc, E.C. (August 2017). Mitochondrial oxidative
metabolism is impaired in TALLYHO mice, a new obesity and type 2 diabetes animal
model. JCESOM Research Day. Huntington, WV.
Hunter, C.A., Kim, JK, Koc, H and Koc, E.C. (June 2017). Regulation of mitochondrial
biogenesis in obesity and type 2 diabetes animal model. UMDF. Washington D.C.
Hunter, C.A., Koc, H. and Koc, E.C. (August 2016). Role of antioxidants in kinasedependent regulation of mitochondrial energy metabolism. JCESOM Research Day.
Huntington, WV.
Hunter, C.A., Koc, H. and Koc, E.C. (June 2016). Fyn-dependent phosphorylation of
mitochondrial elongation factor Tu may lead to metabolic syndrome by mitochondrial
dysfunction. NASA Research Day.
Hunter, C.A., Koc, H. and Koc, E.C. (March 2015). c-Src regulates mitochondrial
translation by elongation factor Tu (mtEF-Tu) phosphorylation. ASBMB/EB. Boston,
MA. ASBMB Travel Award.
Hunter, C.A., Koc, H. and Koc, E.C. (March 2015). Oral Presentation. c-Src regulates
mitochondrial translation by elongation factor Tu (mtEF-Tu) phosphorylation. JCESOM
Research Day. Huntington, WV.

210

Hunter, C.A., Koc, H. and Koc, E.C. (November 2014). Oral Presentation. c-Src
regulates mitochondrial translation by elongation factor Tu (mtEF-Tu) phosphorylation.
ARCC. Huntington, WV.
Hunter, C.A., Koc, H. and Koc, E.C. (October 2014). c-Src regulates mitochondrial
translation by elongation factor Tu (mtEF-Tu) phosphorylation. Midwest Membrane
Trafficking and Signaling Symposium (ASCB). Louisville, KY.
Hunter, C.A., Miller-Lee, J.L, Koc, H and Koc, E.C. (March 2014). Mitochondrial
Elongation Factor Tu: Regulation Through Phosphorylation. JCESOM Research Day,
Huntington, WV. Basic Sciences Poster Presentation Award (1st).
Hunter, C.A., Miller-Lee, J.L, Koc, H and Koc, E.C. (October 2013). Mitochondrial
Elongation Factor Tu: Regulation Through Phosphorylation. Appalachian Regional Cell
Conference. Charleston, WV. Poster Presentation Award (2nd).
Hunter, C.A. and C.A. Sarisky (2011). Gene cloning in the purine biosynthetic pathway
in Archaeoglobus fulgidus. Mid-Atlantic Regional Conference of Undergraduate
Scholarships. Sweet Briar, VA.

211

